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ABSTRACT
INTERACTIONS OF THE SHIGA-LIKE TOXIN-2 (STX-2) FROM ESCHERICHIA 
COLI 0157:H7 AND THE BCL-2 FAMILY OF PROTEINS 
DURING HOST CELL APOPTOSIS
By
Lia K. Jeffrey 
University of New Hampshire, May 2013
Stx-2 is a major contributor to the pathogenesis of Escherichia coli 0157:H7. 
Prior reports suggest that Stx-2 increases necrosis and apoptosis of a variety of host cells 
including those of endothelial origin as well as immune cells such as neutrophils (156). 
However, the role Stx-2 plays in delayed apoptosis of neutrophils is not fully understood 
given that previous studies have shown conflicting results (118, 51). The process of 
apoptosis is mediated by the Bcl-2 protein family (2,46,226). The purpose of this 
research was to define the molecular mechanisms of Stx-2 and Bcl-2 protein family 
interactions. These studies examined the binding of Stx-2 to select Bcl-2 family proteins, 
and outlined the effects that Stx-2 and a newly generated mutant of Stx-2 have on 
neutrophil apoptosis and necrosis rates as well as on caspase-8 and caspase-9 activation. 
Stx-2 did not bind to the select Bcl-2 family proteins examined nor did it consistently 
show decreased apoptosis rates in neutrophils. The mechanisms behind Stx-2-induced
neutrophil apoptosis potentially involved the endoplasmic reticulum (ER) stress response 
and/or interactions with other Bcl-2 family members such as Bak at the mitochondrial 




INTRODUCTION TO ESCHERICHIA COLI 0 1 57:H7 INFECTION AND HOST CELL
RESPONSE
1.0 Microorganism Description
Escherichia coli is a major human disease agent on a world-wide basis. Despite 
this, it was not until almost 100 years after the first description of the microbe that the 
most serious form of the disease it causes became apparent.
The genus name Escherichia was derived from its discoverer, Theodor Escherich, 
a German pediatrician. The genus currently consists of five species: E. hermannii, E. 
fergusonii, E. vulneris, E. blattae, and the type species, E. coli. E. coli was first 
discovered in 1885 from the feces of healthy humans and originally named Bacterium 
coli commune (21, 48). In 1895 Migula renamed the bacterium to Bacillus coli and in 
1919 the name Escherichia was chosen for the genus by Castellani and Chalmers (21). 
The current taxonomic classification for this microorganism places it within the 
Proteobacteria phylum, Gammaproteobacteria class, Enterobacteriales order, 
Enterobacteriaceae family, Escherichia genus, and coli species (21).
1
E. coli is a Gram-negative, cylindrical, straight rod typically 1 -1.5 pm wide by 2 
- 6pm in length. The cells often have a single or paired arrangement, and varying degrees 
of motility from non-motile to motile by way of peritrichous flagella (21). The general 
biochemical profile for E. coli is to ferment various sugars, including D-glucose (which 
results in the formation of gas and acid by-products), lactose, mannitol, sorbitol and 
mucate (which result in the formation of acid by-products only). The organism also 
breaks down indole and decarboxylate lysine, and can use sodium acetate as a sole 
carbon source (21). E. coli is not able to use citrate as a sole carbon source nor can it 
grow on potassium cyanide, use malonate, or form a yellow pigmentation like some other 
members of the Escherichia genus (21).
E. coli is able to survive and proliferate within a temperature range of 15-45°C 
(21-37°C for balanced growth) and is a neutrophilic organism that prefers to grow within 
a pH range of 5.0 -  9.0 (21). Due to the structure of the outer membrane, E. coli is 
intrinsically resistant to hydrophobic antibiotics such as actinomycin D, fusidic acid, 
macrolides, novobiocins, and rifamycins (133). Acquired resistance to other antibiotics 
including, but not limited to aminoglycosides, beta-lactams, chloramphenicol, 
tetracycline, and trimethoprim has also been previously described (158). The mechanisms 
for antibiotic resistance evolved through either genetic mutation or horizontal gene 
transfer and were developed by alteration of the target site, enzymatic detoxification of 
the antibiotic, decreased drug accumulation, and bypass of an antibiotic-sensitive step
(158).
2
As a result, many diverse strains comprise the species of E. coli and they run the 
gamut from commensal to deadly pathogen. E. coli strains are differentiated by three 
distinct antigenic structures; the O antigens, the H antigens, and the K antigens. The 
resulting designation is referred to as the serotype of the microorganism. The O antigens 
are designated based upon lipopolysaccharide (LPS), H antigens on the nature of the 
flagella, and the K antigens on acidic capsular polysaccharide (CPS) composition (21).
In addition to these antigenic classifications, E. coli is also classified into groups 
based upon the pathogenic mechanisms and include enteropathogenic E. coli (EPEC), 
enterotoxigenic E. coli (ETEC), enteroinvasive E. coli (EIEC), enteroaggregative E. coli 
(EAggEC), diffusely adherent E. coli, (DAEC), shiga toxin-producing E. coli (STEC), 
enterohemorrhagic E. coli (EHEC), extraintestinal pathogenic E. coli (ExPEC), 
uropathogenic E. coli (UPEC), and neonatal meningitis E. coli (NMEC) (21). These 
pathogenic groups are described in Table 1.1.
E. coli 0157:H7 is the prototype organism of the STEC group, and has caused 
numerous outbreaks in many countries including the United States. Outbreaks had been 
associated with a wide variety of food types since first appearing in the early 1980’s. It is 
hypothesized that the emergence of this microorganism as a food borne pathogen may be 
related to feeding practices in cattle, the nonhuman reservoir (5). E. coli 0157:H7 is now 
present on most farms and appears to coincide with feeding cattle grain rather than grass 
(64,65). However, the ecology of this organism is complex and not fully
3
I a bl e  1.1: ( ) \ i T \ i e \ \  o f  the  p a t h o g e n i c  g r o u p s  o f  E scher ich ia  co / i  as o u t l i n e d  in
Bcrgcy  "s M a n u a l  o f  S y s t e m a t i c  B ac ter io lo gy  (21)
Group Name Acronym Description
Enteropathogenic 
E. Coli
EPEC This was the first recognized category of diarrheagenic 
E. coli. It has most recently been described to include 
E. coli that have the ability to cause attaching and 
effacing (A/E) lesions without producing Shiga toxins. 
Many serotypes are included in this group, the most 




ETEC This type of E. coli is associated with diarrhea in both 
humans and animals. They have the ability to produce 
one or more enterotoxins that can be either heat-labile 
or heat-stable. These toxins cause intestinal secretions 
and are classified based on their biological activity, 
receptors, and chemical and antigenic properties. 
Strains commonly associated with humans include 




EIEC This type of E. coli is capable of invading and 
propagating within intestinal epithelial cells of the 
intestines. These strains obtain their virulence from 
multiple genes located within the bacterial chromosome 
and on plasmids. There are a very small number of 
serotypes, most of which are non-motile. These 




EAggEC This type of E. coli is generally associated with 
travelers’ diarrhea and other enteric symptoms such as 
cramps. It is characterized by a plasmid-mediated 
aggregative adherence pattern to HEp-2 cells. 
Prominent autoagglutination of cells to each other and 
host cell surfaces are observed. This type of cell 
layering has been described as a “stacked brick” 
configuration. Some of the most frequently reported 
serotypes include 03:H2, 015:H18, 0111:H12, and 
0125:H9.
4
T a b l e  1.1: ( h i T v k  w o f  the p a t h o g e n i c  g r o u p s  o f  E scherich ia  co / i  as o u t l i n e d  in
H crg cx 's  M a n u a l  o f  S y s t e m a t i c  Bac te r io lo gy  (21)
Group Name Acronym Description
Diffusely adherent 
E. coli
DAEC This type of E. coli is defined by a diffuse adherence 
pattern to HEp-2 cells. This phenotype is a result of 
surface fimbriae F I845 and adhesin AIDA-I in serotype 
0126:H27. The role of DAEC in diarrhea is unclear.
Shiga toxin- 
producing E. coli 




This type of E. coli is characterized by its ability to 
produce at least one of two distinct cytotoxins referred 
to as Stx-1 or VT1 and Stx-2 or VT2. The most 
influential serotype of this group is 0157:H7.
Enterohemorrhagic 
E. coli
EHEC This group is a subgroup of STEC/VTEC and includes 
all E. coli strains that commonly cause hemorrhagic 
colitis and have the same clinical and pathogenic 
features as E. coli 0157:H7.
Extraintestinal 
pathogenic E. coli
ExPEC This type of E. coli is commonly associated with 
urinary tract infections, pyelonephritis, neonatal and 
postneurosurgical meningitis, and septicemia. They are 
distinctly different from commensal and intestinal 
strains of E. coli. They typically are pathogenic clones 
of a limited number of 0:K:H serotypes containing host 
defense avoidance mechanisms including capsules, 
serum resistance, and toxins such as a-hemolysin.
Uropathogenic 
E. coli
UPEC This type of E. coli is commonly associated with 
urinary tract infections (UTIs) including pyelonephritis. 
They are characterized by a number of virulence 
factors. Predominantly this type is associated with a 
limited number of 0  groups and K antigens. The most 
common serotypes include 01 :K1 :H7, 02:K1 :H4, 




NMEC This type of E. coli is frequently associated with 
neonatal meningitis and usually includes the 0  groups 
07, 018ac, 01, and 06  that have the K1 antigen 
identical to the capsule of Neiserria meningitidis type 
B.
5
understood. Biochemically, E. coli 0157:H7 differs from that of other E. coli strains. It is 
unable to ferment sorbitol, cannot produce P-glucuronidase which hydrolyzes a 
compound known as MUG (4-methylumbelliferyl-|3-D-glucuronide) which will result in 
cell fluorescence, and it grows poorly above 44°C (86,126). In the clinical laboratory, 
MacConkey agar containing sorbitol and MUG are used to detect E. coli 0157:H7. Due 
to the inability to utilize sorbitol or break-down MUG, colonies will appear colorless and 
non-fluorescent (86). The most important differences between this strain and other non- 
pathogenic strains are those that aid in the pathogenicity of the microorganism and are 
explained below.
2.0 Overview of E. coli Q157:H7 Infection
E. coli 0157:H7 is a major foodbome pathogen in North America and elsewhere 
(125, 159, 220). This serotype (STEC) produces a potent Shiga-toxin that is associated 
with large outbreaks (148). Although many toxic virulence factors are produced by E. 
coli 0157:H7, the Shiga-like toxins are the most likely inducers of hemolytic uremic 
syndrome (HUS) (131). HUS, with associated hemorrhagic colitis (HC), is a rare but 
potentially fatal complication of infection often in children and is characterized by 
hemolytic anemia (a low number of red blood cells due to premature destruction), 
thrombocytopenia (low number of platelets), and renal injury (7).
Symptoms of disease usually present with severe abdominal cramping, nausea, 
and diarrhea that may be watery or bloody (87). After 5-10 days, the gastrointestinal
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symptoms either resolve, or, in approximately 5% of cases, escalate to HUS (7, 87). 
Typical features of HUS include: swollen and detached glomerular endothelial cells, the 
deposition of fibrin and platelets in the renal microvasculature, and systemic thrombotic 
lesions in the microvasculature of the bowel, brain, and pancreas (148,161). Disease 
outcome depends on a number of host and organism factors including patient age, general 
health, and the production of the Shiga-toxins, Stx-1 and/or Stx-2 (88).
Treatment of patients with STEC infection include limiting the severity and 
duration of gastrointestinal symptoms, limiting life-threatening systemic complications 
such as HUS, and preventing spread of infection to close contacts (148). As there is no 
reliable treatment for patients with HUS, therapy usually involves fluid replacement, 
treatment of hypertension, hemodialysis and peritoneal dialysis to maintain balance 
(148). In general, the use of antibiotics is not recommended as they may increase toxin 
production and precipitate HUS (99). Clinical studies showed that children treated with 
antibiotics during the course of an STEC infection had a 17-fold higher chance of 
developing HUS than those who did not receive antibiotic therapy (219).
3.0 Epidemiology of E, coli Q157:H7 Infection
This pathogen was not recognized as a threat until the first major outbreak 
occurred in 1982. From 1982-2002, E. coli 0157:H7 became broadly recognized as an 
important and life-threatening pathogen (162). In the US, it was the cause of 350 
outbreaks in 49 states with 8,958 reported cases, 1,493 hospitalizations, 354 HUS cases,
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and 40 deaths (159). The number of reported outbreaks increased after 1993 and peaked 
in 2000 (Figure 1.1); however, the overall size of the outbreaks decreased over time
(159). It is now estimated that E. coli 0157:H7 causes approximately 73,500 illnesses 
and 61 deaths per year in the US (125).
There are many routes of transmission associated with E. coli 0157:H7 ranging 
from the most common foodbome-related incidences (responsible for 61% of outbreak- 
related cases) to the rare laboratory-related occurrences (2 cases) (159). Historically, E. 
coli 0157:H7 outbreaks are most commonly associated with ground beef; however, 
produce, other beef and dairy products, person-to-person contact, water, animal contact, 
and laboratory accidents have been implicated in disease (Figure 1.2) (1, 11, 13, 30, 31, 
53,159).
A unique and troubling issue is that E. coli 0157:H7 outbreaks remain common 
even with improved US food supply safety regulations (200). For example, from 2006- 
2011 there were 12 foodbome outbreaks in the US. These outbreaks occurred in fresh 
raw spinach, hazelnuts, prepackaged cookie dough, pizza, ground beef, Lebanon bologna 
and cheeses (29). Recently 60 cases of 0157:H7 infection were associated with romaine 
lettuce consumed at salad bars at grocery stores in the central US region in 
October/November 2011 (29). Although this outbreak is considered ended the 
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Figure 1.1: E. coli 0157:H7 outbreaks by year from 1982-2002. Diagram is courtesy 
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Figure 1.2: E. coli 0157:H7 outbreak transmission routes by year from 1982- 
2002. Diagram is courtesy of Rangel et al. (159). The diversity of transmission 
routes increased over time.
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About half the E. coli 0157:H7 produce-related outbreaks are linked to cross­
contamination during food preparation and the remaining half are caused by 
contamination during consumer preparation (159). Outbreaks related to food that is 
intended for raw consumption pose the most serious problem, as once the food is 
contaminated, prevention is difficult (14, 15). In fact, the last four E. coli outbreaks have 
been associated with foods intended for raw consumption (cheese, hazelnuts, Lebanon 
bologna, and romaine lettuce) (29). Key to outbreak termination is the timely recognition 
of E. coli in the food supply and this together with prevention and treatment of HUS 
remain top priorities.
4.0 Virulence Factors of is. coli Q157:H7
E. coli 0157:H7 harbors virulence factors that make it an important pathogen. 
Such factors include shiga-like toxins, adhesins, LPS, enterohemolysin, extracellular 
serine proteases, and enterotoxins. The genes for these virulence factors are located either 
within the chromosome itself or on a distinct virulence plasmid (p0157) within the cell.
4.1 Shiga-like Toxins
Major virulence factors that increase the pathogenicity of E. coli 0157:H7 are the 
shiga-like toxins. Initially designated as verotoxins due to their remarkable cytotoxic 
effects on African green monkey kidney (Vero) cells, at least two of these toxins are 
associated with human disease: Verotoxin 1 (VT1) and Verotoxin 2 (VT2) (87). VT1 was
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first identified by Konowalchuk et al. in 1977 (104). Both VT1 and VT2 were implicated 
in infantile gastrointestinal disease and children with hemolytic uremic syndrome (HUS) 
(89, 104, 148, 162). O’Brien et al (139, 140) reported that the structure and biological 
activity of VT toxins were similar to those of the Shiga toxin produced by Shigella 
dysenteriae type 1, and they could be neutralized by anti-Stx antibody. This led to the 
current toxin nomenclature of shiga-like toxin 1 (SLT-1) or Stx-1 and shiga-like toxin 2 
(SLT-2) or Stx-2 (139, 140). For simplicity and in keeping with international usage, the 
toxins will be referred to as Stx-1 and Stx-2 throughout this thesis and their 
corresponding genes designated as stx 1 and stx2 .
Both Stx-1 and Stx-2 are compound toxins that have a total molecular weight of 
approximately 70,000 Daltons (70 kDa) (138). The nucleotide sequence of the genes that 
encode for Stx-1 and Stx-2 was discovered in the late 1980s (25, 41, 81, 82, 106, 187). 
The gene structure consists of an operon with a single translational unit that encodes both 
the individual A subunit gene and the B subunit gene (148). The AB5 toxin structure (63) 
comprises 2 main subunits: a single 32 kDa A subunit and five 7.7 kDa B subunits (138). 
The B subunit gene has a stronger ribosomal binding site resulting in higher translation of 
the B subunit. The A-subunit has 315 amino acids for Stx-1 and 318 amino acids for Stx- 
2, and the B-subunit has 89 amino acids for both toxins (170).
The protein structure (Figure 1.3) follows an alpha-beta motif and each subunit 
has a unique function. The A-subunit has two fragments; the Al and A2 fragments. The
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Figure 1.3: The structure of Stx. Diagram is courtesy of the European Bioinformatics 
Institute PDBsum [www.ebi.ac.uk/pdbsum]. A) Stx holotoxin B) Stx A-subunit C) Stx B- 
subunit single chain. Both Stx and Stx-1 have similar structures with only minor 
differences in the amino acid sequence whereas Stx-2 has only 56% identity to both 
toxins for the A and B subunits (81).
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Al fragment is the enzymatically active portion of the toxin, and the A2 fragment is the 
portion that serves to bind the Al fragment to the pentameric B-subunit structure. The B- 
subunit is involved in binding to specific glycolipid receptors on the surface of target 
cells (148). Globotriaosylceramide (Gb3) is the eukaryotic glycolipid cell surface receptor 
for Stx-1 and Stx-2 (115,206).
4.2 Adhesins
Adhesins are important as virulence factors in that they augment the pathogenicity 
of E. coli 0157:H7. These adhesins allow for pathogen binding to intestinal epithelial 
cells (156). E. coli 0157:H7 attaches in a localized manner and produces attaching and 
effacing (A/E) lesions on host cells (156). As they bind, the bacteria trigger intercellular 
signals through the Type III secretion system (148). The expression of the Type III 
secretion system is regulated by quorum sensing (183). Proteins such as EspA, EspB, 
EspD, Tir (translocated intimin receptor) and intimin are involved in the intracellular 
signal triggering as well as the formation of the A/E lesion (148). EspA forms 
filamentous structures on the bacterial cell surface that bridge to the host cell surface 
(113). EspB is delivered into the host cell where in combination with EspD, it forms a 
host cell membrane pore (113). This allows other effectors (e.g. Tir) access to the host 
cell (113). Tir functions as the receptor for intimin which is located on the outer surface 
of E. coli 0157:H7 cells. Tir-intimin binding subsequently attaches the bacterium to the 




LPS serves as a third virulence factor that aids in E. coli 0157:H7 pathogenicity. 
LPS is an integral part of gram-negative bacterial cell walls and it stimulates a number of 
immune responses including the production of tumor necrosis factor alpha (TNF-a) and 
other inflammatory intermediates (130). It is noteworthy that high levels of circulating 
antibodies to LPS were observed in 20 out of 22 patients with HUS (17). In addition, 
increased levels of LPS binding protein were also present in patients with HC and HUS 
which implied that these patients had an increased acute phase response to LPS (154, 
156). However, this does not suggest that Lipid A (endotoxin) is expressed (156). Finally, 
results from a number of studies indicated that a synergistic effect between Stx and LPS 
may occur both in vivo and in vitro (8,90,120,156).
4.4 Enterohemolvsin
Bacterial enterohemolysins are well established virulence factors and this is also 
the case for E. coli 0157:H7. Beutin et al. (16) reported that 89% of STEC strains tested 
showed a hemolytic phenotype different from that of the E. coli alpha-hemolysin (Hly). It 
was subsequently shown that this unique hemolysin was encoded by the 60-Mda 
“virulence plasmid” p0157 identified from the 0157:H7 strain EDL933 (176). This 
107 kDa enterohemolysin {EHEC-hlyA) produced by the gene hlyA is controlled by an 
operon (EHEC-/i(yCABD) consisting of four open reading frames. This operon has 60% 
homology to the E. coli alpha-hemolysin operon (/z/yCABD) (148). Production of this
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enterohemolysin has been associated with E. coli 0157:H7 infections that subsequently 
developed into HUS. Of 18 isolates from patients with HUS, 16 were enterohemolytic 
and positive for EHEC-hlyA (148). In addition, antibodies to EHEC-Hly were found in 19 
of 20 patients that were recovering from 0157:H7 STEC-induced HUS. It is not fully 
understood how EHEC-Hly contributes to the pathogenesis of STEC disease, but it is 
thought that the hemoglobin released by the action of the hemolysin may provide a 
source of iron, thereby stimulating growth of STEC in the gut (109). It was discovered 
that alpha-hemolysin is cytotoxic to endothelial cells and increases superoxide production 
by rat renal tubular cells (93, 189). The production of a combination of these 
enterohemolysins may lead to increased toxin production and severe damage to the 
tissues of the kidney and exacerbate HUS.
4.5 Extracellular Serine Protease
In addition to enterohemolysin, the pO 157 plasmid encodes the putative virulence 
factor extracellular serine protease EspP (22). The espP gene encodes this 104 kDa 
protein which is capable of cleaving pepsin and human coagulation factor V (148). By 
these mechanisms it has been suggested that secretion of EspP could result in 
exacerbation of hemorrhagic disease in the gut (22). Antibodies to this protein were 
found in 5 of 6  children with STEC infection; however, it is not believed to be a universal 
virulence factor of STEC as not all E. coli 0157:H7 strains produce EspP (22,148).
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4.6 Enterotoxin
To date, the most recently identified 0157:H7 virulence factor that contributes to 
disease severity is enterotoxin EAST1 which is encoded by the astA gene (148). This 
enterotoxin was detected in 100% of 75 different 0157:H7 strains tested, and may be 
responsible for the watery diarrhea noted in early STEC infection (172).
5.0 Pathogenesis of E. coli Q157:H7 Infection
Induction of disease by E. coli 0157:H7 is a complex process in which the 
preceding virulence factors play a major role. It should be noted that other host and 
microbe components also play a crucial role in disease initiation as well as in disease 
severity (148). Ingested organisms pass through the stomach to replicate in large numbers 
in the intestines. E. coli 0157:H7 is acid-resistant, and withstands the harsh conditions in 
the stomach (62). As a consequence, only a relatively low number (as few as 10 
organisms) is needed to cause disease (157). The incubation period of STEC infection is 
approximately 2-8 days with symptoms appearing, on average, after 3-4 days (157). The 
organisms make their way through the small intestine and typically colonize the lower 
portion of the small intestine and the colon (152). As indicated previously, E. coli 
0157:H7 attaches to epithelial cells of the intestine by way of adhesins that cause A/E 
lesions and induce structural changes in the host cell, including loss of microvilli and 
rearrangement of the structural cytoskeleton components resulting in formation of a 
pedestal (Figure 1.4) (148).
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When the organism has attached and is established in the gut, toxin production 
increases and the toxin is translocated across the epithelial cells into the bloodstream 
(113). Although Stx-1 and Stx-2 favor movement from the apical to the basolateral cell 
surfaces (75), it appears that the mechanisms in which Stx-1 and Stx-2 cross epithelial 
cells differ. Stx-1 makes its way across cells in a microtubule-dependent manner, whereas 
Stx-2 is carried across cells independent of microtubules (75). In addition, translocation 
of Stx-2 is much less efficient than that of Stx-1, and Stx-2 has the ability to translocate 
across the cells in the opposite manner (e.g. from the basolaterial to the apical cell 
surface) (75).
Once shiga-like toxins have reached the bloodstream, they target multiple cell 
types that express Gbs receptors, including endothelial cells of the colon, kidney, and 
central nervous system (CNS), as well as epithelial cells of the kidney (34). In addition, 
shiga-like toxins may also bind to red blood cells (RBCs) through the human P blood 
group antigens as well as the Gb3 -related moiety Pk (193). The binding affinity to RBCs 
is dependent on the binding affinity to surrounding tissues in that when binding affinity to 
RBCs is high, toxin binding to tissues is diminished, thus protecting Gb3 expressing 
tissues (193).
The concentration and nature of the lipid moiety of the Gb3 receptor on the cell 
surface influence whether or not the cell is susceptible to the effects of shiga-like toxins 
(116). For instance, kidney cells express high levels of Gb3 , especially in the cortical
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Figure 1.4: The formation of attaching and effacing (A/E) lesions, caused by 
Escherichia coli. This image is courtesy of Knutton et al. (103). The E. coli observed in 
this electron micrograph is EPEC (strain E2348); however, the mechanism of attachment 
for EPEC and STEC strains are similar. Bacteria are observed attached to intestinal 
epithelial cells on cup-like pedestals (represented by the letter E). Microvilli present on 
the intestinal surface have been disrupted and effaced as a result of the cytoskeletal 
rearrangements (represented by the letters MV) (21).
19
region, which is the principal region of lesions in patients with HUS (19). However, the 
primary cell types that exhibit histopathological lesions in HUS and hemorrhagic colitis 
as a consequence of exposure to the toxin are the endothelial cells (148). Endothelial cells 
are 10-fold to 1,000-fold more sensitive to the effects of Stx-2 than Stx-1 (75,79,142).
After binding to the Gb3 receptor of the target cell, the shiga-like toxin triggers a 
specific, cellular internalization response (Figure 1.5). The entire toxin-glycolipid 
receptor complex is internalized from clathrin-coated pits, following the endocytotic 
pathway and, it is presumed, circumvents late endosomes by way of TGN38 (a Golgi- 
associated protein) (59, 169). The complex is subsequently transported (possibly by way 
of the endosomal perinuclear recycling compartment (ERC)) from sorting endosomes to 
the trans-Golgi network (59). Cells that are not sensitive to Stx-1 or Stx-2 internalize the 
toxin and confine it within lysosomes (169).
Once the toxin has entered the cell it is cleaved by fiirin (a membrane-bound 
protease) within the endosome or within the trans-Golgi network (Figure 1.6) (56). Furin 
recognizes the consensus sequence Arg-X-X-Arg, which is found within the loop region 
of the toxin between the Al and A2 fragments of the A-subunit (56). It cleaves the A- 
subunit and generates a catalytically active 27 kDa N-terminal Al fragment and a 4 kDa 
C-terminal A2 fragment (148). The disulfide bond between the fragments is reduced and 
the enzymatically active portion of the A-subunit is transported in a retrograde fashion to 
the endoplasmic reticulum (ER) and eventually to the cytosol (80, 191). It is possible that 











Figure 1.5: Pathogenesis of Shiga toxin binding to ceils with Gb3 receptors. Diagram 
is courtesy of Sandvig et al. (169). The toxin is internalized by a clathrin coated pit- 
dependent process, cleaved by furin, and transported to the trans Golgi network, 
endoplasmic reticulum and eventually the cytosol.
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AFigure 1.6: Furin cleavage site of Stx-1 and Stx-2. Drawing is adapted from Sandvig et 
al. (170).
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sequence-like hydrophobic domain at the C-terminus into the endoplasmic reticulum 
membrane (167). The Al fragment is responsible for death of the cell by way of RNA N- 
glycosidase activity (47,141). It inactivates the 60S ribosomal unit by cleaving the N- 
glycosidic bond at A-4324 in 28S ribosomal RNA (47). This inhibits elongation-factor 1 
dependent binding of aminoacyl-tRNA to ribosomes and interferes with protein synthesis 
within the cell, impeding peptide chain elongation, and results in necrosis of the cell (47).
6.0 Host Response to E. coli 0157:H7 Infection
It is possible that not all cells exposed to toxin die from RNA N-glycosidase- 
related necrosis. Patients with hemorrhagic colitis and HUS have significant tissue 
damage which generates an inflammatory response through leukocyte activation and 
cytokine production and further exacerbates damage in the affected area (156). 
Neutrophils, macrophages, cytokines, and chemokines play an important role in the 
pathogenesis of disease and development of HUS (Figure 1.7) (156).
Neutrophils are the first line of cellular defense in the human’s host immune 
system. As many as 5 x 1010 cells are released from the bone marrow each day (28). This 
number is necessary in order to maintain a sufficient level to protect against infection 
(28). The main reason why so many cells are required is due to their short half-life (28). 
In the circulation, neutrophils are constitutively undergoing apoptosis with an estimated 
half- life of 6  to 18 hours (3, 67, 173, 213). However, once neutrophils have crossed into 
the tissues they can survive for longer periods depending upon the environmental factors
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Figure 1.7: Hypothetical sequence of events of E. coli 0157:H7 infection from 
ingestion to the development of HUS. Diagram is courtesy of Proulx et al. (156). The 
order of events is labeled numerically from 1-10. Events that may occur simultaneously 
are sub-bulleted by letter (e.g. 4a, 4b, etc...). Hypothesis for which data are not known or 
pending are shown in italics.
24
surrounding them (28). For instance, neutrophils can be kept alive longer by exposure to 
cytokines such as IL-lp, IL-2, IL-4, IL-15, INF-y, G-CSF, and GM-CSF as well as to 
LPS. The effect of this is to decrease their normal rate of apoptosis (20, 38, 60, 61, 102, 
128, 149). Apoptotic neutrophils are incapable of normal function and will not elicit 
cellular responses such as chemotaxis, degranulation, adherence, phagocytosis, and the 
respiratory burst (28, 6 6 , 186). In addition, cell surface receptor expression is decreased 
by way of either receptor shedding or internalization.
TNF-a can have varying effects on neutrophils depending upon where in the host 
the neutrophils reside. In the circulation neutrophils are more likely to undergo apoptosis 
when exposed to TNF- a whereas apoptosis in neutrophils exposed to TNF- a in tissues 
will be delayed. This may be due to the ability of TNF-a to activate a cell death caspase- 
activating pathway or a cell survival nuclear factor kappa B (NF-icB)-activating pathway 
(28).
The NF-kB pathway may be an important pathway for the control of neutrophil 
apoptosis (28). NF-kB is a transcription factor that is a central regulator of the 
inflammatory and immune process. It occurs as a dimer and the constituent proteins are 
part of the NF-kB /Rel family. These proteins have the ability to bind DNA through the 
conserved Rel homology domain, which is also required for homo- and hetero- 
dimerization. The role of the NF-kB pathway has been examined and results indicate that 
there is evidence to suggest that the NF-kB pathway does play a protective role in both 
spontaneous and modulated neutrophil apoptosis (45,134, 135,212,214).
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TNF-a induced NF-kB is more potent in the neutrophils from newborns relative 
to neutrophils from adults and it correlates well with the elevated IL- 8  production 
reported in neonatal neutrophils (148). This may be important to the pathology of E. coli 
0157:H7 infection, as infants are more susceptible to the complications of HUS than are 
adults.
Increased circulating numbers of both neutrophils and macrophages have been 
associated with the severity of renal failure during HUS (156). In addition, increased 
numbers of neutrophils and macrophages in the glomeruli of the kidneys have been 
observed in children with HUS (77,203). Leukocytosis (increased number of white blood 
cells) in the circulation is commonly associated with children that have HUS and is also 
identified as an independent risk factor for developing HUS (12, 23, 37, 49, 50, 52, 74, 
122, 127, 168, 208, 218). Circulating neutrophils activated in HUS patients can be 
demonstrated by the increased elastase levels observed in the blood (49, 50, 52, 74). In 
addition, levels of granulocyte colony-stimulating factor and IL- 8  have been reported in 
children with HUS and IL- 8  levels correlated with white blood cell counts (50, 205). 
These neutrophils also have a higher ability to adhere to cultured human endothelium and 
induce injury by breaking down endothelial fibronectin (52). Stx-1 has the ability to bind 
to a non-Gbs receptor on human neutrophils, and in the presence of endothelial cells will 
relocate from the neutrophil to the endothelial cell (194). This suggests that neutrophils 
may also serve as an additional transport mechanism for the toxin from the intestines to 
the kidney (194). In addition to neutrophils, monocytes may play a role in pathogenesis 
by binding Stx and subsequently secreting a number of other inflammatory mediators
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including TNF-a, IL-ip, IL-6 , and IL- 8  independent of the effects of LPS (204).
Not only do the cells of the immune system play a role in the pathogenesis of E. 
coli 0157:H7, but other inflammatory mediators also have a significant effect. 
Interleukins, chemokines, growth factors, acute phase response proteins, and soluble 
adhesion molecules can all contribute to the host inflammatory response to infection 
(156). Patients with HUS have presented with higher levels of pro- (IL- 8  and IL-6 ) and 
anti- (IL-10 and IL-1 receptor antagonist) inflammatory chemokines than those without, 
and these levels have been correlated to the severity of renal failure (117, 155). In 
addition, shiga-like toxins may induce IL- 8  secretion from intestinal epithelial cells (197, 
223). It appears that not all immune system cell types are involved in response to E. coli 
0157:H7 infection. Lymphokines such as IL-2, IL-4, and IL-13 were not detected in 
patients presenting with HC or HUS, and only low levels of interferon-y were detected. 
This infers that T-cells are not part of the host immune response (156).
7.0 Mechanisms of Eukaryotic Cell Death
The two main pathways that cells follow to undergo cell death are necrosis and 
apoptosis. There are distinct differences between these mechanisms of cell death. A 
necrotic cell has undergone oncosis which is characterized by karyolysis (dissolution of 
the nucleus) due to DNase activity and by expansion of the cell eventually leading to 
leakage of the outer membrane (46). In general, necrosis is a “messy” process and will 
invoke an inflammatory immune response due to the contents of the cell leaking into the
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extracellular matrix. In contrast, when a cell undergoes apoptosis it shrinks in size, the 
cytoplasm becomes denser and the organelles tightly packed, the chromatin condenses 
and marginalizes (pyknosis), the DNA-containing nucleus becomes fragmented 
(karyorrhexis), and cell fragments are separated into apoptotic bodies (“budding”) (108, 
226). The apoptotic bodies are then phagocytosed by macrophages or other similarly 
functioning immune cells and degraded within the phagolysosome (46). Apoptosis does 
not elicit an immune response. This is because cellular contents are not released into the 
surrounding extracellular matrix, the apoptotic bodies are quickly phagocytosed after 
being released from the cell and the macrophages do not produce cytokines (46). This 
could be a beneficial way of increasing pathogenicity without the disadvantages 
associated with a local immune-mediated response.
Apoptosis is commonly referred to as “programmed cell death” (46). There are a 
number of possibilities as to why a cell may undergo apoptosis: it occurs normally during 
development and aging; as a homeostatic mechanism to maintain cell populations; and as 
a defense mechanism when cells are damaged by disease or noxious agents (136). As a 
result there are many stimuli and conditions that may trigger apoptosis, but the cellular 
response to these triggers will vary depending on the cell type (46). Apoptosis is a 
complicated process, and the activity of many genes influence the likelihood of a cell 
activating its self-destruction program (6 8 ).
The process of apoptosis is mediated by a family of proteins known as the Bcl-2 
protein family. Approximately 15 proteins and 25 genes have been identified as members 
of the Bcl-2 family in mammalian cells (32, 39, 40, 185, 224). These proteins are
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classified into two functional roles: pro-survival and pro-apoptosis; and are divided into 
three subfamilies: the Bcl-2 subfamily, the Bax subfamily, and the BH3 subfamily (2). 
The Bcl-2 subfamily promotes cell survival while the Bax and BH3 subfamilies promote 
apoptosis (2). Examples of proteins that belong to each subfamily are listed in Table 1.2.
All of these proteins share at least one of four possible conserved motifs (BH1, 
BH2, BH3 and BH4) known as Bcl-2 homology domains which are critical to the 
function of the proteins, and most pro-survival proteins (those that inhibit apoptosis) 
contain at least the BH1 and BH2 domains (2). The proteins closest in resemblance to 
Bcl-2 contain all four homology domains (2). Alternatively, the Bax and BH3 subfamilies 
(pro-apoptotic) differ in their homology domain content despite their shared cellular role 
(95). The Bax subfamily contains BH1, BH2 and BH3 domains and more closely 
resemble Bcl-2, whereas the BH3 subfamily contain only the BH3 domain (2). Both pro­
survival and pro-apoptosis proteins have the ability to form homodimers and 
heterodimers with each other, thereby keeping themselves in balance or check. This 
suggests that the concentration of the proteins may be important in the outcome of the 
cell’s fate (144). It is known that the BH1, BH2, and BH3 domains strongly influence the 
formation of homodimers and heterodimers, and that these regions create an elongated 
hydrophobic cleft to which a BH3 amphipathic alpha helix can bind (129,171).
Heterodimerization is not required for pro-survival function, but is required for the pro- 
apoptosis functions of the BH3 subfamily, and it may also play a role in apoptosis in the
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Table 1.2: The Bcl-2 Protein Family
S i i b l ' a m i h  N a m e  I m u t i o n  P r o t e i n  M e m b e r s
Bcl-2 Pro-survival Bcl-2, Bc1-Xl, Bcl-w, Mcl-1, Al
Bax Pro-death Bax, Bak, Bok
BH3 Death domain Bik, Blk, Hrk, BNIP3, Bim, Bad, Bid
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Bax subfamily (36,95). It is noted that there may be a preference in which proteins bind, 
as not all pro-apoptosis and pro-survival proteins interact (2 ).
Apoptosis is regulated through three main pathways: the extrinsic or death 
receptor pathway; the intrinsic or mitochondrial pathway; and the perforin/granzyme 
pathway (either through granzyme A or granzyme B) (Figure 1.8 ) (46). The extrinsic, 
intrinsic, and granzyme B pathways converge into a common downstream execution 
pathway, which results in cellular changes commonly associated with apoptosis. 
Research suggests that the apoptotic pathways are linked and molecules from one 
pathway can interact and influence the other (76). In contrast, the Granzyme A pathway 
results in direct DNA cleavage (46).
The extrinsic pathway is triggered by transmembrane receptor-mediated 
interactions (46). When a trimeric ligand comes in contact with the surface of the cell, 
death receptors trimerize and bind to the ligand (119). This activates adapter proteins 
which in turn are recruited to the cellular membrane and bind to the death receptors (72, 
207). The adapter proteins subsequently associate with procaspase- 8  (the inactive form of 
caspase-8 ), form a death-inducing signaling complex (DISC), and activate procaspase- 8  
to form caspase- 8  (101). Once caspase- 8  is activated, the execution pathway is set in 
motion. The extrinsic pathway can be inhibited by alternative proteins which bind to 
adapter proteins and caspase-8 , rendering them ineffective and therefore stopping the 
execution pathway from being set in motion (92, 174).
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Figure 1.8: The three main pathways of apoptosis: extrinsic, intrinsic and perforin/granzyme. Diagram is 
courtesy of Elmore et al. (46). Each pathway activates an initiator caspase (8 , 9, and 10 respectively) which in turn 
activates a common downstream executioner caspase-3. Note that Granzyme A has a unique pathway that is caspase- 
independent.
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The perforin/granzyme pathway is triggered by T-cell mediated cytotoxicity. 
Perforin (a transmembrane pore-forming molecule) is secreted and forms pores within the 
target cell (198). Cytoplasmic granules are subsequently released from the T-cell into the 
target cell through this newly formed pore (198). These granules contain either granzyme 
A or granzyme B which are both known serine proteases (146).
Granzyme A activates a caspase-independent pathway (46). Once it is released 
into the cell, the SET complex (responsible for suppressing DNase expression and 
protecting DNA and chromatin structure) is cleaved (114). This results in active 
expression of DNase which leads to DNA nicking and apoptotic DNA degradation and 
thus blocks maintenance of DNA and chromatin structure integrity (46).
Granzyme B cleaves proteins at aspartate residues, and it is through this function 
that procaspase-10 is activated to form caspase-10 (46). Once activated, caspase-10 sets 
the execution pathway in motion. Granzyme B also has several other functions including 
the cleavage of apoptotic inhibiting factors such as inhibitor of caspase activated DNase 
(ICAD) (166). In addition, research has shown that Granzyme B can also use the intrinsic 
pathway in two other ways; by cleaving Bid which causes cytochrome C release from the 
mitochondria; and by directly activating caspase-3, thereby eliminating the upstream 
signaling pathways and setting the execution pathway into motion (9,164).
The intrinsic pathway is triggered by a number of stimuli. These stimuli act 
directly on targets within the cell and are always mitochondrial-initiated events (46).
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Intracellular signals are activated within the cell and cause changes within the inner 
mitochondrial membrane (46). Mitochondrial permeability transition (MPT) pores are 
opened and allow the release of two main groups of pro-apoptotic proteins into the 
cytosol that function in both the intrinsic and the execution pathways (165). The first 
group consists of cytochrome c, Smac/DIABLO, and a serine protease Htr2A/Omi, all of 
which are responsible for activating a caspase-dependent mitochondrial pathway where 
Cytochrome c binds with Apaf-1 and Procaspase-9 to form active Caspase-9 (24, 44, 57, 
202). Caspase-9 or the other “initiator” caspases (caspase- 8  or caspase-10) will activate 
caspase-3 and set the execution pathway into motion.
The execution pathway is the final pathway for apoptosis regardless of the 
initiation pathway type (intrinsic, extrinsic or perforin/granzyme) (46). The “executioner” 
caspases (caspase-3, caspase- 6  and caspase-7) activate cytoplasmic endonuclease and 
proteases which degrade nuclear and cytoskeletal materials and proteins such as PARP, 
cytokeratins, alpha fodrin (a plasma membrane cytoskeletal protein), and NuMA (nuclear 
protein). This results in the classic morphological changes observed in apoptosis (182). In 
particular, Smac/DIABLO and Htr2A/Omi are responsible for preventing the activity of 
inhibitors of apoptosis proteins (IAP) thereby increasing the effectiveness of the pro- 
apoptotic response (175, 202). A second group of proteins consisting of apoptosis 
inducing factor (AIF), endonuclease G, and caspase-activated DNase (CAD) is also 
released from the mitochondria, but only in the late stages of apoptosis after cells are 
committed to die, and act in a caspase-independent manner (with the exception of CAD) 
(46). AIF translocates to the nucleus where it fragments DNA and condenses peripheral
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nuclear chromatin (85). Endonuclease G is also translocated to the nucleus, and it cleaves 
nuclear chromatin to produce oligonucleosomal DNA fragments (112). CAD functions 
similarly to AIF and endonuclease G after it is translocated to the nucleus; however, it 
does not function until it is cleaved by caspase-3 (166). Once cleavage has occurred, 
CAD causes DNA fragmentation, resulting in a more pronounced (Stage II) chromatin 
condensation (188). In addition, Gelsolin (an actin binding protein) is cleaved by 
activated caspase-3 and will subsequently cleave actin filaments in a calcium- 
independent manner leading to cytoskeletal, intracellular transport, cell division and 
signal transport disruption (105).
The mechanisms of how Stx affects these cell death pathways are unclear. Toxins 
typically trigger apoptosis through the intrinsic pathway (46), and previous studies have 
shown that an interaction occurs between Stx-2 and Bcl-2 (190). The goal of this research 
is to confirm Stx-2 and Bcl-2 protein interactions and further examine the interactions of 
Stx-2 with other members of the Bcl-2 protein family in order to propose a mechanism of 
action. The protein interactions will be observed in cell types that are associated with the 
pathogenesis of HUS; human intestinal epithelial cells and neutrophils. Elucidating the 
mechanisms of Stx-2 action in programmed cell death can lead to a better understanding 




PROTEIN-PROTEIN INTERACTIONS BETWEEN SHIGA-LIKE TOXINS AND THE
BCL-2 PROTEIN FAMILY
1.0 Abstract
Data from previous studies by Suzuki et al. (190) indicated that Stx-2 but not Stx-
1 interacts with the pentameric sequence, NWGRI within the BH1 domain (a highly 
conserved region) on the anti-apoptotic protein, Bcl-2 (residues 143 to 147). This 
interaction induces target cell death as a consequence of caspase-3 activation (190). Stx-2 
contains this same sequence (residues 223-227) (190) as do other members of the Bcl-2 
protein family. This may indicate that Stx-2 binds to other Bcl-2 family proteins. It is 
hypothesized that Stx-2 interacts with the Bcl-2 family of proteins via this NWGRI 
amino acid motif. If true, Stx-2 should interact with Bcl-2, B c 1 -X l, Mcl-1, A l, Bax, and 
Bak. In order to test this hypothesis, Stx-2 was purified from E. coli 0157:H7 strain 90- 
2380 and the interaction of the toxin with the various members of the Bcl-2 family of 
proteins isolated from Caco-2 cells was determined. The cytotoxicity of Stx-2 towards 
Caco-2 cells was investigated. Next, proteins produced by Caco-2 cells were examined 
by western blot analysis to identify the Bcl-2 family of proteins and interactions with Stx-
2 were assessed by far western blot analysis and co-immunoprecipitation. Data indicated 
that the methods utilized did not show clear evidence that protein interactions occurred
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using caco-2 cells as a model system.
2.0 Introduction
Suzuki et al. showed that Stx-2 but not Stx-1 interacts with Bcl-2, an anti- 
apoptotic protein, via a pentameric amino acid sequence NWGRI located at residues 143 
to 147, and this resulted in caspase-3 activated cell death (190). More precisely, this 
interaction occurs within the BH1 domain (residues 136 to 155) of Bcl-2 (190) which is 
highly conserved and critical for pro-survival protein function (180, 225). This same 
sequence, NWGRI, is also found on Stx-2 at residues 223-227 (190). On Stx-1 the 
sequence differs by one amino acid (NWGRL) and is found at residues 234-238 (190).
Evidence suggests that the ratio of anti- to pro-apoptotic proteins determines the 
sensitivity of a target cell to an apoptotic stimulus by mediating mitochondrial 
cytochrome c release (84). Therefore, it is postulated that Stx-1 and Stx-2 directly interact 
with these proteins and act to disrupt the equilibrium between the anti-apoptotic and pro- 
apoptotic members of the Bcl-2 family, thereby enhancing caspase activation and 
apoptosis within the cell. It is also hypothesized that since the NWGRI sequence is 
present on more than one type of anti-apoptotic protein, it may offer explanation as to 
why Stx-2 displays higher virulence during the course of disease than does Stx-1. It is 
also possible that Stx-2 may mimic the acceptor surface of Bcl-2 and bind either Bcl-2 or 
Bax depending upon its affinity for either protein. The interaction of these proteins was
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investigated at the molecular level in order to determine their role in Stx-triggered 
apoptosis of host cells.
A study performed by Zhang et al. (227) reported that two distinct binding 
surfaces play a role in homodimerization and heterodimerization of the Bcl-2 family of 
host-cell proteins (227). The two surfaces, known as the “acceptor surface” and the 
“donor surface”, are oriented at approximately 90° to each other on the Bcl-2 protein 
(227). The acceptor surface has the ability to bind Bcl-2 molecules as well as Bax, while 
the donor surface binds only Bcl-2 (227). In healthy cells, Bax primarily resides in the 
cytosol of the cell and does not form dimers (227). When apoptotic stimuli occur, Bax is 
switched to an active confirmation and is translocated to the mitochondria and 
endoplasmic reticulum (227). At these locations, Bax forms homo-oligomers or 
heterodimers with other Bcl-2 family members at the acceptor surface (227). It should be 
noted that the glycine at position 145 in the middle of the acceptor surface is located 
within the middle of the NWGRI pentameric sequence, which is the same sequence also 
observed in Stx-2. When this glycine in Bcl-2 was mutated to alanine, 
heterodimerization but not homodimerization was abolished at the acceptor surface (227). 
This may indicate that the NWGRI sequence was important in establishing the ratio of 
dimerization between anti- and pro-apoptotic proteins, and thus determines the sensitivity 
of a target cell to apoptotic stimuli (84). It is possible that Stx-2 may mimic this acceptor 
surface and bind to either Bcl-2 or Bax depending upon its affinity for either protein.
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3.0 Hypothesis
Extrapolating from the studies by Suzuki et al. (190) and Zhang et al. (227), it is 
hypothesized that Stx-1 and Stx-2 interact with the Bcl-2 family of proteins via the 
NWGRL or NWGRI amino acid motifs. If true, then Stx-2 should interact with Bcl-2, 
B c1-Xl, Mcl-1, Al, Bax, and Bak based upon its pentameric sequence (NWGRI).
4.0 Materials and Methods
The bacterial strains, toxins they produce and their origins together with all media 
and reagent composition and preparation instructions are located in Appendix A. 
Authorization to complete these experiments was obtained from the Institutional Review 
Board for the Protection of Human Subjects In Research (IRB) under approval number 
3679 (Appendix C).
4.1 Stx Protein Sequence Analysis
An analysis of Stx-1 and Stx-2 protein structures was made using ClustalX to 
compare these with the members of the Bcl-2 family of proteins. The purpose of this 
analysis was to determine if any sequence similarity was observed in other Bcl-2 family 
members with the NWGRI sequence, located in a highly conserved region of Bcl-2.
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4.2 Purification of Stx-2 from Escherichia coli 0157:H7 strain 90-2380
E. coli 0157:H7 strain 90-2380 was inoculated into Luria Burtani (LB) Broth and 
allowed to grow overnight at 37°C with shaking. The following day, the culture was 
aliquoted into sterile 100x15mm Petri dishes (lOmL per dish). The lids were removed, 
and the culture was exposed to ultraviolet (UV) light in a biosafety cabinet for 30 
minutes. Subsequent to UV exposure, the dishes were transferred to a 37°C incubator and 
allowed to incubate for an additional 48 hours. Following incubation, the culture was 
pooled, centrifuged at 16,000 x g for 15 minutes at 4°C, and supernatant collected and 
sterile filtered using Acrodisc 0.45pm low protein-binding membranes (Pall Corp, Port 
Washington, NY). Ammonium sulfate precipitation was used to precipitate the toxin. 
Initially, ammonium sulfate was slowly added to the supernatant until the concentration 
reached 40% (w/v). The suspension was centrifuged and the supernatant was transferred 
to a new beaker. The ammonium sulfate concentration was increased to 70%, and 
centrifuged again. The pellet was resuspended in 15mL distilled water and dialyzed in 
lOmM Tris pH 7.4 for 48 hours with a 30 kDa molecular weight cut-off dialysis 
membrane (pre-soaked in 2% sodium bicarbonate, ImM EDTA dialysis membrane 
preparation buffer at 60°C for 15 minutes).
Once dialysis was complete, the sample was concentrated using a Centricon 50 
(Millipore Corp, Bedford, MA) with a 50 kDa molecular weight cut-off membrane. Then, 
to obtain higher purification and eliminate large proteins, the toxin was processed 
through a Centricon 100 (Millipore Corp) with a 100 kDa molecular weight cut-off
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membrane, the filtrate was collected, and a final concentration was performed using a 
Centricon 50 filter unit.
4.3 Stx-2 Characterization
4.3.1 Native Analysis of Semi-Purified Stx-2
Sterile-filtered supernatants from E. coli 0157:H7 strain 90-2380 were analyzed 
to assess overall protein content by native gel electrophoresis. Semi-purified Stx-2 was 
analyzed to determine overall purity and the effectiveness of the purification method 
outlined in section 4.2 (page 39-40). All samples were combined with 5x sample loading 
buffer (5:1 ratio), loaded onto two identical 6% stacking /12% resolving gels, and placed 
in a buffer tank containing native running buffer. A total of 4 gels was run at 120V for 
approximately 1 h, 2 of these were used to assess the purity of the sterile-filtered 
supernatants, and 2 to determine the purity of the semi-purified Stx-2.
Three gels were placed in Coomassie blue for at least 2 h to stain the proteins in 
the gel. The gels were then placed in the destaining buffer described in Appendix A, 
section 4.18 until the background was no longer blue, and visible protein bands were 
observed.
One gel was aligned onto a polyvinylidene fluoride (PVDF) membrane (Millipore 
Corp), and placed into a transfer sandwich consisting of fiber pads and filter paper
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(Figure 2.1). The transfer sandwich was placed into a buffer tank containing Tris-Glycine 
buffer (Appendix A, 4.19) and proteins were transferred at 60V for 4-5 h. After transfer, 
the membrane was “blocked” overnight in Tris Buffered Saline containing 5% 
dehydrated skim milk (Appendix A, 4.20) at 4°C. On the following day, the membrane 
was incubated for 2 h at room temperature with lOpg/mL of primary antibody, STX2- 
11E10 (Toxin Technology, Sarasota, FL) raised in mice against Stx-2. Membranes were 
then rinsed 3x in Tris Buffered Saline containing 0.05% Tween (TTBS) (Appendix A, 
4.22) for 10 min at room temperature, and subsequently treated with anti-mouse alkaline 
phosphatase-conjugated secondary antibody (Sigma-Aldrich, St. Louis, MO) for 2 h at 
room temperature. After the secondary antibody incubation, the membrane was rinsed 
twice in TTBS followed by one rinse in TBS for 10 min at room temperature. The blot 
was developed with Nitro-Blue Tetrazolium Chloride / 5-Bromo-4-Chloro-3'- 
Indolyphosphate p-Toluidine Salt (NBT/BCIP) tablets (Roche Diagnostics, Indianapolis, 
IN).
4.3.2 SDS-PAGE Analysis of Semi-Purified Stx-2
Semi-purified Stx-2 was analyzed to detect the toxin in the sample by sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Samples were diluted 
1:2 in sample preparation buffer (Appendix A, 4.13), boiled at 95°C for 5 min, loaded 
onto a 6% stacking / 12% resolving gel (Appendix A, 4.16), placed in a buffer tank 
containing SDS-PAGE running buffer (Appendix A, 4.14), and run at 180V for 30-40 
min. The gel was removed and stained in Coomassie blue (Appendix A, 4.17) for at
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Figure 2.1: Western Blot Transfer Sandwich Assembly. Diagram is courtesy of Bio-Rad 
Trans-Blot Electrophoretic Transfer Cell Instruction Manual.
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least 2 h. After staining, the gel was added to a destain buffer (Appendix A, 4.18) until 
the background was no longer blue, and protein bands were visible.
4.3.3 Western Blot Analysis of Semi-Purified Stx-2
Triplicate samples were diluted 1:2 in sample preparation buffer, boiled at 95°C 
for 5 min, loaded onto a 6% stacking / 12% resolving gel, placed in a buffer tank 
containing SDS-PAGE running buffer, and run at 180V for 30-40 min. One set of 
samples was added to Coomassie blue for at least 2 h and then destained with destain 
buffer. The remaining samples were each divided into two separate gels and aligned on 
polyvinylidene fluoride (PVDF) membranes (Millipore Corp), and placed in a transfer 
sandwich (Figure 2.1) consisting of fiber pads and filter paper. The transfer sandwich was 
placed in a buffer tank containing Tris-glycine buffer (TGB) and the proteins transferred 
at 60V for 4-5 h. After transfer, the membranes were blocked overnight in TBS 
containing 5% dehydrated skim milk at 4°C. On the following day, one membrane was 
incubated for 2 h at room temperature with 10p,g/mL STX2-11E10 (Toxin Technology) 
while the other remained in blocking buffer as a negative control. Both membranes were 
rinsed 3x in TTBS for 10 min at room temperature, and subsequently treated with anti­
mouse alkaline phosphatase-conjugated antibody (Sigma-Aldrich) for 2 h at room 
temperature. The membranes were rinsed twice in TTBS followed by one rinse in TBS 
for 10 min at room temperature. The blots were developed with nitro-blue tetrazolium 
chloride / 5-bromo-4-chloro-3'-indolyphosphate p-toluidine Salt (NBT/BCIP) tablets 
(Roche Diagnostics).
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4.3.4 Cleavage Analysis of Semi-Purified Stx-2 and Al Fragment Generation
Semi-purified Stx-2 was analyzed to ensure that cleavage at the Arg-X-X-Arg 
consensus sequence would occur during subsequent experimentation in mammalian cells, 
and to obtain a semi-pure suspension of toxin containing the Al fragment that is 
generated after cleavage. This was performed by mimicking the natural cleavage of furin 
with trypsin. Five pL of trypsin was added to 0.5mL of semi-pure Stx-2, vortexed briefly 
and incubated at room temperature for 2 min. PMSF (2.5pL) and lpL of beta 
mercaptoethanol was subsequently added to the solution to deactivate the enzyme and 
ensure the disulfide bond was broken.
The preparation was analyzed by SDS-PAGE to determine if cleavage had been 
successful. Samples were analyzed on a 6% stacking /12% resolving gel. Ten pL of each 
sample were diluted 1:2 in sample preparation buffer. The samples were boiled at 95°C 
for 5 min, loaded onto the gel, placed in a buffer tank containing SDS-PAGE running 
buffer, and run at 180V for approximately 45 min. The gel was removed and placed in 
Coomassie blue for at least 2 h. After staining was complete, the gel was placed in 
destain buffer until the background was no longer blue, and protein bands were observed.
In addition a Western blot was performed to confirm that the Al fragment was 
generated in the trypsin-treated toxin sample. A gel was prepared and run as described 
above and the trypsin-treated toxin and untreated toxin samples were loaded onto the gel 
in triplicate. Once the gel was electrophoresed, it was cut into thirds. One third was
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placed in Coomassie blue to stain while the remaining two samples of the gel were 
prepared for a Western blot. The gels were aligned onto PVDF membranes (Millipore 
Corp), and placed into a transfer sandwich consisting of fiber pads and filter paper. The 
transfer sandwich was placed in a buffer tank containing TGB and proteins were 
transferred at 60V for 4-5 h. After transfer, the membranes were blocked overnight at 
4°C in TBS containing 5% dehydrated skim milk. On the following day, one membrane 
was incubated for 2 h at room temperature with lOpg/mL STX2-11E10 (Toxin 
Technology) and the other remained in blocking buffer as a negative control. The 
membranes were rinsed 3x in TTBS for 10 min at room temperature, and subsequently 
treated with anti-mouse alkaline phosphatase-conjugated antibody (Sigma-Aldrich) for 2 
h at room temperature. The membranes were rinsed twice in TTBS followed by one rinse 
in TBS for 10 min at room temperature. The blots were developed with NBT/BCIP 
tablets (Roche Diagnostics).
4.3.5 Biological Activity Verification of Semi-Purified Stx-2
In order to verify that the toxin preparation was biologically active after the 
purification procedure, African green monkey kidney (Vero) cells were exposed to the 
semi-purified preparation. Vero cells were grown to confluency in two 25cm2 tissue 
culture flasks (one to serve as a toxin assay and the second as a control). Semi-purified 
Stx-2 (50pL) was added to the test flask. The test and control flasks were incubated at 
37°C in 5% CO2  for 96 h. Each flask was observed at lOOx total magnification by 
inverted phase-contrast microscopy to look for the presence of rounded, refractile or
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floating cells (indicating toxin activity). Following microscopic examination of the flasks, 
the media was removed and lmL of crystal violet was added for 5 min. Monolayers in 
the flasks were then gently rinsed with distilled water and allowed to air dry.
4.3.6 Quantitation of Semi-Purified Stx-2
The total protein concentration of the semi-purified Stx-2 preparation was 
measured using the Bradford assay. A standard curve was set up in duplicate with bovine 
serum albumin (BSA) (lmg/mL) and the following amounts were added per well: 0, 2,4, 
8, 10, 15, and 20pL. The test samples were prepared by adding lpL of semi-purified 
toxin sample to each of 6 wells. For all standards and test samples, 40pL of Bradford 
reagent was added to each well and the final volume was brought to 200pL using distilled 
water. Sample preparation was performed at the same time as the standard curve was 
prepared. All standards and samples were placed in the plate reader immediately, shaken 
for 10 sec and read at 595nm. The final protein concentration was calculated by 
interpolation from the average standard curve regression equation.
4.4 Interactions of Stx-2 with Caco-2 Cells
Caco-2 cells are a transformed cell line derived from a colon carcinoma, and in 
culture resemble enterocytes that line the small intestine and colon (69, 153). They 
contain microvilli on their cell surfaces and connect by way of tight junctions. These cells 
were examined to determine both the Bcl-2 family protein content within them, and to
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assess the effects of Stx-2. They were cultured and maintained as described in Appendix 
B.
4.4.1 Susceptibility of Caco-2 Cells to Stx-2
Two T25 flasks were seeded with O.lmL of a suspension of Caco-2 cells and 
allowed to grow for 7 days by which time the monolayers were 60-70% confluent. The 
media were exchanged for fresh Caco-2 media and 200pL of Stx-2 supernatant (sterile- 
filtered) was added to one flask while 200pL of PBS was added to the second flask. After 
1 and 5 days of incubation, the cell monolayers in each flask were examined at lOOx total 
magnification using an inverted phase-contrast microscope for rounded, retractile, and 
floating cells (indicating toxin induced damage). At this point, the media were removed 
from each flask and lmL of crystal violet added. After 5 min, the monolayers in the 
flasks were gently rinsed with distilled water and allowed to air dry.
4.4.2 Protein Analysis of Caco-2 Cells
Caco-2 cells were allowed to grow to 100% confluency and harvested. Instead of 
resuspending the cell pellet in cell culture media, it was resuspended in lmL of 
autoclaved, distilled water. The suspension was vortexed briefly and divided into 2 x 
500pL fractions (Sample A and Sample B). Fifty pL of protease inhibitor cocktail was 
added to Sample B, and both samples were vortexed. Each sample was further divided in 
two to give 4 tubes (Fractions 1 and 2 from Sample A, and fractions 3 and 4 from
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Sample B) each containing 250pL. Fractions 3 and 4 were centrifuged at 1,000 x g for 10 
min. The supernatants from these tubes were transferred to fresh tubes, and the pellets 
were discarded.
All 4 fractions were analyzed on a 6% stacking / 12% resolving gel using SDS- 
PAGE. Ten pL of each supernatant sample of Fraction 3 and 4 was diluted 1:2 in sample 
preparation buffer and 5pL of each whole cell sample of Fraction 1 and 2 was diluted 1:4 
in sample preparation buffer. All samples were boiled at 95°C for 5 min, loaded onto the 
gel, placed in a buffer tank containing SDS-PAGE running buffer, and run at 180V for 
approximately 45 min. The gel was removed and placed in Coomassie blue for at least 2 
h. After staining, the gel was destained in buffer until the background was no longer blue, 
and protein bands were visible.
The caco-2 whole cell suspension with added protease inhibitor (Sample B) was 
chosen for more detailed analysis to determine if Bcl-2 family proteins were present in 
the cells. Gels were prepared and run as described previously and the samples were 
loaded onto the gel in triplicate. Once the gel was run, each triplicate sample was cut into 
thirds. One third was placed in Coomassie blue to stain while the remaining two thirds of 
the gel were prepared for Western blot. The gels were cut into 6 pieces and aligned onto 
PVDF membranes (Millipore Corp), and placed in a transfer sandwich consisting of fiber 
pads and filter paper. The transfer sandwich was placed into a buffer tank containing
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Table 2.1: Bcl-2 Protein Family Primary Detection Antibodies
A n t i l x H h  N a i m 1 ( o n c ' c n t i a l i m i
Anti-Bcl-2 (Biolegend Clone Poly 6119) 2|iL/mL
Anti-Bcl-w (Biovision Cat #3034-100) 2.5(ig/mL
Anti-Bcl-XL (Biovision Cat #3312-100) 2.5ng/mL
Anti-Mcl-1 (R&D Systems Cat#AF828) 1.5ng/mL
Anti-Bax (Biolegend Clone Poly 6251) 2(o.L/mL
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TGB and proteins were transferred at 60V for 4-5 h. After transfer, the membranes were 
blocked overnight in TBS containing 5% dehydrated skim milk at 4°C. On the following 
day, a total of five membranes was incubated for 2 h at room temperature with one of the 
primary antibodies outlined in Table 2.1 and the other remained in blocking buffer as a 
negative control. A commercial antibody for Al was unavailable and as a result, Bcl-w 
which contained the NWGRL pentameric sequence was chosen to be investigated in its 
place. The membranes were rinsed 3 times in TTBS for 10 min at room temperature, and 
subsequently treated with anti-rabbit alkaline phosphatase-conjugated secondary antibody 
(1:10,000 dilution) for 2 h at room temperature. The membranes were rinsed twice in 
TTBS followed by a rinse in TBS for 10 min at room temperature. The blots were 
developed with NBT/BCIP tablets (Roche Diagnostics).
4.4.3 Interactions of Bcl-2 (from Caco-2 Cells) and Stx-2
To assess the interactions of Bcl-2 and Stx-2, a far western blot was performed. 
For this, the Caco-2 whole cell lysate with added protease inhibitors was run in 
quadruplicate on two 6% stacking /12% resolving SDS-PAGE gels. Seven pL of sample 
was added to 13pL of sample preparation buffer for each replicate. The samples were 
boiled at 95°C for 5 min, loaded onto the gels, placed in a buffer tank containing SDS- 
PAGE running buffer, and run at 180V for approximately 45 min. Once the gels were 
run, they were cut into four pieces. One fourth was placed in Coomassie blue to stain 
while the other three quarters of the gels were prepared for far Western blot. The samples 
were transferred to PVDF membranes and blocked overnight in TBS containing 5%
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dehydrated skim milk at 4°C as described above. The membranes were rinsed 3 times in 
TTBS for 10 min each at room temperature, and then renatured with 3% Nonidet P-40 
(NP-40) for 30 min. After renaturing, they were rinsed in TTBS 3x for 10 min each at 
room temperature. One membrane (Far WB Test) was treated with the semi-purified, 
trypsin-treated Stx-2 suspension containing the Al fragment, while the control 
membranes (labeled as NCI and NC2) remained in blocking solution for 2 h at room 
temperature. After treatment, all three membranes were rinsed as before with TTBS and 
two membranes (NC2 and Far WB Test) were subsequently probed with STX2-11E10, 
and the third (NCI) was put in blocking buffer at room temperature for an additional 2 h. 
After incubation in the primary antibody was complete, the membranes were rinsed in 
TTBS and all three membranes were treated with anti-mouse alkaline phosphatase- 
conjugated antibody (diluted 1:10,000) (Sigma-Aldrich) for 2 h at room temperature. 
Finally, the blots were rinsed twice in TTBS followed by a rinse in TBS for 10 min each 
at room temperature and developed with NBT/BCIP tablets (Roche Diagnostics).
4.4.4 Caco-2 Cell Lysate Preparation for Co-Immunoprecipitation
Caco-2 cells were grown in 5 x T25 flasks to give 95-100% confluency. One mL 
of sterile-filtered E. coli 0157:H7 supernatant was added to each flask and incubated for 
an additional 24 h to collect the floating cells. The media was harvested from each flask 
and these were pooled, centrifuged at 1000 x g for 10 min at 4°C, and the supernatant 
fluid removed. The pellet was washed three times by centrifugation in 5mL PBS at 1000 
x g for 10 minutes at 4°C.
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To collect the attached cells from each flask, lmL of NP-40 lysis buffer was 
added and the cells were removed from the flask surface using a rubber scraper. The 
resultant cell suspension was added to the tube containing the washed floating cells prior 
to the last centrifugation step and this was centrifuged at 1000 x g for 10 min at 4°C. The 
pellet was resuspended in lOmL of NP-40 lysis buffer and lOOpL of each of the 
following protease inhibitors was added to the lysate: aprotinin, leupeptin, and PMSF 
(frozen in absolute ethanol). The cell lysate was sub-divided into 10 cryovials (lmL per 
vial), flash-frozen in liquid nitrogen, and stored at -80°C.
4.4.5 Co-Immunoprecipitation of Stx-2 and Bcl-2 Family Proteins
Protein A/G resin (1.5mL) was prepared by adding lOmL NP-40 lysis buffer and 
gently mixing. This slurry was then centrifuged at 3000 x g for 1 min. The supernatant 
fluid was decanted and the pellet resuspended in lOmL NP-40 lysis buffer. This washing 
step was repeated twice to give a total of 3 washes after which the resin was resuspended 
in 1.5mL lysis buffer.
The Caco-2 cell lysate was prepared for co-immunoprecipitation by centrifuging 
400pL of the washed resin slurry in a separate tube at 15,000 x g for 30 sec to remove the 
liquid phase from the resin. One mL Caco-2 cell lysate was added to the tube and gently 
rocked at 4°C for 20 min to bind any molecules having high affinity for the resin. After 
incubation, the sample was centrifuged at 15,000 x g for 5 min at 4°C.
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The antibodies were prepared for the co-immunoprecipitation by transferring 1 
aliquot of each test antibody (Table 2.2) in a 1.5mL screw cap centrifuge tube. The tubes 
originally containing the antibody were rinsed with lOOpL NP-40 lysis buffer and this 
rinse containing any residual antibodies was added to the 1.5mL screw cap centrifuge 
tube. One hundred pL of resin-treated Caco-2 lysate was added to each antibody tube and 
these were shaken gently, incubated on ice for 1 hour, and 75pL Protein A/G resin was 
added. The samples were then incubated on ice for an additional 30 min and centrifuged 
at 15,000 x g for 10 sec. Fifty pL of supernatant fluid was collected from each tube and 
set aside. One mL of NP-40 lysis buffer was added to each tube to wash and resuspend 
the gel, and the samples were centrifuged at 15,000 x g for 10 sec. This step was repeated 
four times to give a total of 5 washes. The remaining supemate was removed to just 
above the surface of the gel and frozen at -20°C until analyzed.
The samples were loaded onto four 6% stacking /12% resolving SDS-PAGE gels. 
Ten pL of sample was added to lOpL of sample preparation buffer for each replicate. The 
samples were boiled at 95 °C for 5 min, loaded onto the gels, placed in a buffer tank 
containing SDS-PAGE running buffer, and run at 150V for 45-60 min. After 
electrophoresis, gels were cut into pieces and stained with Coomassie blue or transferred 
to PVDF membranes for Western blotting as described previously. Once transfer was 
complete, the membranes were blocked overnight in TBS containing 5% dehydrated skim 
milk at 4°C. After blocking, the membranes were either left in blocking buffer (negative
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Table 2.2: Co-immunoprecipitation Pull-Down Antibodies
\ n t i b o ( h  N a m e  A m o u n t
Anti-Bcl-2 (Biolegend Clone Poly 6119) 10fiL
Anti-Bcl-w (Biovision Cat #3034-100) 5>iL
Anti-Bcl-XL (Biovision Cat #3312-100) 5nL
Anti-Mcl-1 (R&D Systems Cat#AF828) 5(iL
Anti-Bax (Biolegend Clone Poly 6251) 10^L
STX2-11E10 (Toxin Technology) 5(j.L
NP-40 Lysis Buffer (Negative Control) 100^L
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controls) or were probed with the following primary antibodies for 2 h: STX2-11E10 
(10pg/mL), Anti-Bcl-2 (2pL/mL), Anti-Bax (2pL/mL), Anti-Mcl-1 (1.5|ig/mL), Anti- 
Bcl- Xl (2.5pg/mL), and Anti-Bcl-w (2.5pg/mL). Following incubation, the membranes 
were rinsed 3 times in TTBS for 10 min each at room temperature. The co- 
immunoprecipitation samples pulled-down with Bcl-2 family antibodies and probed with 
STX2-11E10 were incubated with anti-mouse alkaline phosphatase-conjugated antibody, 
diluted 1:10,000, (Sigma-Aldrich) for 2 h at room temperature. The samples pulled-down 
with STX2-11E10 and probed with the Bcl-2 family antibodies were incubated with anti­
rabbit phosphatase-conjugated antibody, diluted 1:10,000, (Sigma-Aldrich) for 2 h at 
room temperature. Lastly, the blots were rinsed twice in TTBS followed by one rinse in 
TBS for 10 min each at room temperature and developed with NBT/BCIP tablets (Roche 
Diagnostics).
5.0 Results
5.1 Stx-2 Protein Sequence Analysis
Alignment of Stx-1 and Stx-2 with Bcl-2 family protein sequences were 
performed to examine which proteins contained the pentameric sequences NWGRI, 
NWGRL or NWGRV (Fig. 2.2). The NWGRI sequence was observed in Stx-2 as well as 
in the BH1 domain of Bc1-Xl, Mcl-1, and Al. The NWGRL sequence was observed in 
Stx-1 as well as in the BH1 domain of Bel-w. The proteins Bcl-XL, Bcl-w, Mcl-1, and Al 

























Figure 2.2: Alignment of Stx-1 and Stx-2 protein sequences. Exact matches between all sequences are depicted by the (*) at 
the top of the outlined box. The bar graph below the aligned amino acid sequences shows relative sequence homology.
for the smaller valine [V] molecule as the final amino acid, was observed only in the BH1 
domain of the Bax and Bak pro-apoptotic members of the Bcl-2 family.
5.2 Stx-2 Characterization
5.2.1 Native Analysis of Semi-Purified Stx-2
A native gel and western blot of UV-induced (to enhance toxin production) and 
non UV-induced E. coli 0157:H7 strain 90-2380 sterile-filtered supernatant fluids 
(Figure 2.3) was performed to determine protein content. Lane 2 and 4 show protein band 
patterns of samples that had not been induced with UV light while lane 3 shows the 
protein band pattern of the sample that was exposed to UV light. Differences in protein 
content were observed between these sample types, the most important of which has been 
highlighted by the box in Figure 2.3. This band corresponds with the band (also boxed) 
observed in the Western blot that had been probed with anti-Stx-2 antibody, confirming 
the protein as Stx-2. Native gels illustrating the effectiveness of Centricon 100 and 50 
concentration units to purify and concentrate proteins between 50-100 kDa are shown in 
Figure 2.4.
5.2.2 SDS-PAGE and Western Blot Analysis of Semi-Purified Stx-2
The SDS-PAGE gel of semi-purified Stx-2 from E. coli 0157:H7 strain 90-2380 
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Figure 2.3: Native analysis of Stx-2 produced by E. coli 0157:H7 strain 90-2380. A)
Native gel of the molecular weight markers, bovine serum albumin and lysozyme (Lane 1 
& 5), and non UV-induced (Lane 2 & 4) and UV-induced (Lane 3) sterile-filtered 
supemate from E. coli 0157:H7 strain 90-2380. The box represents the area in which the 
toxin is located. B) Western Blot of non UV-induced (Lane 2) and UV-induced (Lane 3) 
sterile-filtered supemate from E. coli 0157:H7 strain 90-2380. The box represents the 




and concentration of Stx-2 
produced by E. coli 
0157:H7 strain 90-2380 
using Centricon devices. 
Native gel of the molecular 
weight markers, bovine 
serum albumin and lysozyme 
(Lane 1 & 4), the semi­
purified Stx-2 sample prior 
to Centricon 100 processing 
(Lane 2), the semi-purified 
Stx-2 sample after Centricon 
100 processing (filtrate) 
(Lane 3 & 5), and the semi­
purified Stx-2 sample after 
Centricon 50 processing 
(Lane 6).
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Figure 2.5: SDS-PAGE analysis of Stx-2 produced by E. coli 0157:H7 strain 90- 
2380. Pre-stained molecular weight markers are in Lane 1 and the semi-purified Stx-2 
sample is in Lane 2. The box represents the area in which the toxin is located.
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Figure 2.6: Western blot confirmation of Stx-2 in the semi-purified toxin 
preparation. Pre-stained molecular weight markers are in Lane 1 and the semi-purified 
Stx-2 sample is in Lane 2. A) SDS-PAGE. B) Negative control Western blot probed with 
anti-mouse IgG only, in the absence of Stx-2 specific antibody. No bands were detected. 
C) Western Blot probed with STX2-11E10 mouse antibody and anti-mouse IgG. Stx-2 
was seen in the boxed areas.
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Stx-2. Of interest are the bands between the 25 and 32.5 kDa markers indicating the 
presence of the Stx-2 A-subunit (Fig. 2.5). Pre-stained molecular weight markers were 
used for these procedures, and molecular weight estimates are not as accurate as 
unstained markers. Panel A shows the SDS-PAGE gel in which multiple bands were 
observed. However, the most important has been highlighted by the box and corresponds 
to the molecular mass of Stx-2. Panel B shows a Western blot of the negative control 
membrane that was treated only with secondary antibody and as expected, no bands were 
detected. Panel C illustrates the Western blot treated with the anti-stx-2 antibody and the 
secondary antibody. One band was clearly detected between the 25 and 32.5 kDa markers 
and confirmed the presence of the A-subunit of Stx-2 in the purified sample.
5.2.3 Cleavage Analysis of Semi-Purified Stx-2 and A l Fragment Generation
Semi-purified Stx-2 was analyzed to ensure that cleavage at the Arg-X-X-Arg 
consensus sequence would occur during subsequent experimentation in mammalian cells, 
and results indicated that trypsin treatment effectively cleaved the toxin. The Stx-2 A- 
subunit comprises an Al and A2 fragment. The Al fragment has an approximate size of 
28 kDa while the A2 fragment is 4 kDa. For these experiments the generation of the 
larger Al fragment was determined. Figure 2.7 shows a gel containing molecular weight 
markers, the trypsin treated Stx-2, and Stx-2 without trypsin treatment. Treatment of Stx- 
2 resulted in the disappearance of a band located at approximately 32 kDa in lane 3 of 
Figure 2.7. In addition, a new band was observed in the trypsin-treated sample in lane 2 
of Figure 2.7 just under the 27 kDa marker. In order to ensure that this new band was not 
from the added trypsin (molecular weight of approximately 24 kDa) a Western blot was
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Figure 2.7: SDS-PAGE analysis of trypsin-treated semi-purified Stx-2. Broad range 
molecular weight markers are in Lane 1, trypsin-treated Stx-2 sample is in Lane 2, and 
the Stx-2 sample without treatment is in Lane 3. The box represents the area in which the 
32 kDa A subunit of Stx-2 is located. The arrows indicate the cleavage of the A-subunit 
by trypsin in Lane 3, resulting in a new band (the Al fragment) in Lane 2 that is 

















Figure 2.8: Western blot confirmation of Stx-2 cleavage and Al fragment generation 
in the trypsin-treated Stx-2 preparation. A) SDS-PAGE of Stx-2. Pre-stained 
molecular weight markers are in Lane 1, trypsin-treated Stx-2 is in Lane 2, and Stx-2 
without treatment is in Lane 3. B) Negative control Western blot probed with anti-mouse 
IgG in the absence of specific anti-Stx-2 antibody. Lanes are as outlined for A. C) 
Western Blot probed with STX2-11E10 anti-Stx-2 antibody and anti-mouse IgG. Lanes 
are as outlined for A. The band noted in the box in Lane 2, panel C, shows the Al 
fragment in the sample while the box in Lane 3 shows the full (untreated) A-subunit of 
Stx-2. The slightly smaller size of the band in Lane 2 (Al fragment) as compared to that 
in Lane 3 (whole A-subunit) corresponds to the loss of the 4 kDa A2 fragment.
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performed. Results of the western blot are shown in Figure 2.8. These results confirmed 
that the bands observed were the toxin, and not trypsin. Pre-stained molecular weight 
markers were used for this procedure, and hence the molecular weight estimates were 
slightly smaller than those shown in the SDS-PAGE gel. However, the molecular weight 
of Stx-2 did correspond with the initial Western blot confirmation in Figure 2.6. Two 
distinct bands were observed in the samples tested, with the trypsin-treated Stx-2 band 
(Figure 2.8, panel C, lane 2) being approximately 4 kDa smaller than the untreated 
sample in lane 3. This indicated that the A-subunit of Stx-2 was cleaved by trypsin 
treatment (analogous to that of furin cleavage within host cells) and that the two 
fragments (Al and A2) were separated and successfully detected in Western blots using 
the specific antibody.
5.2.4 Biological Activity Verification of Semi-Purified Stx-2
After 96 h incubation, the T25 flasks containing monolayers of Vero cells that had 
previously been inoculated with “semi-purified” Stx-2 preparation (as outlined in the 
Materials and Methods section 4.3.5) were removed from the incubator and examined for 
cytotoxic effects. The cells in the control flask were confluent and showed typical Vero 
cell morphology (Figure 2.9 A & B). There were minimal cells floating in the medium. 
However, the cells in the flask inoculated with 50pL of Stx-2 were approximately 50% 
confluent and were lifting off the flask surface (Figure 2.9 C & D). There were many 
rounded and refractile cells floating in the medium, indicating a large number of dead 
cells typical of Stx-2 toxicity. Once the flasks were stained with crystal violet and dried,
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Figure 2.9: Biological activity of semi-purified Stx-2. A) Control flask containing no toxin and shown stained with 
crystal violet. The density of the cell monolayer is evident in the intensity of the crystal violet staining. B) Image of Vero 
cells viewed at lOOx magnification. Morphology typical of healthy Vero cells is seen. C) Test flask inoculated with Stx-2 
and stained with crystal violet. Note the reduced staining indicating major loss of cells from the monolayer. D) Image of 
Vero cells viewed at lOOx magnification. Note rounded, refractile cells and loss of monolayer integrity typical of Stx-2 
o\ action.
the difference in the density of the cell monolayers between the flasks was evident 
(Figure 2.9).
5.2.5 Quantitation of Semi-Purified Stx-2
Duplicate bovine serum albumin (BSA) standards ranging from 0 to 8  mg/mL 
were used to construct a standard curve to quantify the total protein concentration of the 
Stx-2 preparation (Figure 2.10). The average background absorbance was calculated 
between duplicate blanks and this value was subtracted from the total absorbance reading 
in each well. The duplicate standard values were averaged and plotted to produce a 
standard curve with a correlation coefficient (r2) of 0.9861. The total protein 
concentration for the semi-pure Stx-2 was calculated by averaging the absorbance of the 
six replicates assayed. This value was then entered into the standard curve regression 
equation, and a final protein concentration of 3.07 mg/mL was obtained.
5.3 Interactions of Stx-2 with Caco-2 Cells
5.3.1 Susceptibility of Caco-2 Cells to Stx-2
Caco-2 cells required 9 days of culture to achieve 100% confluency (Figure 2.11, 
A). These cells when subsequently exposed to Stx-2 for an additional 5 days and then 
stained with crystal violet (Figure 2.11, B) showed monolayer destruction as compared to 
the control. However, as expected this was much less pronounced than with the Vero cell
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Figure 2.10: Total protein concentration of semi-purified Stx-2. The standard curve 
shown by the ▲ symbol with correlation coefficient of r1-  0.9861 and regression 
equation of y= 0.1023x + 0.0356. The total calculated protein concentration was 
3.07mg/mL and is shown by the ■ symbol.
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Figure 2.11: Cytotoxicity of Stx-2 on Caco-2 cells. Flasks were incubated for 9 days to 
ensure confluency of monolayers at which point the test flask was inoculated with Stx-2. 
Inoculated and control cells were examined daily for 5 days. After a total of 14 days of 
incubation, flasks were stained with crystal violet. A) Control flask with no toxin present. 
Note relative confluency of cell monolayer. B) Test flask inoculated with 200pL of 
sterile-filtered Stx-2 supernatant fluid. Note destruction of monolayer integrity.
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monolayers which are highly susceptible to Stx, and this enhanced toxicity gave the toxin 
its initial name of verotoxin.
5.3.2 Protein Analysis of Caco-2 Cells
SDS-PAGE of prepared Caco-2 cell lysates determined which preparation would 
be best suited to detect Bcl-2 family proteins. Figure 2.12 shows the results of the SDS- 
PAGE analysis. As can be seen, all samples resulted in preparations with multiple bands. 
However, the Caco-2 whole cell lysate preparations resulted in more protein bands than 
the supernatant fluid lysate preparations. The Caco-2 whole cell lysate preparation with 
added protease cocktail inhibitors was selected for Western blot to determine the 
presence of Bcl-2. These inhibitors would prevent proteases from degrading proteins in 
the lysate. Figure 2.13 panel A illustrates the SDS-PAGE of Caco-2 cell lysate following 
protease inhibitor treatment while panel B shows the Western blot of the negative control 
membrane treated with anti-rabbit IgG and without prior treatment with rabbit anti-Bcl-2 
antibody. No bands were detected on the control membrane. Panel C shows the Western 
blot treated with rabbit anti-Bcl-2 antibody and then probed with alkaline phosphatase 
conjugated anti-rabbit IgG. A band was detected at approximately 26 kDa which was 
previously shown to correspond to the molecular weight of Bcl-2 (58). The second band 
was detected just above the 175 kDa marker. It is thought that this band indicates Bcl-2 
oligomers.
Using a range of specific antibodies (outlined in Table 2.1 in Materials and
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Figure 2.12: SDS-PAGE analysis of Caco-2 lysates. Broad range molecular weight 
markers are in Lane 1, Caco-2 whole cell lysate preparation is in Lane 2, Caco-2 
supernatant lysate preparation is in Lane 3, Caco-2 whole cell lysate preparation with 
protease inhibitor cocktail is in Lane 4, and Caco-2 supernatant lysate preparation with 














Figure 2.13: Western Blot confirmation of Bcl-2 in Caco-2 whole cell lysate 
preparation with protease inhibitors. A) SDS-PAGE. Pre-stained molecular weight 
markers are in Lane 1 and the Caco-2 whole cell lysate preparation with protease 
inhibitor cocktail is in Lane 2. The bands noted in the boxes represent Bcl-2 in the 
sample. B) Negative control Western blot probed with anti-rabbit IgG in the absence of 
specific rabbit anti-Bcl-2 antibody showing no bands. Lanes are as outlined for A. C) 
Western Blot probed with rabbit anti-Bcl-2 antibody and anti-rabbit IgG. Lanes are as 
outlined for A. The bands noted in the boxes represent Bcl-2 in the sample. The larger 
band is believed to be Bcl-2 oligomers.
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Figure 2.14: Analysis of Bcl-2 family proteins in Caco-2 whole cell lysate preparation with protease inhibitors. A) SDS- 
PAGE. Pre-stained molecular weight markers are in Lane 1 and the Caco-2 whole cell lysate preparation with protease 
inhibitor cocktail is in Lane 2. B) Negative control Western blot probed with anti-rabbit IgG in the absence of specific rabbit 
antibodies showing no bands. Lanes are as outlined for A. C) Western Blot probed with rabbit anti-Bcl-w antibody and anti­
rabbit IgG. Lanes are as outlined for A. No bands were detected. D) Western Blot probed with rabbit anti-BcI-XL antibody 
and anti-rabbit IgG. Lanes are as outlined for A. The bands noted in the boxes represent detected proteins. The bands detected 
at 28 kDa and 5 3  kDa are believed to be B c 1-Xl and B c1-X l dimers. The larger bands are believed to be cross-reactions of the 
antibody to other unknown proteins present in the caco-2 lysate. E) Western Blot probed with rabbit anti Mcl-1 antibody and 
anti-rabbit IgG. Lanes are as outlined for A. The bands noted in the boxes represent detected proteins. The smaller band is 
believed to be a cross-reaction of the antibody to another unknown protein present in the caco- 2  lysate while the larger is 
believed to be Mcl-1 dimers. F) Western Blot probed with rabbit anti-Bax antibody and anti-rabbit IgG. Lanes are as outlined 
-j for A. The band noted in the box represents Bax in the sample.
Methods) the nature of the Bcl-2 family proteins was further investigated (Figure 2.14). 
There were no bands detected with the Bcl-w antibody. Bcl-w has an expected molecular 
weight of 22 kDa as previously reported by Wilson et al. (217). Since no bands were 
detected, this indicates that the Caco-2 cell line does not produce Bcl-w.
There were five bands detected on the membrane probed with anti-Bcl-XL. These 
bands were at approximately 53 kDa, 4 7  kDa, 4 5  kDa, 4 0  kDa, and 2 8  kDa. Since so 
many bands were detected, the specificity of this antibody to B cI-X l appears to be poor. 
The expected molecular weight of B cI -X l is 2 8 -3 0  kDa (5 8 ) . It is possible that the band 
detected at 2 8  kDa corresponds with the presence of B cI-X l and that the band detected at 
53  kDa corresponds with the detection of B cI-X l dimers since pre-stained markers were 
used and molecular weight estimations are smaller than actual values. This would 
indicate that the Caco- 2  cell line does in fact produce B cI-X l ; however it appears the 
polyclonal nature of the antibody also results in cross-reactions with other unknown 
proteins in the Caco-2 lysate.
There were two bands detected on the membrane probed with anti-Mcl-1. These 
bands were at approximately 2 6  kDa and 78  kDa. The expected molecular weight of Mcl- 
1 is 3 7  kDa for the short form and 4 2  kDa for the long form (5 8 , 111). Neither of the 
detected bands matched the expected size for Mcl-1, however the 7 8  kDa band may be 
indicative of Mcl-1 dimers. The strong band detected at 2 6  kDa may be indicative of an 
antibody cross-reaction with other pro-apoptotic proteins such as Bak, which has an 
expected molecular weight of 2 5 -2 8  kDa (5 8 ). Since the bands detected were not at the
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expected molecular weight for Mcl-1 it cannot be confirmed that Caco-2 cells produce 
Mcl-1. Cross-reactions with other proteins in the Caco-2 lysate were due to the 
polyclonal nature of the antibody.
There was one band detected on the membrane probed with anti-Bax. This band
was detected at approximately 20 kDa, which matches the expected molecular weight of
Bax. Therefore this indicates that the Caco-2 cell line produces Bax.
5.3.3 Interactions of Bcl-2 (from Caco-2 Cells) and Stx-2
Interaction of Stx-2 with the Bcl-2 family proteins was interrogated by far
Western blot (Fig. 2.15). Panel A illustrates the SDS-PAGE of Caco-2 cell lysate 
following protease inhibitor treatment while panel B shows the far Western blot negative 
control membrane treated with anti-mouse IgG in the absence of Stx-2 and specific 
mouse anti-Stx-2 antibody. No bands were detected on this control membrane. Panel C 
shows the far Western blot control membrane treated with mouse STX2-11E10 antibody 
and then probed with alkaline phosphatase conjugated anti-mouse IgG. A band was 
detected at approximately 55 kDa and it is believed that this is due to non-specific 
binding of the primary antibody (STX2-11E10) to a highly concentrated protein band in 
the caco-2 lysate. Panel D shows the far Western blot incubated with Stx-2 followed by 
subsequent treatment with STX2-11E10 antibody and alkaline phosphatase conjugated 
anti-mouse IgG. A band at 55 kDa was detected, identical to the one in panel C. 
However, it is interesting to note that the exposure time of all membranes were the same,
76
Figure 2.15: Far Western blot of Caco-2 whole cell lysate preparation with protease 
inhibitors. A) SDS-PAGE. Pre-stained molecular weight markers are in Lane 1 and the 
Caco-2 whole cell lysate preparation with protease inhibitor cocktail is in Lane 2. B) 
Negative control far Western blot probed with anti-mouse IgG in the absence of Stx-2 
and specific mouse anti-Stx-2 antibody showing no bands. Lanes are as outlined for A. 
C) Negative control far Western blot probed with mouse STX2-11E10 antibody and anti­
mouse IgG. Lanes are as outlined for A. The band noted in the box represents non­
specific binding of the primary antibody (STX2-11E10) to a highly concentrated protein 
band in the Caco-2 lysate. D) Far Western blot probed with Stx-2 followed by mouse 
STX2-11E10 antibody and anti-mouse IgG. Lanes are as outlined for A. The band noted 
in the box corresponds with the band observed in panel C, but is of increased intensity 
which is believed to be a possible interaction of Stx-2 and this unidentified protein that 
has a molecular mass of 55 kDa.
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but the intensity of the band in panel D is greater than that of the control in frame C, 
indicating a possible interaction of Stx-2 with this unidentified protein.
5.3.4 Co-Immunoprecipitation of Stx-2 and Bcl-2 Family Proteins
A co-immunoprecipitation was performed using two different methods. In the 
first method, potential immunocomplexes were isolated by binding them to the Bcl-2 
family antibodies; anti-Bcl-2, anti-Bax, anti-Mcl-1, anti-Bcl-XL, and anti-Bcl-w. These 
samples were then probed with the Stx-2 antibody, STX2-11E10 raised in mice followed 
by alkaline phosphatase conjugated anti-mouse IgG antibody (Fig. 2.16 and 2.17). In all 
samples except the negative control, the SDS-PAGE showed protein bands at 
approximately 48 kDa, in particular with the Caco-2 pull-down processed with anti-Mcl- 
1 and anti-Bcl-XL. This most likely corresponds to the molecular weight of the heavy 
chain of the IgG antibodies. In addition, a second band was observed at 27 kDa in the 
Caco-2 pull-down processed with anti-Mcl-1. This band most likely corresponds to the 
light chain of the IgG antibodies. No other bands were detected. On the negative control 
blot, there was one very faint band detected in the Caco-2 pull down processed with anti- 
Mcl-1 suggesting there may be a cross reaction between anti-Mcl-1 and anti-mouse IgG 
antibodies. On the blot probed with STX2-11E10, there were bands detected in all lanes 
at approximately 48 kDa and bands detected in lane 4, 5, and 8  at approximately 27 kDa. 
Again it is thought that these bands correspond to the heavy and light chains of the Bcl-2 
family antibodies used for the co-immunoprecipitation pull-down.
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Figure 2.16: SDS-PAGE of Caco-2 cell lysate and Stx-2 co-immunoprecipitation 
interactions using Bcl-2 protein family antibodies. Pre-stained molecular weight 
markers are in Lane 1, 4, and 8 , Caco-2 pull down with anti-Bcl-2 antibody is in Lane 2, 
Caco-2 pull down with anti-Bax antibody is in Lane 3, Caco-2 pull down with anti-Mcl-1 
antibody is in Lane 5, Caco-2 pull down with anti-Bcl-XL antibody is in Lane 6 , Caco-2 
pull down with NP-40 lysis buffer (negative control) is in Lane 7, and Caco-2 pull down 
with anti-Bcl-w antibody is in Lane 9.
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Figure 2.17: Western blot of Caco-2 cell lysate and Stx-2 co-immunoprecipitation interactions using Bcl-2 protein family 
antibodies. A) Negative control Western blot probed with anti-mouse IgG in the absence of specific mouse antibodies. Pre-stained 
molecular weight markers are in Lane 1 and 1, Caco-2 pull down with anti-Bcl-2 antibody is in Lane 2, Caco-2 pull down with anti- 
Bax antibody is in Lane 3, Caco-2 pull down with anti-Mcl-1 antibody is in Lane 4, Caco-2 pull down with anti-Bcl-XL antibody is 
in Lane 5, Caco-2 pull down with NP-40 lysis buffer negative control is in Lane 6 , and Caco-2 pull down with anti-Bcl-w antibody 
is in Lane 8 . The band noted in the box represents a cross reaction between anti-Mcl-1 and anti-mouse IgG antibodies. B) Western 
blot probed with mouse STX2-11E10 antibody and anti-mouse IgG. Lanes are as outlined in A. The bands noted in the boxes 
represent detected proteins. The bands detected at 48 kDa and 27 kDa are believed to be the heavy and light chains of the Bcl-2 
family antibodies used for the pull-down procedure. No other bands were detected.
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In the second method, potential immunocomplexes were isolated by binding them 
to the STX2-11E10 antibody. These samples were then probed with anti-Bcl-2, anti-Bax, 
anti-Mcl-1, anti-Bcl-XL, and anti-Bcl-w, and detected with the anti-rabbit IgG. The 
results are summarized in Figure 2.18. Neither the SDS-PAGE nor the negative control 
membrane showed any bands. In addition, the membrane probed with anti-Bcl-2 also did 
not detect any bands. However, membranes probed with anti-Bax, anti-Mcl-1, anti-Bcl- 
XL, and anti-Bcl-w showed the same band pattern of 6  distinct bands with molecular 
weights between approximately 50 kDa and 27 kDa. Since the band pattern was the same 
for almost all the probing antibodies, it is hypothesized that these results are most likely 
not true protein-protein interactions. The top and bottom bands (50 kDa and 27 kDa, 
respectively) appear to correspond to the heavy and light chains of the pull-down 
antibody (STX2-11E10) which was also observed in the previous pull-down method. The 
remaining 4 bands present at approximately 48 kDa, 40 kDa, 32 kDa, and 28 kDa are 
hypothesized to be complexes of Stx-2 and/or cross-reactions of the antibody with 
unknown caco-2 proteins (48 kDa and 40 kDa), whole Stx-2 A-subunit remaining in the 
caco-2 lysate (32 kDa), and Stx-2 that was processed by the caco-2 cells and reduced to 
the A1 fragment (28 kDa). Further evidence to support this hypothesis was observed as 
these protein-protein interactions were only detected when using the STX2-11E10 pull­
down method. If a true protein-protein interaction was detected, then the interactions 
would have been detected using both pull-down methods. Since there was no evidence 
that these interactions were true, it was decided that an examination of the cross-reaction 
of the Bcl-2 family antibodies with Stx-2 was not necessary.
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Figure 2.18: Western blot of Caco-2 and Stx-2 co-immunoprecipitation interactions using STX2-11E10 antibody. A)
SDS-PAGE. Pre-stained molecular weight markers are in Lane 1 and the caco-2 pull down with STX2-11E10 antibody is in 
Lane 2. B) Negative control Western blot probed with anti-rabbit IgG in the absence of specific rabbit antibodies showing 
no bands. Lanes are as outlined for A. C) Western blot probed with rabbit anti-Bcl-2 antibody and anti-rabbit IgG. Lanes 
are as outlined for A. No bands were detected. D) Western blot probed with rabbit anti-Bax antibody and anti-rabbit IgG. 
Lanes are as outlined for A. E) Western blot probed with rabbit anti-Mcl-1 antibody and anti-rabbit IgG. Lanes are as 
outlined for A. F) Western blot probed with rabbit anti-Bcl-XL antibody and anti-rabbit IgG. Lanes are as outlined for A. G) 
Western blot probed with rabbit anti-Bcl-w antibody and anti-rabbit IgG. Lanes are as outlined for A. All membranes 
probed with anti-Bax, anti-Mcl-1, anti-Bcl-XL, and anti-Bcl-w showed 6  distinct bands with molecular weights between 
50kDa and 27kDa indicating that these results are most likely not true protein-protein interactions. Instead, the top and 
bottom bands (50kDa and 27kDa respectively) correspond to the heavy and light chains of the pull-down antibody (STX2- 
11E10). The remaining 4 bands present at approximately 48kDa, 40kDa, 32kDa, and 28kDa are hypothesized to be 
complexes of Stx-2 and/or cross-reactions of the antibody with unknown caco-2 proteins (48kDa and 40kDa), whole Stx-2 
A-subunit remaining in the caco-2 lysate (32kDa), and Stx-2 that was processed by the caco-2 cells and reduced to the A1 
fragment (28kDa).
6.0 Discussion
Understanding what happens to Stx-2 once it has been endocytosed into the cell is 
critical to finding treatments for patients infected with E. coli 0157:H7. A study 
published by Watanabe-Takahashi et al. (215) confirmed the importance of intracellular 
Stx-2 transport to the endoplasmic reticulum in intestinal epithelial Caco-2 cells in order 
for cytotoxicity to occur. Therefore, it is likely that the cytotoxic mechanisms of action 
occur in the endoplasmic reticulum or cytosol, where Bcl-2 family proteins are known to 
reside (4). The goal of these experiments was to assess the interactions of the Bcl-2 
family of proteins with Stx-2 in vitro. Previous studies show there is an association 
between Stx-2, Bcl-2, and the NWGRI peptide that suggested binding of these proteins 
within a host cell by way of the BH1 domain (190). As a result, it was hypothesized that 
Stx-1 and Stx-2 interact with the Bcl-2 family of proteins by way of the NWGRL or 
NWGRI amino acid motifs, respectively. In particular, Stx-2 should interact with Bcl-2, 
B c1-Xl, Mcl-1, A l, Bax, and Bak based upon the pentameric sequence of its NWGRI. 
Bcl-2, B c1-X l, Bax, and Bak are known to be located in the endoplasmic reticulum and 
cytosol of cells (73,107,137,178).
The data from the Stx protein sequence analysis suggested that Stx-1 shared the 
NWGRL sequence only with Bcl-w, a pro-survival protein not originally within the scope 
of these experiments. As such, it was decided that only the Stx-2 interactions would be 
investigated since it is associated with the more serious form of HUS (18, 145, 179,196). 
These data also indicated that Stx-2 shared the NWGRI sequence with Bcl-2, Bc1-Xl,
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Mcl-1, and A1, all of which are pro-survival proteins containing BH1 and BH2 domains 
(2). Finally, the sequence analysis suggested that the pro-apoptotic proteins Bax and Bak 
did not share either of these sequences, but rather they shared with each other a sequence 
of NWGRV. The last amino acid of each of these three pentameric sequences (NWGRI, 
NWGRL, and NWGRV) is isoleucine, leucine, and valine. These amino acids are 
nonpolar, aliphatic (do not contain nitrogen, oxygen, or sulfur in the side chain) and are 
hydrophobic molecules (132). The structures between valine and leucine have a higher 
similarity than isoleucine, and in terms of size, valine is the smallest of the three 
molecules. This may provide a binding advantage to proteins containing valine such as 
Bax and Bak by creating a binding site with the least amount of steric hindrance; thus 
giving these pro-apoptotic proteins the ability to interact with more molecules than their 
pro-survival counterparts and so encourage apoptosis. This is true especially if Stx-2 is 
binding these pro-survival counterparts. Although not examined as part of this work, Stx- 
1 may preferentially bind with Bax and Bak due to the amino acid structure similarity 
between valine and leucine, leading to an increase in free intracellular pro-survival 
proteins thus encouraging cell survival. It is possible that these interactions may explain 
why Stx-2 induces higher virulence compared to Stx-1 in patients with EC or HUS (18, 
145,179,196).
Previous studies by Suzuki et al. (190) used human hepatoma HepG2 cells that 
overexpressed human Bcl-2 to study the interaction between Bcl-2 and Stx-2. 
Hepatocytes are not typically associated with Stx-2 pathogenesis, therefore the 
investigation of protein-protein interactions between Stx-2 and the Bcl-2 protein family
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in the studies described herein used Caco-2 cells as the model cell line. These cells are 
epithelial cells of the human colon where colonization of E. coli 0157:H7 typically 
occurs (152). The susceptibility of Vero and Caco-2 cells to a semi-pure preparation of 
Stx-2 with a total protein concentration of 3.07 mg/mL was confirmed in these studies 
and even though the cytotoxic effects were not as dramatic as that of Vero cells, distinct 
effects were observed. Previous studies by Garred et al. (55) have noted that the disulfide 
bond responsible for stabilizing the Stx-2 A-subunit also prevents dissociation of the A1 
fragment from the toxin-receptor complex during transport, therefore it is critical this 
dissociation occurs properly to ensure toxin activity. The A-subunit of the semi-purified 
toxin was cleaved when subjected to trypsin treatment to produce an Al and A2 fragment 
that matched the expected molecular weights of 28 kDa and 4 kDa, respectively. This 
cleavage mimicked the actual cleavage by Furin that occurs within cells and confirmed 
that the toxin would indeed function as expected once taken into the cells.
Data indicated that Caco-2 cells expressed Bcl-2, B c1-Xl , Bax, and an unknown 
protein corresponding to the molecular weight of Bak, however an antibody specific for 
Bak was not available to confirm its identity. Mcl-1 and Bcl-w were confirmed to be 
absent. It is important to bear in mind that detection of these pro-survival and pro- 
apoptotic proteins was taken at a specific point in time while the expression of the Bcl-2 
family proteins is known to vary during the lifespan of the cell (163). No true protein 
interactions were observed between Stx-2 and Bcl-2, B c1-Xl , or Bax, however one band 
in the far western blot was detected in both the control and test membranes at 
approximately 55 kDa and this indicated that there was a cross reaction between the
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mouse anti-Stx2 antibody (STX2-11E10) and an unknown protein in the Caco-2 lysate. 
There was an increase in the intensity of this band on the test membrane which could 
indicate possible binding of Stx-2 to this unknown protein, but confirmation of this 
interaction was not obtained using co-immunoprecipitation. There may be alterations to 
the Bcl-2 family proteins, such as phosphorylation, that occur within the cell during a 
potential interaction that can impact the binding of these proteins as has been observed in 
other studies (42, 83). Clearly, these alterations do not occur when the proteins have been 
immobilized on a PVDF membrane prior to their interaction.
The data gathered by Suzuki et al. (190) showed a direct correlation of Bcl-2 and 
Stx-2 in HepG2 cells using far Western blot and co-immunoprecipitation, however the 
molecular weight of these complexes and the methods used for co-immunoprecipitation 
were not given, making it difficult to verify the validity of this data. In addition, the 
effects of Bcl-2 overexpression on protein binding within the host cell are unknown. It is 
possible that excess concentrations of Bcl-2 lead to an interaction with Stx-2 that would 
not normally occur during E. coli 0157:H7 infection.
The data gathered in this study did not show clear evidence that protein 
interactions occurred between Stx-2 and Bcl-2, Bcl-XL, or Bax, using either the far 
Western blot or co-immunoprecipitation methods, despite the previous data obtained by 
Suzuki et al. (1 9 0 ) . This suggests that Stx-2 does not directly interact with Bcl-2, B c1-Xl , 
or Bax in colonic epithelial cells.
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CHAPTER 3
IMPACT OF STX-2 ON NEUTROPHIL APOPTOSIS AND NECROSIS
1.0 Abstract
Hemolytic Uremic Syndrome (HUS) is a severe complication in children and the 
elderly that frequently follows infection with Escherichia coli 0157:H7. Stx-2 is a potent 
toxin produced by this pathogen, and it has been identified as a key player in kidney 
failure associated with HUS (131). Stx-2 may inhibit neutrophil apoptosis (118); 
however, this has yet to be confirmed (51). If true, this would have the effect of Stx-2- 
carrying neutrophils remaining in the bloodstream and tissues longer than normal, thus 
exacerbating the potential for tissue damage. Apoptosis is under the control of the Bcl-2 
family of proteins (2, 46, 226). These consist of both pro-death (Bax) and pro-survival 
(Mcl-1) proteins. In the present study, it is hypothesized that Stx-2 decreases the 
normally rapid rate of neutrophil apoptosis by binding to the pro-apoptotic protein Bax 
resulting in a higher concentration of unbound pro-survival proteins such as Mcl-1, thus 
leading to an extended neutrophil lifespan. Stx-2 interactions with the Bcl-2 family 
proteins may occur through the amino acid motif, NWGRI, found in Stx-2 as well as in a 
highly conserved region of the Bcl-2 family proteins. In order to test this hypothesis, Stx- 
2 was harvested from E. coli 0157:H7 and applied to human neutrophils. At intervals of 
0, 6 , 12, 18, 24, 48, and 72 h, samples were assayed using a cell death detection kit to
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determine the impact Stx-2 had on neutrophil apoptosis rates. Data indicated that there 
was a significant difference in neutrophil apoptosis rates (p < 0.05, n=9) up to and 
including 12 h after the neutrophils were exposed to Stx-2. These data suggest that Stx-2 
delays neutrophil apoptosis by a mechanism other than binding to Bcl-2, B c1-Xl , Bax, 
Bcl-wor Mcl-1.
2.0 Introduction
According to the Centers for Disease Control (CDC), Escherichia coli 0157:H7 
causes 73,000 illnesses per year (159). Primary symptoms include hemorrhagic colitis 
(HC) but Hemolytic Uremic Syndrome (HUS), a potentially severe, often life- 
threatening, complication of E. coli 0157:H7 infection, may also occur in the elderly and 
children under 5 years of age. Typically, HUS presents as non-idiopathic, non-immune 
hemolytic anemia, thrombocytopenia, acute renal failure, and occasionally central 
nervous system (CNS) manifestations and may lead to death (148, 156). Stx-1 and Stx-2 
are major toxins produced by E. coli 0157:H7 and they serve to increase the virulence of 
this organism. Stx-2 is a 74 kDa, AB5 structured toxin consisting of alpha-beta motifs. 
The A subunit has a molecular mass of 32 kDa and each B subunit chain is 7.7 kDa 
(138). The role of the B subunit pentamer is to attach to the globotriaosylceramide (Gb3) 
receptor on host cells. After the toxin is endocytosed into the cell, it is transported to the 
Golgi apparatus, endoplasmic reticulum, and cytosol (59, 80, 169, 191). The A subunit is 
cleaved into 2  fragments within clathrin-coated pits by furin (a membrane bound 
protease) (56). The A2 fragment remains attached to the B subunit and is degraded by the
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cell (170). The Al fragment is the enzymatically active portion of the toxin and has been 
shown to elicit a necrotic response by preventing host-cell protein synthesis (47). In 
addition, it is thought that this fragment may also play a role in the apoptotic pathway 
once it is retrograde-transported into the cytoplasm of the host cell.
Apoptosis (programmed cell death) is a normal function of cells. The process is 
mediated by the Bcl-2 protein family (2, 46). These proteins consist of anti-apoptotic 
(pro-survival) and apoptotic (pro-death) proteins that possess conserved homology 
domains. It is through these conserved homology domains that these proteins interact 
with each other, and the ratio of protein type (pro-survival vs. pro-death) determines the 
fate of the cell (46).
Human neutrophils routinely undergo relatively rapid apoptosis and have a typical 
circulating lifespan of 6-18 hours (3, 67, 173, 213). Approximately 1010 neutrophils are 
produced daily, and these account for 45-75% of the total white blood cell count (28). 
During infection, neutrophils are the first responders capable of phagocytozing invading 
pathogens, foreign cells, toxins, and viruses and, in an attempt to clear the infection, 
release reactive oxidative intermediates (28).
Previous studies have shown conflicting results on whether neutrophil apoptosis is 
delayed following exposure to Stx-2. Liu et al. (118) concluded that Stx-2 derived from 
E. coli 0157:H7 exhibited both a dose- and time- dependent inhibition of spontaneous 
neutrophil apoptosis, possibly involving the protein kinase C pathway. Flagler et a l (51)
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was unable to demonstrate a Stx-2 and neutrophil interaction nor did they observe an 
altered apoptosis rate when these cells were exposed to 1 pg/mL of Stx-1 or Stx-2. Suzuki 
et al (190) reported that Bcl-2 bound Stx-2. Further analysis of the Bcl-2 protein family 
(Chapter 2, pg. 56-57) has also indicated that Stx-2 may bind with multiple Bcl-2 family 
members through a conserved NWGRI amino acid motif, however no binding was 
detected between Stx-2 and Bcl-2, Bcl-XL, or Bax using Caco-2 cells. The timing (delay 
or otherwise) of human neutrophil apoptosis was examined in this study over the course 
of 72 h following exposure to supernatant fluid from E. coli 0157:H7, strain 90-2380; a 
strain that produces Stx-2.
3.0 Hypothesis
Stx-2 influences neutrophil apoptosis by a mechanism unrelated to Bcl-2, Bc1-Xl, 
Bax, Bcl-w or Mcl-l binding, leading to a decrease in the baseline apoptosis rate and 
thereby extending neutrophil lifespan.
4.0 Materials and Methods
4.1 Verification of Stx Genes
Four strains of E. coli 0157:H7 (Appendix A, 1.0) were analyzed for the presence 
of either the stxl or stx2 gene by polymerase chain reaction (PCR) using primer 
sequences published by Wang et al (210) and shown in Table 3.1. Strains 90-2380
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(stx2+), 95-2157 (stxl+), 43895 (stxl+, stx2+), and 43888 (stxl- , stx2~) were evaluated. 
DNA from each strain was extracted from a loopful of bacterial cells which were 
resuspended in 20pL of lysis buffer. The samples were heated in boiling water for 15 min 
and 180pL of sterile, nuclease-free water was added to each sample and then centrifuged 
at 13,000 rpm for 5 min. The supernatant fluid was used as the template DNA for the 
PCR assay. For each sample, a 25 pL PCR reaction was prepared using 2pL of template 
DNA, lpL of each primer (forward and reverse), lOpL PCR master mix (Promega, 
Madison, WI) and l lpL  nuclease-free water. The samples were held at 94°C for 5 min 
and run for 30 cycles consisting of denaturation at 94°C for 30 sec, annealing at 54°C for 
1 min, and extension at 72°C for 1 min. Upon conclusion of the cycling, the samples 
were held at 72°C for 10 min for a final extension. Five pL of each PCR product was 
loaded onto a 2.5% agarose gel along with 3.3pL of nuclease-free water and 1.7pL of 6x 
gel loading dye (Promega). In addition, 1.6pL of a 100 base pair (bp) marker was loaded 
into the first and last lane with 10.9pL nuclease-free water and 2.5pL 6x gel loading dye. 
The gel was run at 100 volts for 30-45 min.
4.2 Isolation of Stx-2 Supernatant
E. coli 0157:H7 strain 90-2380 was grown overnight in 300mL Luria Burtani 
(LB) broth (Appendix A, 2.2) at 37°C, and lOmL samples were placed in Petri dishes in a 
BSL-2 biosafety cabinet. The lids were removed and the cultures were exposed to 
ultraviolet (UV) light for 30 min. After UV exposure, the cultures were incubated for an
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additional 48 h and centrifuged at 16,000 x g for 15 min at 4°C. Each supernatant fluid 
was collected and filtered through Pall Acrodisc® 0.2pm Supor® membranes.
4.3 Verification of Stx-2 Presence and Activity
Ten pL of sterile-filtered E. coli 0157:H7 strain 90-2380 supernatant was 
analyzed to ensure that Stx-2 was present. This was achieved by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) and western blot using STX2-11E10 
antibody raised in mice against Stx-2. Triplicate samples were diluted 1:2 in sample 
preparation buffer (Appendix A, 4.13), boiled at 95°C for 5 min, loaded onto a 6% 
stacking /12% resolving gel (Appendix A, 4.16), placed in a buffer tank containing SDS- 
PAGE running buffer (Appendix A, 4.14), and run at 180V for 30-40 min. One set of 
samples was placed in Coomassie Blue (Appendix A, 4.17) to stain for at least 2 h and 
then destained with destain buffer (Appendix A, 4.18). The remaining samples were cut 
to give two gels. These were aligned onto polyvinylidene fluoride (PVDF) membranes 
(Millipore Corp, Bedford, MA), and placed into a transfer sandwich consisting of fiber 
pads and filter paper. The transfer sandwich was placed into a buffer tank containing 
Tris-glycine buffer (TGB) (Appendix A, 4.19) and proteins were transferred at 60V for 4- 
5 h. After transfer, the membranes were blocked overnight in Tris buffered saline (TBS) 
containing 5% dehydrated skim milk (Appendix A, 4.20) at 4°C. On the following day, 
one membrane was incubated for 2 h at room temperature with 10p,g/mL of the STX2- 
11E10 antibody (Toxin Technology, Sarasota, FL) and the other remained in blocking 
buffer as a negative control. The membranes were rinsed 3 times in Tris buffered saline
93
containing 0.05% Tween (TTBS) (Appendix A, 4.22) for 10 min each at room 
temperature, and subsequently treated with anti-mouse alkaline phosphatase-conjugated 
antibody (Sigma-Aldrich, St. Louis, MO) for 2 h at room temperature. The membranes 
were rinsed twice in TTBS followed by a rinse in TBS for 10 minutes each at room 
temperature. The blots were developed with nitro-blue tetrazolium chloride / 5-bromo-4- 
chloro-3'-indolyphosphate p-toluidine salt (NBT/BCIP) tablets (Roche Diagnostics, 
Indianapolis, IN).
The activity of the Stx-2 toxin was investigated using 50pL of sterile-filtered E. 
coli 0157:H7 strain 90-2380 supernatant fluid. This was added to a 25cm2 tissue culture 
flask with a confluent monolayer of African green monkey kidney (Vero) cells grown in 
DMEM modified with 5% fetal bovine serum (FBS) (Appendix A, 5.5) and allowed to 
incubate for 4 days. After incubation was complete, the flasks were observed at lOOx 
magnification using an inverted phase-contrast microscope for rounded, retractile, or 
floating cells (indicating dead cells).
4.4 Isolation and Cultivation of Neutrophils
Neutrophils were collected from human blood using a leukocyte separation 
method (Sigma Aldrich) (Fig. 3.1). In a 15mL conical tube, 3mL of Histopaque™ 1119 
was added followed by 3mL of Histopaque™ 1077, and 6mL of human blood. The tubes 
were centrifuged at 700 x g for 30 min at room temperature. After centrifugation, layer 
“B-Granulocytes” was aseptically transferred using a pipette to a 50mL conical tube and
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Figure 3.1: Sigma-Aldrich leukocyte separation method. This diagram is courtesy of 
Sigma-Aldrich. Whole blood is separated into its cellular components by differential 
centrifugation. Neutrophils are present in layer B -  Granulocytes.
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an equal volume of Hank’s Balanced Salt Solution (HBSS) without magnesium or 
calcium ions was added. The cells were washed by centrifugation at 250 x g for 10 min at 
room temperature. Once centrifugation was complete, the supernatant fluid was removed 
and the pellet resuspended in 12mL of 0.2% NaCl for 30 sec to lyse any remaining blood 
cells. The fluid phase of the suspension was then returned to an isotonic state with the 
addition of 12mL of 1.6% NaCl and centrifuged at 250 x g for 10 min. This was repeated 
until all red blood cells were lysed. Neutrophils were subsequently stained with trypan 
blue (Appendix A, 5.2) to assess viability and counted using a hemocytometer. 
Neutrophils were seeded into a 96-well plate at a concentration of 10,000 cells in 200 pL 
RPMI-1640 (Appendix A, 5.4) per well, and incubated at 37°C in a 5% CO2  atmosphere.
4.5 Assessment of Bcl-2 Family Proteins in Neutrophils
Isolated neutrophils were examined for Bcl-2 family protein content at three 
different time points after isolation: 0 h chosen to represent healthy neutrophils, 6 h to 
represent early apoptotic neutrophils, and 18 h corresponding to late apoptotic 
neutrophils. At each time point the neutrophils were lysed with lmL Nonidet P-40 (NP- 
40) lysis buffer, treated with leupeptin (10pM), and examined using SDS-PAGE and 
western blot analysis for Mcl-1, Bax, Bcl-2, Bcl-w, and Bcl-XL. Negative controls using 
secondary antibody only were also performed to ensure there was no cross-reaction of the 
antibody to the lysate.
Triplicate or quadruplicate samples (as determined by the number of test
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antibodies) were diluted 1:2 in sample preparation buffer, boiled at 95°C for 5 min, 
loaded onto a 6 % stacking / 12% resolving gel, placed in a buffer tank containing SDS- 
PAGE running buffer, and run at 180V for 30-40 min. One set of samples was placed 
into Coomassie Blue to stain for at least 2 h and then destained with destain buffer. The 
remaining samples were cut, aligned onto PVDF membranes (Millipore Corp), and 
placed into a transfer sandwich consisting of fiber pads and filter paper. The transfer 
sandwich was placed into a buffer tank containing TGB and proteins were transferred at 
60V for 4-5 h. After transfer, the membranes were blocked overnight in TBS containing 
5% dehydrated skim milk at 4°C. On the following day, each test membrane was 
incubated with the appropriate antibody (1.5pg/mL of Anti-Mcl-1 [R&D Systems 
Cat#AF828]; 2|iL/mL of Anti-Bax [Biolegend Clone Poly 6251]; 2jiL/mL of Anti-Bcl-2 
[Biolegend Clone Poly 6119]; 2.5pg/mL of Anti-Bcl-w [Biovision Cat #3034-100]; or 
2.5|ig/mL of Anti-Bcl-XL [Biovision Cat #3312-100]) while the negative control 
membrane remained in blocking buffer. The membranes were rinsed 3 times in TTBS for 
1 0  min each at room temperature, and subsequently treated with anti-mouse alkaline 
phosphatase-conjugated antibody (Sigma-Aldrich) for 2 h at room temperature. The 
membranes were washed twice in TTBS followed by one rinse in TBS for 10 min each at 
room temperature. The blots were developed with nitro-blue tetrazolium chloride / 5- 
bromo-4-chloro-3'-indolyphosphate p-toluidine salt (NBT/BCIP) tablets (Roche 
Diagnostics).
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4.6 Analysis of Neutrophil Apoptosis & Necrosis Rates when Exposed to Stx-2
Neutrophil apoptosis and necrosis rates were measured over time at 0, 6 , 12, 18, 
24, 48, and 72 hours using a cell death detection ELISA kit (Roche Diagnostics). This 
ELISA system detects fragmented DNA and histone complexes, markers of cell death. 
Neutrophils were isolated as described previously, a suspension was made containing
50,000 cells/mL and 200pL was dispensed into each well of a 96-well plate (Table 3.2). 
All samples were tested at each of the time points indicated above. Three sample types 
were tested in triplicate in 3 individual trials. The negative control consisted of 
neutrophils only, the media control consisted of neutrophil suspension plus 10 pL of LB 
broth, and the test sample consisted of the neutrophil suspension plus lOpL of Stx-2 
supernatant from E. coli 0157:H7 strain 90-2380.
At each time point, the 96-well plate was centrifuged at 200 x g for 10 min and 
the supernatant fluids were collected and held at 2-8°C to assay for necrosis. The cell 
pellet was lysed for 30 min at room temperature with the lysis buffer provided in the kit 
and the plate was centrifuged again at 200 x g for 10 min. The supernatant fluid was then 
analyzed for apoptosis. Twenty uL of each supernatant (pre-lysis and post-lysis), positive 
control (DNA-histone-complex), and background control (incubation buffer) was 
transferred to a strepavadin coated plate and 80uL of immunoreagent (consisting of 
incubation buffer, anti-histone biotin, and anti-DNA-POD) was added. The samples were 
shaken at approximately 300rpm for 2 h at room temperature, rinsed three times with 
300pL incubation buffer, and developed with lOOpL 2,2'-Azinobis [3-
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Table 3.2: Neutrophil Cell Death Detection Time Point Setup1
96-well Plate 
Row/Column 1 2 3 4 5 6 7 8 9 1 0 1 1 1 2
A C C C
B M M M






1 1 0 , 0 0 0  cells were ac ded to each well suspencled in 200pL RPMI-164C1. A separate plate
was used for each time point.
Sample Kev:
‘C’ = Negative Control (nothing added)
‘M’ = Media Control (10 pL LB broth added)
‘T’ = Test Sample (lOpL Stx-2 supernatant added)
Blank well
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ethylbenzothiazoline-6 -sulfonic acid]-diammonium salt (ABTS). Absorbance was 
measured at 405nm using a Biorad 3550 microplate reader (Bio-Rad, Hercules, CA).
5.0 Results
5.1 Verification of Stx Genes
An agarose gel containing the PCR products from E. coli 0157:H7 strains was 
prepared and it can be seen in Figure 3.2. Amplicons were not obtained for stxl or stx2 in 
the negative control reactions (Lanes 2 & 3), indicating that the primers were specific to 
the target genes. Amplicons were also not obtained for stxl or stx2 in E. coli 0157:H7 
strain 43888 reactions (Lanes 4 & 5), indicating that neither toxin is produced in this 
strain. An amplicon was not obtained for sfccl (Lane 6 ) but an amplicon of approximately 
115 bp in size was obtained for stx2 (Lane 7) in the E. coli 0157:H7 strain 90-2380 
reactions, indicating that only Stx-2 is produced in this strain. An amplicon of 
approximately 340 bp in size was obtained for stxl (Lane 8 ), but no amplicon was 
obtained for stx2 (Lane 9) in E. coli 0157:H7 strain 95-2157 reactions, indicating that 
only Stx-1 is produced in this strain. Finally, amplicons of approximately 340 bp for .stxl 
and 115 bp for stx2 (Lanes 10 & 11) were obtained for E. coli 0157:H7 strain 43895 
reactions, indicating that both Stx-1 and Stx-2 are produced in this strain. These data 










Figure 3.2: Agarose gel analysis of PCR products. DNA from four strains of 
Escherichia coli 0157:H7 was amplified with primers specific to stxl and stx2. The 100 
base pair ladder is in Lanes 1 and 12, negative controls for stxl and stx2 are in Lanes 2 
and 3, strain 43888 for stxl and stx2 is in Lanes 4 and 5, strain 90-2380 for stxl and stx2 
is in Lanes 6  and 7, strain 95-2157 for stxl and stx2 is in Lanes 8  and 9, and strain 43895 
for stxl and stx2 is in Lanes 10 and 11. Amplicons were detected for stxl in strains 95- 
2157 and 43895 and stx2 in strains 90-2380 and 43895.
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5.2 Verification of Stx-2 Presence and Activity
SDS-PAGE and Western blot of Stx-2 containing supernatant fluid from E. coli 
0157.H7 strain 90-2380 were prepared in Figure 3.3. Panel A shows the SDS-PAGE gel 
in which multiple bands were observed. However, the most important one has been 
highlighted by the box and corresponds to the molecular mass of Stx-2. Panel B shows a 
Western blot of the negative control membrane that was treated only with secondary 
antibody and as expected, no bands were detected. Panel C illustrates the Western blot 
probed with the anti-stx-2 antibody, STX2-11E10, raised in mice and the anti-mouse 
alkaline phosphatase conjugated secondary antibody. There was one band visible at 
approximately 25 kDa confirming the presence of the A-subunit of Stx-2. A second band 
was visible around the 47.5KD marker and this may be Stx-2 that was not completely 
denatured during sample processing.
Stx-2 was confirmed in the sterile-filtered supernatant and was active and able to 
elicit a cytotoxic response in Vero cells exposed to 50pL of supernatant fluid. 
Examination of treated and untreated monolayers at lOOx final magnification showed 
active Stx-2 (Figure 3.4). In the control without supernatant added, a confluent cell 
monolayer with intact cells was observed (Fig. 3.4, A), while in the sample with 50pL of 
Stx-2 supernatant fluid, many rounded, retractile (bright), and floating cells were seen as 
well as a decrease in confluency of the monolayer (Fig. 3.4, B). These studies confirmed 
the presence of the Stx-2 gene and the production of Stx-2 by E. coli 0157:H7 strain 90- 
2380.
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Figure 3.3: Western blot confirmation of Stx-2. Pre-stained molecular weight markers 
are in Lane 1 and the supernatant fluid containing Stx-2 is in Lane 2. A) SDS-PAGE. The 
band noted in the box represents Stx-2. B) Negative control Western blot probed with 
anti-mouse IgG only, in the absence of Stx-2 specific antibody. No bands were detected. 
C) Western Blot probed with STX2-11E10 mouse antibody and anti-mouse IgG. Stx-2 
was seen in the boxed area just below the 25 kDa marker. The additional band is believed 
to be Stx-2 that was not completely denatured during sample processing.
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Figure 3.4: Biological activity of semi-purified Stx-2. A) Vero cells without E. coli 
0157:H7 strain 90-2380 supernatant fluid viewed at lOOx magnification. B) Vero cells 
after 4 days incubation with 50pL E. coli 0157:H7 strain 90-2380 supernatant fluid 
viewed at lOOx magnification. Cytotoxic effects typical of Stx-2 are shown by the large 
number of rounded and refractile cells and loss of the cell monolayer confluency.
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5.3 Assessment of Bcl-2 Family Proteins in Neutrophils
SDS-PAGE and Western blot of the neutrophil lysates were prepared at times 0, 
6 , and 18 h to determine the presence of Bcl-2 family proteins. Figure 3.5 shows the 
results of these SDS-PAGE and Western blot analyses. In the figure, horizontal panel A 
illustrates the SDS-PAGE and Western blot for the assessment of Mcl-1 while horizontal 
panel B shows the assessment of Bax and Bcl-2, and finally, horizontal panel C presents 
the results for Bcl-w and B c1-Xl. In panel A, four bands were observed, one in the 
control blot and one at each time point on the blot probed with anti-Mcl-1. The first band 
on both blots observed at time 0  h corresponding to freshly isolated neutrophils was 
approximately 60 kDa in size; however, this was very faint and may have resulted from 
non-specific antibody binding due to high protein concentration of this band. Two 
identical bands at 26 kDa were seen in the 6  and 18 h preparations. Neither of these bands 
corresponded to the expected size of Mcl-1 (37 kDa for the short form and 42 kDa for the 
long form) ( 1 1 1 , 128); however, these bands did correspond with previously observed 
similar bands from Caco-2 cells perhaps indicating an antibody cross-reaction with other 
pro-apoptotic proteins such as Bak, which has an expected molecular weight of 25-28 
kDa (58, 111). Thus, it cannot be definitively stated that the neutrophils expressed Mcl-1 
at any of the three time points.
In panel B, a band was detected at approximately 62 kDa for both Bax (column 3) 
and Bcl-2 (column 4) in freshly isolated neutrophils, however this band was also
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Figure 3.5: Assessment of Bcl-2 family proteins in neutrophils over 18 hours. A)
SDS-PAGE (column 1) and western blots probed with anti-rabbit IgG (negative control, 
column 2) and anti Mcl-1 followed by anti-rabbit IgG (anti-Mcl-1, column 3). One non­
specific interaction was noted on both blots at 60 kDa, and two bands were noted on the 
anti-Mcl-1 blot which are indicative of a reaction with an unknown 26 kDa protein, 
potentially Bak. B) SDS-PAGE (column 1) and western blots probed with anti-rabbit IgG 
(negative control, column 2), anti-Bax followed by anti-rabbit IgG (anti-Bax, column 3), 
and anti-Bcl-2 followed by anti-rabbit IgG (anti Bcl-2, column 4 ). One non-specific 
interaction was noted on all blots at 60 kDa, and one band representative of Bcl-2 dimers 
was observed on the blot probed with anti-Bcl-2. C) SDS-PAGE (column 1) and western 
blots probed with anti-rabbit IgG (negative control, column 2), anti-Bcl-w followed by 
anti-rabbit IgG (anti-Bcl-w, column 3), and anti-Bcl-XL followed by anti-rabbit IgG (anti- 
B c1-Xl, column 4 ). Two similar bands were observed on the blots probed with anti-Bcl-w 
and anti-Bcl-XL at 60 kDa but this was thought to be a non-specific interaction related to 
high sample protein load.
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observed very faintly in the negative control (column 2). It is believed that neither result 
was specific for the antibody tested, and probably was the consequence of non-specific 
secondary antibody binding due to the high protein concentration of this band. In 
addition, there was a second pronounced band detected on the membrane probed with 
anti Bcl-2 at approximately 52 kDa. This band does not correspond to the expected size 
of 26 kDa for Bcl-2, although it is possible that it may represent a dimer of Bcl-2.
In panel C, a faint band was detected for both Bcl-w (column 3) and B c1-Xl 
(column 4) in freshly isolated neutrophils at approximately 60 kDa, however much like 
that of Mcl-1, it is believed that this may be a result of non-specific antibody binding due 
to high protein concentrations of this band as seen in the SDS-PAGE (column 1). A 
similar phenomenon was found in the 18 h sample and the same band was again observed 
for both samples due to the higher protein load as seen in the SDS-PAGE. Neither result 
was specific for the antibody tested, nor were Bcl-w and B c1-Xl detected in any 
neutrophil samples.
In summary Bcl-2 was the only protein detected in this study. These studies were 
not repeated since the only bands observed were associated with non-specific binding due 
to high protein load. Loading less protein would not increase the chances of protein 
detection. A study by Moulding et a l indicated that freshly isolated neutrophils produced 
Bax, Mcl-1, and very low levels of Bcl-2 (128). Even though the results in the present 
study do not match, it is believed that these proteins may be present at some point during 
the cell’s lifespan and potential interactions could still occur.
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5.4 Analysis of Neutrophil Apoptosis & Necrosis Rates when Exposed to Stx-2
The cell death detection ELISA was used to determine, over time, the apoptosis 
and necrosis rates induced by Stx-2 in neutrophils. For this assay, absorbance readings 
were adjusted for background interference by subtracting the average background control 
value from the results on each respective plate and these results were then standardized 
by expressing the final result as a percent of the positive control provided in the kit for 
each assay. This was done in order to assess the rates of apoptosis/necrosis over time 
since the assay development time was not standardized between plates. Necrosis rates 
have been summarized in Figure 3.6 and apoptosis rates in Figure 3.7. Once the data had 
been standardized across all tests, a t-test was performed to assess the effects of the 
culture medium (LB broth) and the Stx-2-containing supernatant fluid on neutrophil 
apoptosis and necrosis rates. The negative control (without medium or toxin) was 
compared to the LB medium control (medium only), and the medium control was 
compared to the Stx-2 containing supernatant fluid to determine if significant differences 
between neutrophil apoptosis and necrosis rates were observed.
There was a significant decrease (p < 0.05) between the negative control and 
medium control necrosis rates up to and including 18 h suggesting that the medium may 
have provided some protective effect to the neutrophils against necrosis. There was also a 
significant decrease (p < 0.05) in neutrophil necrosis rates between the medium control 
and the neutrophils exposed to Stx-2 up to and including 18 h. At 24 h, the necrosis rates
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Figure 3.6: Necrosis rates of neutrophils exposed to Stx-2 supernate for 72 h. Data 
are presented as the average percent necrosis when compared to the positive assay 
control. Error bars represent the standard deviation calculated between the averaged 
triplicates. Necrosis rates of neutrophils exposed to Stx-2 were significantly reduced 
(p<0.05) at all time points except 24 h.
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Neutrophil Apoptosis Rates Over Time
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Figure 3.7: Apoptosis rates of neutrophils exposed to Stx-2 supernate for 72 h. Data 
are presented as the average percent apoptosis when compared to the positive assay 
control. Error bars represent the standard deviation calculated between triplicates. 
Apoptosis rates of neutrophils exposed to Stx-2 were significantly reduced (p<0.05) at 
the 6  h and 1 2  h time points.
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were similar, but decreased at 48 and 72 h, most likely due to the simultaneous increase 
in apoptosis.
There were no significant differences observed between the negative control and 
medium control apoptosis rates; however, there was a significant decrease (p < 0.05) in 
neutrophil apoptosis rates between the medium control and the neutrophils exposed to 
Stx-2 up to and including 12 h. After that point, the apoptosis rates were similar to the 
controls.
In summary, the data obtained during this study show that neutrophils exposed to 
Stx-2 have less necrosis than the untreated controls at all time points except 24 h, where 
the rates are similar. In addition, the data show that these neutrophils exhibit a delay in 
apoptosis for the first 1 2  h of exposure, followed by an increase in apoptosis that matched 
the controls for the remaining time points tested. This shows that Stx-2 did play a role in 
increasing neutrophil lifespan. The exact mechanism of how this occurs is still to be 
elucidated but it may potentially be due to the interaction of Stx-2 and pro-apoptotic 
proteins other than those tested in this study.
6.0 Discussion
It is thought that neutrophils may provide a way for Stx-2 to be distributed 
throughout the body during infection (195). Therefore, during pathogenesis, it is critical 
that neutrophils remain within the circulation and tissues to provide maximum
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distribution of the toxin, and indeed this is observed (37, 208). Previous studies on the 
impact of Stx-2-induced neutrophil apoptosis have shown conflicting results. Liu et al. 
(118) observed a time- and dose-dependent delay in spontaneous neutrophil apoptosis 
when exposed to Stx-2 whereas Flagler et al. (51) did not. The goal of the present 
experiments was to assess the effects that Stx-2-containing E. coli 0157:H7 supernatant 
fluid had on neutrophil apoptosis and necrosis rates. A cell death detection ELISA was 
used to obtain simultaneous neutrophil apoptosis and necrosis rates following exposure to 
Stx-2. It was hypothesized that Stx-2 influences neutrophil apoptosis by a mechanism not 
related to Bcl-2, Bcl-XL, Bax, Bcl-w or Mcl-1 binding (as determined in Chapter 2) and 
this leads to a decrease in the baseline apoptosis rate, thereby extending neutrophil 
lifespan. A study by Moulding et al. (128) indicated that freshly isolated neutrophils 
produced Bax, Mcl-1, and very low levels of Bcl-2. The data obtained in this study 
showed that neutrophils did not contain B c1-Xl, Bax, Mcl-1 or Bcl-w at 0, 6 , and 18h 
after isolation, but did contain Bcl-2 dimers in freshly isolated neutrophils. In addition, an 
unknown protein was detected in an antibody cross-reaction that corresponded to the 
molecular weight of Bak as seen previously with Caco-2 cells (Chapter 2), however an 
antibody specific for Bak was not available to confirm this. This data and data generated 
previously by Moulding et al. (128) and Ruemmele et al. (163) support the notion that 
Bcl-2 family protein expression does vary during the lifespan of the cell. This may 
influence the interactions of Stx-2 within the cell depending upon at what point the toxin 
is endocytosed.
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Data produced in this study also showed that medium used to grow E. coli 
0157:H7 was protective against Stx-2 induced necrosis but had no effect on Stx-2 
induced neutrophil apoptosis. The reasons for this are unknown, but it is suspected that 
the extra nutrients in the medium allowed the cells to live longer or prevented oxidative 
burst from occurring. Bax was not detected in neutrophils in this study, yet a delay in 
Stx-2 induced apoptosis up to and including 12 h was observed (p<0.05). It is possible 
that Stx-2 bound with the unknown protein suspected to be Bak, in turn reducing 
neutrophil apoptosis. A similar study performed with Helicobacter pylori water extracts 
showed that the expression of Bax and Bak was upregulated in HL-60 cells, human 
promyeolocytic leukemia cells which can differentiate into neutrophil-like cells, during 
neutrophilic differentiation (98). If Bak was upregulated in the experiments performed 
here, it may provide high concentrations of protein for Stx-2 to bind to in the 
endoplasmic reticulum or cytosol, thus leaving the anti-apoptotic proteins free to promote 
cell survival. Stx-2 induced neutrophil necrosis was significantly decreased (p<0.05) at 
all time points except 24 h, showing an overall trend of reduced cellular necrosis. No 
difference in the oxidative burst of neutrophils was found between patients with and 
without HUS (74), therefore it seems that inhibition of oxidative burst could not be the 
cause of reduced necrosis. It is possible, that if Stx-2 bound Bax within the endoplasmic 
reticulum, there would be less Stx-2 available to elicit N-glycosidase activity on the 
ribosomes of the cell, which is the primary cause of Stx-2 induced cellular necrosis (47).
Overall, the data from these assays confirm that a delay in neutrophil apoptosis 
occurs up to and including 12 h after exposure to Stx-2 and a significant decrease in
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necrosis at all time points except 24 h after exposure. It is theorized that this may be a 
result of Stx-2 triggering apoptosis within the endoplasmic reticulum of the cell.
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CHAPTER 4
GENERATION OF MUTANT STX-2 G225A
1.0 Abstract
A mutation was generated in the gene encoding Stx-2 in E. coli 0157:H7 at 
amino acid position 225 using splicing by overlap extension PCR (PCR SOE). The 
objective of this mutation was to change this sequence from NWGRI to NWARI, thereby 
abolishing the ability of the mutated Stx-2 to trigger apoptosis and so demonstrating a 
decreased pathogenicity for the toxin. The mutated gene was ligated to pBR322 and 
transformed into E. coli 0157:H7 strain 43888 (a strain that produced neither Stx-1 nor 
Stx-2) in order to express and purify the toxin and determine its pathogenicity compared 
to native Stx-2.
2.0 Introduction
Apoptosis (programmed cell death) is a normal function of cells. It is mediated by 
the Bcl-2 protein family (46). These proteins are classified into two groups based on 
functional activity; they are either pro-survival or pro-apoptosis proteins, and they are 
divided into three subfamilies: the Bcl-2 subfamily, the Bax subfamily, and the BH3 
subfamily (2). The Bcl-2 subfamily promotes cell survival while the Bax and BH3 
subfamilies promote apoptosis (2). All of these proteins share at least one of four possible
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conserved motifs (BH1, BH2, BH3 or BH4) known as Bcl-2 homology domains which 
play a role in the function of the proteins (2). The proteins with the closest resemblance 
to Bcl-2 contain all four homology domains (2). On the other hand, the Bax and BH3 
subfamilies differ in their homology domain content despite their shared pro-apoptosis 
cellular role and contain only the BH3 domain (95).
The process by which Bcl-2 family proteins regulate apoptosis has been 
documented (4, 151, 177, 181). In essence, BH3-only proteins are activated by signaling 
pathways, and then these activate either proapoptotic proteins or inhibit antiapoptotic 
proteins (or both). Activated proteins form oligomers in the mitochondrial outer 
membrane leading to the release of cytochrome c and other proapoptotic proteins, unless 
they are inhibited by Bcl-2 proteins. These proteins then activate caspases which 
eventually cause the cell to undergo apoptosis (4, 151,177,181).
Both pro-survival and pro-apoptosis proteins have the ability to form homo- and 
heterodimers with each other, suggesting that the relative concentration of the proteins 
may play a role in the outcome of the cell’s fate (144). It is known that the BH1, BH2, 
and BH3 domains strongly influence the formation of homodimers and heterodimers, and 
that these regions create an elongated hydrophobic cleft into which a BH3 amphipathic 
alpha helix can bind (129, 171). Heterodimerization is not required for pro-survival 
function, but it is required for the pro-apoptosis function of proteins in the BH3 
subfamily and possibly also those of the Bax subfamily (2, 36, 95). It is noted that these
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proteins may bind in a preferential fashion, as it has been shown that not all pro-apoptosis 
and pro-survival proteins interact (2 ).
Zhang et al. (227) investigated the mechanisms of Bcl-2 protein family 
interactions under normal and apoptotic conditions in an effort to understand homo- and 
heterodimerization regulation. Their work was accomplished by performing mutations to 
different areas of the Bcl-2 protein and measuring the resultant ability to form homo- and 
heterodimers. Results of the study determined that Bcl-2 dimerization involved the use of 
an acceptor and donor surface shown in Figure 4.1. The acceptor surface was able to bind 
both Bcl-2 and Bax; however, the donor surface was only able to bind Bcl-2 (227).
Suzuki et al (190) investigated the binding capabilities of Bcl-2 and Stx-2 and 
determined that these proteins were able to bind. It is suspected that this interaction 
occurs by mimicking the Bcl-2 protein family. The pentameric amino acid sequence, 
NWGRI that is common to both Bcl-2 and Stx-2 occurs within the center of the acceptor 
surface described by Zhang et al. (227). In order to determine if Stx-2 has the ability to 
heterodimerize with the Bcl-2 family of proteins within neutrophils in the manner 
described by Zhang et al. (227), the present study was designed to examine the rate at 
which neutrophil apoptosis occurs when a point mutation at the center of the aligning 
NWGRI sequence (G225A) is introduced by PCR SOE, a method first described by 
Higuchi et al. (70).
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Figure 4.1: The Bcl-2 dimerization interface. This diagram, adapted from Zhang et al. 
(227), was modeled based upon previously determined Bcl-2 core structure (150). Two 
distinct surfaces were discovered: A) the acceptor surface and B) the donor surface. The 
middle of the binding surface is located at the G145 position (see arrows). This portion of 
the molecule is the same portion that contains the pentameric sequence found in Stx-2 
(NWGRI).
3.0 Hypothesis
An introduced mutation of glycine to alanine at amino acid position 225 in Stx-2 
will result in reduced virulence of Stx-2 due to the inability of the toxin to trigger the 
apoptotic pathways, thereby interrupting the normal apoptotic process in these cells.
4.0 Materials and Methods
Authorization to complete this recombinant DNA project was obtained from the 
UNH Institutional Biosafety Committee (IBC) under approval number R:2-2007 
(Appendix D).
4.1 Determination of E. coli Q157:H7 strain 43888 Susceptibility Profile to 
Ampicillin
A minimum inhibitory concentration (MIC) assay was performed to determine the 
antibiotic susceptibility pattern of E. coli to ampicillin. A solution of ampicillin (Sigma 
Aldrich, St. Louis, MO) was prepared at a concentration of 25mg/mL in sterile PBS and 
filter sterilized. Thirty two pL of this solution was added to 1968pL of LB broth to give a 
final concentration of 400pg/mL ampicillin. A 1:2 dilution series was prepared in 
duplicate by transferring lmL of this broth to a new tube containing lmL fresh LB broth. 
Six tubes were prepared with ampicillin concentrations ranging from 400pg/mL to 
25pg/mL. A positive control was also prepared without ampicillin. Each tube was
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inoculated with 50pL of an overnight culture of E. coli 0157:H7 strain 43888 and 
incubated at 37°C for 24 h. Two hundred pL of each suspension from the 6  tubes 
containing ampicillin and bacteria were added in duplicate to the wells of a 96 well plate, 
and the opacity was read at 600nm on a Biorad 3550 microplate reader (Biorad, Hercules, 
CA).
4.2 Creation of a Recombinant Plasmid: Mutant stx2 with Vector pBR322
4.2.1 Primer Design and PCR
The sequence of Stx-2 producing E. coli 0157:H7 VT2-Sakai (NCBI Reference 
Sequence NC 002695.1) was used for primer design. The stx2 gene comprises two parts; 
the Stx-2 subunit A gene and the Stx-2 subunit B gene with a promoter region. The 
genome encompassing these genes is depicted in Figure 4.2. Primers were created that 
cloned the sequence from base pair 1266525 to 1268219, and these are shown in Table 
4.1. Primers were designed using the GeneFisher2 Interactive PCR Primer Design 
program on the Bielefeld University Bioinformatics Server (BiBiServ) and checked with 
NetPrimer software (Premier Biosoft, Palo Alto, CA). Primers were synthesized 
(Integrated DNA Technologies, Coral ville, I A) and purified using standard desalting 
processes. The complete sequence that was cloned is listed in Figure 4.3. NEBcutter 
(New England Biolabs, Ipswich, MA) was used to determine the appropriate enzyme 
restriction sites to add to the end of the primer sequences to allow for insertion into
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pBR322 (Figure 4.4), thereby eliminating the risk of cutting the cloned sequence during 
insertion.
4.2.2 Mutation of stx2 using PCR SOE
E. coli 0157:H7 strain 90-2380 was grown overnight at 37°C, and genomic DNA 
was isolated using the UltraClean™ Microbial DNA Isolation Kit (MoBio Laboratories 
Inc., Carlsbad, CA) following the manufacturer’s instructions. An alternative lysis 
method was used in order to reduce the amount of DNA shearing and lessen the chance 
of unwanted damage to large DNA. PCR was performed using genomic DNA and the 
primers listed in Table 4.1. The mutagenesis primers were designed using Stratagene’s 
Quick Change Primer Design Program (http://www.stratagene.com/qcprimerdesign.com) 
and the suggested guidelines for mutagenesis primer design in the QuickChange® Site- 
Directed Mutagenesis kit instruction manual. Primers were synthesized by Integrated 
DNA Technologies and purified using polyacrylamide gel electrophoresis (PAGE).
An stx2 mutant construct was generated by PCR SOE following published 
protocols by Horton et al. (71) using the Expand Long Template PCR system and 
supplied Buffer 3 (Roche Applied Science, Indianapolois, IN). The outer forward and 
reverse primers contained engineered restriction enzyme sites (SphI and EcoRI 
respectively) to aid in directional cloning of the cloned stx2 gene. Internal, 
complementary forward and reverse SOE primers containing a single base pair mutation 
(G to C, resulting in a change in protein coding from glycine to alanine) were also
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designed (Table 4.1). The first two PCR amplicons were generated with 1) Stx2-Sphl-F 
with G225A_reverse mutagenic primer and 2) G225A forward mutagenic primer with 
Stx2-EcoRI-R, using the stx2 gene (amplified with Expand HiFi plus enzyme) as a 
template. Following amplification, the PCR products were gel purified (Epock Biolabs, 
Missouri City, TX), combined at equal molarity, and a second round of SOE was 
performed using the purified PCR products as a template and outer primers only (Stx2- 
Sphl-F and Stx2-EcoRI-R). A second PCR amplification was conducted with the purified 
SOE product to increase the yield, and the amplicon was gel purified prior to cloning. 
The expected size of the mutant stx2 gene was 1743bp.
4.2.3 Insertion of Mutant stx2 into pBR322
In order to insert the mutant stx2 gene into pBR322 (see Fig. 4.5), both the SOE 
product and pBR322 were double digested with SphI and EcoRI (New England Biolabs) 
at 37°C for 2 h in the manufacturer’s suggested buffer and this was then heat inactivated 
at 65°C for 20 min. This was performed to remove the tetR gene, allowing screening for 
inserts by sensitivity to tetracycline. Once digestion was complete, the mutant stx2 gene 
was ligated into pBR322 using a 3:1 insert:vector ratio with T4 ligase (New England 
Biolabs). The ligation was performed overnight with thermal cycling alternating between 
10°C for 30 sec and 30°C for 30 sec. This temperature-cycle ligation method was 
demonstrated to have higher cloning efficiency than the typical method ( 1 2 1 ).
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Figure 4.2: Genome map of the stx2 gene. This genome map (base pair 1266525 - 1268219) is courtesy of the 
Comprehensive Microbial Resource (http://cmr.icvi.org/tigr-scripts/CMR/CmrHomePage.cgi). This map is derived from the 
Escherichia coli 0157:H7 VT2-Sakai strain (NCBI Accession # NC 002695) and includes the stx2 subunit A (base pair 
1266965 - 1267924) and stx2 subunit B (base pair 1267936 - 1268205) genes as well as the upstream sequence containing the 
gene promoters (base pair 1266525 - 1266924).
Table 4.1: Primer Sequences
Name Sequence Description
Stx2-Sphl-F 5’- TAT TAA GCA TGC CGG GCG TTTTGAGCA -3’
Forward stx2 primer 
with SphI cutting site
Stx2-EcoRI-R 5’- TAA TGA ATT CGT TAC CCA CAT ACC ACG A -3’
Reverse stx2 primer 
with EcoRI cutting site
G225A1 5’- CTC ACT CTG AAC TGG GCG CGA ATC AGC AAT GTG -3’
Forward stx2 
mutagenesis primer
G225A_antisense1 5’- CAC ATT GCT GAT TCG CGC CCA GTT CAG AGT GAG -3’
Reverse stx2 
mutagenesis primer








Stx2-A2 5’- GCG GTT TTA TTT GCA TTA GC-3’ Forward stx2 primer
Stx2-B2 5’- TCC CGT CAA CCT TCA CTG TA-3’ Reverse stx2 primer
1 These mutagenesis primers were designed using Stratagene’s quick change primer 
design program.
2  These primers were previously designed by Wang et al. (210).
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GTGCAATTGGCGTTGAGCTGGAGAGfGGGCGTTTTGAGCAfiACGGTCAGGGAAGT




















CCTTT AAT AAT AT ATC AGCG AT ACTGGGG ACTGTGGCCGTT ATACTG AATTGCC ATC A
TCAGGGGGCGCGTTCTGTTCGCGCCGTGAATGAAGAGAGTCAACCAGAATGTCAGAT
AACTGGCGAC AGGCCTGTT ATAAAAAT AAAC AAT AC ATT ATGGG AAAGT AAT AC AG








Figure 4.3: Genomic sequence of stx2 from Escherichia coli 0157:117 VT2-Sakai.
Nucleotides 1266500- 1268300 (forward strand). The forward and reverse primers used 
to clone the gene are bolded and boxed respectively near the beginning and end of the 
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Figure 4.4: Restriction enzyme map of the cloned stx2 gene. This restriction enzyme map (base pair 1266525 - 1268219) 
is courtesy of NEBcutter (http://tools.neb.com/NEBcutter2/index.php) and derived from Escherichia coli 0157:H7 VT2- 
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Figure 4.5: Vector map of pBR322. This map is courtesy of New England Biolabs. The 
vector will confer ampicillin and tetracycline resistance to the transformed bacteria 
without inserts. The mutated stx2 segment was inserted at the EcoRI and SphI restriction 
sites, highlighted by the boxes above.
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4.3 Transformation of the Recombinant Plasmid into E. coli Q157:H7 Strain
43888
4.3.1 Preparation of Electrocompetent E. coli Q157:H7 Strain 43888
E. coli 0157:H7 strain 43888 cells were made competent and prepared for 
electroporation through a series of ice-cold centrifugation and washing steps. Fifty mL of 
LB broth was inoculated with E. coli and allowed to incubate overnight at 37°C with 
vigorous shaking. On the following day, lmL of overnight culture was transferred to 
200mL of fresh LB broth and the optical density was measured at 600nm. The new 
culture was placed into the 37°C incubator and monitored hourly until the optical density 
reached approximately 0.400. At that point, the culture was placed on ice and swirled 
gently until well chilled. The culture was split in half, placed into 2 x 250mL pre-chilled 
sterilized centrifuge bottles, and centrifuged at 4,000 x g for 10 min at 4°C. The 
supernatant was discarded, each cell pellet was washed by resuspending in 200mL 
sterilized ice-cold water, and the samples were centrifuged again under the same 
parameters. The cells were washed once more with lOOmL sterilized ice-cold water, and 
centrifugation was repeated a third time. The supernatant was discarded and the pellets 
were resuspended in lOOmL sterilized ice-cold 10% glycerol and combined into one 
centrifuge tube. A final centrifugation at 4,000 x g for 10 min at 4°C was done and the 
electrocompetent cells were resuspended in 2mL sterilized ice-cold 10% glycerol. The 
culture was dispensed into individual microcentrifuge tubes (40pL/tube) and frozen 
immediately at -80°C.
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4.3.2 Electroporation of Electrocompetent E. coli 0157:H7 Strain 43888 cells
with stx2 and pBR322
Clean, sterile electroporation cuvettes with a 1mm gap between side walls were 
placed into an ice bucket and allowed to chill. Each sample was processed separately to 
ensure DNA degradation did not occur prior to exposure to electrical current. Just before 
electroporation, four tubes of electrocompetent E. coli were removed from the -80°C 
freezer and allowed to thaw on ice. Two pL of DNA was added to one tube containing 
thawed electrocompetent E. coli cells for each of the sample types listed in Table 4.2. The 
contents of each tube were subsequently transferred to pre-chilled electroporation 
cuvettes and immediately placed into the electroporator where 1800 volts were applied 
for 4 milliseconds. At this time 400pL of SOC medium (Appendix A, 2.7) was added. 
The suspension was immediately transferred to a sterilized 1.5mL microcentrifuge tube 
and the cells were allowed to recover at 37°C for 1 h with gentle shaking. Upon 
completion of the recovery step, each sample was spun at 10,000 x g for 30 sec, 
resuspended in lOOmL fresh SOC medium, and plated as follows: lOpL was spread onto 
a LB plate as a control to ensure viability of the cells, 90pL was spread onto LB plates 
containing lOOpg/mL ampicillin in triplicate, and 90pL was spread onto a LB plate 
containing 20pg/mL tetracycline.
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Table 4.2: Samples Electroporated Into E. coli 0157:H7 strain 43888
N u m b e r  S a m p l e  N a m e
1 Nuclease-free water (negative control)
2 Supercoiled pBR322 plasmid (positive control)
3 stx2  vector only ligation
4 stx2 vector and pBR322 insert ligation
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4.4 Verification of Recombinant Plasmid Transformation into E. coli Q157:H7
Strain 43888
A selection of ampicillin-resistant colonies was patched onto LB agar plates with 
tetracycline (20pg/mL). The colonies that showed sensitivity to tetracycline were 
screened with PCR using Stx2-Sphl-F and Stx2-EcoRI-R to determine if the mutant stx2 
insert was detected. A plasmid prep and additional PCR reaction using the same primers 
were also performed to confirm that the cells had the mutant 5 /x2 -containing plasmid. An 
additional PCR reaction used cross-junction primers (pBR322-653-R and pBR322-4327- 
R) to ensure that the mutant stx2 gene was inserted into the plasmid at the correct 
location.
Plasmids were purified using the Pure Yield Plasmid Miniprep System (Promega, 
Madison, WI) according to the manufacturer’s instructions. Plasmid DNA was probed 
with two sets of primers. Set 1 consisted of Stx2-A and Stx2-B primers, which amplify a 
115bp product located within stx2. Set 2 consisted of Stx2-B and pBR322-653R primers, 
which amplify a 1649bp segment that spans the stx2 insert and pBR322 vector junction.
Sequencing was performed on four clones (L4, L14, L42, and L94) using 
pBR322-653R and pBR322-4327-R primers. The sequences were blasted using NCBI 
Blast: Nucleotide Sequence and aligned to E. coli 0157:H7 strain Sakai, complete 
genome (Accession # NC_002695.1) to determine homology to stx2.
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4.5 Creation of Mutant Clone Stocks
Overnight cultures of E. coli 0157:H7 mutant clones were frozen at -80°C in LB 
broth containing 15% glycerol and lOOpg/mL ampicillin.
5.0 Results
5.1 Determination of E. coli Q157:H7 strain 43888 Susceptibility Profile to 
Ampicillin
The assay was performed with duplicate samples and results are summarized in 
Table 4.3. No growth was detected in any of the wells containing antibiotic indicating 
that E. coli 0157:H7 strain 43888 was inhibited by ampicillin at concentrations greater 
than or equal to 25pg/mL.
5.2 Creation of a Recombinant Plasmid: Mutant stx2 with Vector pBR322
Primer design, PCR SOE, enzyme digestion, and insert-vector ligation were 
performed and a recombinant plasmid was created as outlined in Figure 4.6. Gel 
electrophoresis indicated a successful PCR SOE product was obtained with a length of 
approximately 1734bp, and analysis of the stx2-pBR322 recombinant plasmid indicated 
successful ligation with the expected overall size of approximately 5,500bp.
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Table 4.3: MIC Assay for E. coli 0157:H7 Strain 43888 and Ampicillin
1 0.485 0.017 0 . 0 0 0 0.005 0.007 -0 . 0 0 1
Ampicillin 2 0.493 0.027 0.008 0.013 0 . 0 1 0 0.004
(Sigma) 3 0.521 0.023 0.029 0.013 0.004 0 . 0 0 1
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Figure 4.6: Vector map of recombinant plasmid stx2-pBR322. This map is adapted 
from New England Biolabs. The mutated stx2 gene is shown inserted at the EcoRI and 
SphI restriction sites. This vector conferred only ampicillin resistance to the transformed 
bacteria.
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5.3 Verification of Recombinant Plasmid Transformation into E. coli Q157:H7
Strain 43888
The stx2-pBR322 recombinant plasmid was successfully transformed into E. coli 
0157:H7 strain 43888. Nine colonies were identified to be ampicillin resistant and 
tetracycline sensitive. PCR results indicated that the following clones contained the 
mutant stx2 inserted at the correct location within the plasmid: L4, LI4, L25, L31, L42, 
L43, L87, L93, and L94 and these are shown in Figure 4.7. The secondary PCR showed 
positive results for the stx2 specific gene primers that produced a 118bp amplicon for all 
samples (Figure 4.8). Results of the plasmid preparation show plasmid bands aligned 
approximately with the 6 ,0 0 0 bp marker; however, the resolution of this marker was not 
very high so it was difficult to detect the precise molecular weight (Figure 4.9). It is 
suggested that this is the stx2-pBR322 plasmid. The remaining bands in the preparation 
were thought to be supercoiled and knicked plasmid DNA.
Results of the sequencing indicated that three (L14, L42, and L94) of the four 
clones contained the point mutation at G225 (Figure 4.10, 4.11, 4.12, and 4.13). The 
identity match of these clones to E. coli 0157:H7 strain Sakai, complete genome 
(Accession # NC_002695) was 94% (L14), 99% (L42), and 92% (L94). The clone that 




Figure 4.7: Verification of recombinant stx2-pBR322 plasmids. A) Lane 2-9 contains 
ampicillin resistant and tetracycline sensitive clones showing the correct insert size of 
1743bp. B) Lane 2 shows ampicillin resistant and tetracycline sensitive clone L94 
showing the correct insert size of 1743bp, Lane 3-5 shows clones having incorrect insert 
sizes, Lane 6  shows PCR SOE control (product prior to ligation with pBR3222), and 
Lane 7-8 show genomic DNA controls for E. coli 0157:H7 strain 90-2380 and 43888 
respectively.
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Lane Description Lane Description
1 500 bp -  10 kbp Ladder 9 L87
2 L4 1 0 L87
3 L14 1 1 L93
4 L25 1 2 L94
5 L31 13 LI (control)
6 L31 14 L7
7 L42 15 L13
8 L43
Figure 4.8: Verification of the stx2 insert within the recombinant stx2-pBR322 
plasmid. The boxed area shows all clones contained the stx2 insert as illustrated by a 
band at approximately 1 2 0 bp.
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Lane Description Lane Description
1 500 bp -  10 kbp Ladder 9 Plasmid prep L31
2 stx2 SOE Product 1 0 Plasmid prep L43
3 90-2380 (positive control) 1 1 Plasmid prep L87
4 43888 (negative control) 1 2 Plasmid prep L42
5 water only control 13 Plasmid prep L93
6 Plasmid prep L4 14 Plasmid prep L94
7 Plasmid prep LI4 15 50 bp-2 kbp Ladder
8 Plasmid prep L25
Figure 4.9: Verification of recombinant plasmid size. Lane 6-14 shows ampicillin 
resistant and tetracycline sensitive E. coli 0157:H7 strain 43888 clones indicating the 
presence of the recombinant stx2-pBR322 plasmid (expected size ~5.5Kbp).
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CTTGGAA— CTCAATTTTACCTTTAGCACAATCCGCCGCCATTGCATTAACAGAAGCTAA
l l l l l l l  l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l  l l l l l l l l l l !  Mi l l  
CTTGGAAAACTCAATTTTACCTTTAGCACAATCCGCCGCCATTGCATTAACAGAAGCTAA
TGCAAATAAAACCGCCATAAACATCCTTCTCCATGCTTAACTACCTTCCTCCACCCGTCA
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1  ini iiiiiiiiiii ini i n u n
TGCAAATAAAACCGCCATAAACATC-TTCTTCATGCTTAACT-CCTTTATTTACCCGTT-
GTCTCTAAAAACAGTGACTCCATCGTCACAGAAACGCTCGCAGCTCGTACTACTCCCCCC
ii i i i i i i i i  m m  i m  m u m  m m  m  m i  m
GTATATAAAAACTGTGACTTTCTGTTCA— GAAACGCT-GCAGCT-GTATTACTTTCCC- 
ATAATCGTACCGCCTACCCCC-TAGCAGGCCTCGTCGCCAGTTACCCGACACCCTGGTCG
h i m  m  i n  ii i i i i i i i  i i i i i i i i i i i  i m i  h i m  i
ATAAT -  GTATTGTTTATTTTTATAAC AGGC C T  -  GTC GC CAGTTATC TGAC ATTC TGGTTG 
ACTCTtTTCATTCACGGCGCGAACAGAACGCGCCCCCTGATGATGGCAACTCAGTATAAC
I I I  I I I I I I  I I I  I I I I  I I I  I I I  I I I I  I I I 11 I I I I  I I I I  I I I  I I I  I I I I l l l l l i l l l l
ACTCTCTTCATTCACGGCGCGAACAGAACGCGCCCCCTGATGATGGCAATTCAGTATAAC 
GGCCACAGTCCCCAGTATCGCTGATATATTATTAAAGGATATTCTCCCCACTCTGACACC
I I I II I I I I I I I I II I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
GGCCACAGTCCCCAGTATCGCTGATATATTATTAAAGGATATTCTCCCCACTCTGACACC
Q u e ry 12
sb jc t 1268028
Q u e ry 70
Sbjct 1267968
Q u e ry 130
Sbjct 1267911
Q u e ry 190
s b jc t 126785 6
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s b jc t 1 2 6779 8
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Q u e ry 369
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Q u e ry 4 2 9
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sb jct 126755 8
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sb jct 126749 8
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sb jc t 126743 8
Q u e ry 669
Sbjct 1 2 6737 8
Q u e ry 729
sb jc t 12 6731 9
Q u e ry 789
Sbjct 1267262
Q u e ry 849
sb jc t 1267203
Q u e ry 909
sb jc t 1267143
ATCCTCTCCCCGATACTCCGGAAGCACATTGCTGATTC( CGC|D
I I I  I I I  I I I  I I I I  I I I I  I I I  I I I  I I I  111111111111!
ATCCTCTCCCCGATACTCCGGAAGCACATTGCTGATTC< CCCtl
CAGTTCAGAGTGAGGTC
I I I I  I I I I I  I I I I  I I I
CAGTTCAGAGTGAGGTC
C ACGTCTCCCGGCGTCATCGTATAC ACAGGAGC AGTTTC AGACAGTGCCTGACGAAATTC 
l l l l l l l l l l l l l l l l l l l l l l l l l l l l l  l l l l l l l l l l l l  l l l l l l l l l l l l l l l l l l l  
CACGTCTCCCGGCGTCATCGTATACACAGGAGCAGTTTCAGACAGTGCCTGACGAAATTC
TCTCTGTATCTGCCTGAAGCGTAAGGCTTCTGCTGTGACAGTGACAAAACGCAGAACTGC
I I I I I II I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II I I 
TCTCTGTATCTGCCTGAAGCGTAAGGCTTCTGCTGTGACAGTGACAAAACGCAGAACTGC
TCTGGATGCATCTCTGGTCATTGTATTACCACTGAACTCCATTAACGCCAGATATGATGA
I I I I I I I I I I I I I I I I I I 11 I I I I I I I 11 I I I I I I I I I I I I I I I I 11 I I I I I I I I I I I I I
TCTGGATGCATCTCTGGTCATTGTATTACCACTGAACTCCATTAACGCCAGATATGATGA
AACCAGTGAGTGACGACTGATTTGCATTCCGGAACGTTCCAGCGCTGCGACACGTTGCAG






i i i i i i i i m i  h i i m i m 1111111m m h i m m 111m i  h i m
GTGTAAAATCTG-AAAAACGGTAGAAAGTATTTGTTGCCGTATTAACGAACCC- -GGCCA 
CATATAAATTATTTTTGCTCAATAATCAGACGAAGATGGTCAAAACGCGCCTGATGGACA
i i i i i i i i i i i  m m m m m m m m m m m m m m i  m i
CATATAAATTA-TTTTGCTCAATAATCAGACGAAGATGGTCAAAACGCGCCTGATAGACA
TCAAGCCCTCGTATATCCACAGCAAAATAACTGCCCGGTGGGGTGTGGTTAATAACAGAC
m m  m m m m m m m m m m m m m m i  i i i i i i i  i i i i
TCAAGCCCTCGTATATCCACAGCAAAATAACTGCCCGGTGGGGTGTGGTTAATAACAGAC 
ACCGATGTGG 918
































Figure 4.10: E. coli clone L14 sequence alignment. Alignment of E. coli clone L14 to 
Accession NC 002695.1 (E. coli 0157:H7 strain Sakai, complete genome). Identity 
match was 94% and the mutation was observed (C->G) at nucleotide 409 of the query 
strand (see boxed area).
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TCCTTAAACTTTGGAAACTCA-TTTTACCTTTAGCACAATtCGCCGCCATTGCATTAACA
ii i i i  m i  i i i i i i i i  i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i n i
tcattatacttggaaaactcaattttacctttagcacaatccgccgccattgcattaaca
GAAGCTAATGCAAATAAAACCGCCATAAACATCTTCTTCATGCTTAACTCCTTTATTTAC
II m i  i ii 11 ii ii i  i i i i  i m i  m u  m i  m i  11 m i  i i i i  11 ii i i i  11 ii i
GAAGCTAATGCAAATAAAACCGCCATAAACATCTTCTTCATGCTTAACTCCTTTATTTAC 
CCGTTGTATATAAAAACTGTGACTTTCTGTTCAGAAACGCTGCAGCTGTATTACTTTCCCI I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II I I I I I........... I I I I I I I I I I I I I I
CCGTTGTATATAAAAACTGTGACTTTCTGTTCAGAAACGCTGCAGCTGTATTACTTTCCC
ATAATGTATTGTTTATTnTATAACAGGCCTGTCGCCAGTTATCTGACATTCTGGTTGAC
n n n n n i n i n n n n i n i i i n i n i n i n n n n n n n n n n  i n
ATAATGTATTGTTTAI I l l'l ATAACAGGCCTGTCGCCAGTTATCTGACATTCTGGTTGAC 
TCTCTTCATTCACGGCGCGAACAGAACGCGCCCCCTGATGATGGCAATTCACTATAACGG
III m i  m i  i n n  11 n  111 n  i m i  i m i  11 n u n  n  i i n  n  11 m i  i n
TCTCTTCATTCACGGCGCGAACAGAACGCGCCCCCTGATGATGGCAATTCAGTATAACGG
CCACAGTCCCCAGTATCGCTGATATATTATTAAAGGATATTCTCCCCACTCTGACACCAT
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
CCACAGTCCCCAGTATCGCTGATATATTATTAAAGGATATTCTCCCCACTCTGACACCAT
CCTCTCCCCGATACTCCGGAAGCACATTGCTGATTC






l l l l l l l l l l l l l l l l l l l
tCAGTTCAGAGTGAGGTCCA
CGTCTCCCGGCGTCATCGTATACACAGGAGCAGTTTCAGACAGTGCCTGACGAAATTCTC
i i n  m i  m i  i n  i n  m i  i i n n  i n  11 m i  m i  n  i n  i m i  i n  m i  n
CGTCTCCCGGCGTCATCGTATACACAGGAGCAGTTTCAGACAGTGCCTGACGAAATTCTC
'rCTGTATCTGCCTGAAGCGTAAGGCTTCTGCTGTGACAGTGACAAAACGCAGAACTGCTC
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II I I I I I
TCTGTATCTGCCTGAAGCGTAAGGCTTCTGCTGTGACAGTGACAAAACGCAGAACTGC'TC
TGGATGCATCTCTGGTCATTGTATTACCACTGAACTCCATTAACGCCAGATATGATGAAA
m m n n m n n m n m m m i n n m n i m n m n i i m i  ii
TGGATGCATCTCTGGTCATTGTATTACCACTGAACTCCATTAACGCCAGATAT6ATGAAA
CCAGTGAGTGACGACTGATTTGCATTCCGGAACGTTCCAGCGCTGCGACACGTTGCAGAG
i n  i i i i i i i  i n  i i i i n i i  i m i i i i  i n  i i i i i i i m i  m i  m n i i i m i  i
CCAGTGAGTGACGACTGATTTGCATTCCGGAACGTTCCAGCGCTGCGACACGTTGCAGAG
TGGTATAACTGCTGTCCGTTGTCATGGAAACCGTTGTCACACCGGGCACTGATATATGTGI I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 11 I I I I I I I I I I I I I I I I I
TGGTATAACTGCTGTCCGTTGTCATGGAAACCGTTGTCAC ACCGGGCACTGATATATGTG
TAAAATCTGAAAAACGGTAGAAAGTATTTGTTGCCGTATTAACGAACCCGGCCACATATA 
I I I I I  1 I I I I I I I I  I l l  I I I I I I I I I I I I I I I I I I I I I I I I I I
TAAAATCTGAAAAAC GGTAGAAAGTATTTGTTGCC GTATTAAC GAACCC GGCCAC ATATA 
AATTATTTTGCTCAATAATCAGACGAAGATGGTCAAAACGCGCCTGATAGACATCAAGCC
i n n i n i i i i i m i  m i i i n i  i n m i i i m i  i m i i i i i i  m m  i m i
AATTATTTTGCTCAATAATCAGACGAAGATGGTCAAAACGCGCCTGATAGACATCAAGCC
CTCGTATATCCACAGCAAAATAACTGCCCGGTGGGGGTGTGGTTAAATAACAGACACCGA



































Figure 4.11: E. coli clone L42 sequence alignment. Alignment of E. coli clone L42 to 
Accession NC 002695.1 (E. coli 0157:H7 strain Sakai, complete genome). Identity 
match was 99% and the mutation was observed (C->G) at nucleotide 400 of the query 
strand (see boxed area).
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CTTGGAA—CTCAATTTTACCTTTAGCACAATCCGCCGCCATTGCATTAACAGAAGCTAA
I I I I I I I  l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l
CTTGGAAAACTCAATTTTACCTTTAGCACAATCCGCCGCCATTGCATTAACAGAAGCTAA 
TGCAAATAAAACCGCCATAAACATCTTCCTCATGCTTAACTCCTTTATT -ACCCGTCTGT
i i i  m i  i i i  i n  m m  ii i i  i i i 11 111111111111111111n  m m  i i i
TGCAAATAAAACCGCCATAAACATCTTCTTCATGCTTAACTCCTTTATTTACCCGT-TGT 
AC-TAAAAACAGTGACTTCATCGCCCAGAAACGCAGCAGCAGTAATACAAACCCATAACG
i i i i i i i i  i i i i i i i  i i 111111111 m u  i i i  i i i  i i i i i i i  i
ATATAAAAACTGTGACTTTCT- GTTCAGAAAC GC TGCAGCTGTATTACTTTCCCATAATG 
TAAAGCATAAAAAC-TAACGGGCCAGTCGCCAGCTACCAGACAAATAGGCCGACACA-TC
i i  i i i  m i  m i  m u m  11 i m i  n  i n  i i
TATTGTTTA T rrriATAACAGGCCTGTCGCCAGTTATCTGACATTCTGGTTGACTCTCTT 
AAAACACGGCGCGAACAGAACGCGCCCCCTGACGACGGCAACCCAGTATAACGGCCACAG
i m m m m m m m m m i  11 m u  m m m m m i i
CATTCACGGCGCGAACAGAACGCGCCCCCTGATGATGGCAATTCAGTATAACGGCCACAG 
TCCCCA6TATCGCTGAC-TATTATTAAAGGATACTCTCCCCACTCTGACACCATCCTCTC
i i i i i i i i i i H i m  m m m m m  i i i i i i i i i i i i m i i i i i i i i i i i i
TCCCCAGTATCGCTGATATATTATTAAAGGATATTCTCCCCACTCTGACAiCCATCCTCTC
Q u e ry 10
s b j c t 12 6802 8
Q u e ry 68
s b j c t 12 6796 8
Q u e ry 127
S b jc t 12 6 7 9 0 9
Q u e ry 18 6
s b jc t 12 6 7 8 5 0
Q u e ry 244
s b j c t 12 6 7 7 9 0
Q u e ry 304
S b jc t 1 2 6773 0
Q u e ry 363
S b jc t 1 2 6767 0
Q u e ry 423
S b jc t 1 2 6761 0
Q u e ry 483
S b jc t 1 2 6755 0
Q u e ry 543
S b jc t 1 2 6749 0
Q u e ry 603
s b j c t 1 2 6743 0
Q u e ry 663
S b jc t 126737 0
Q u e ry 723
S b jc t 1267312
Q u e ry 783
s b j c t 1 2 6725 8
Q u e ry 843
S b jc t 1 2 6719 9
Q u e ry 903
s b j c t 1 2 6714 0
CCCGATACTCCGGAAGCACATTGCTGATTCC :GC
I I I I I I I  I I I  I I I I  I I I  I I I  I I I I  I I I  I I I  I I I
CCCGATACTCCGGAAGCACATTGCTGATTCC :CC
ICAGTTCAGAGTGAGGTCCACGTCTC
11 i i  111 m i  i i  11 i i i  i i  i i i i  i
ICAGTTCAGAGTGAGGTCCACGTCTC
CCGGCGTCATCGTATACACAGGAGCAGTTTCAGACAGTGCCTGACGAAATTCTCTCTGTA
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II I I I I I I I II I I I I I I
CCGGCGTCATCGTATACACAGGAGCAGTTTCAGACAGTGCCTGACGAAATTCTCTCTGTA 
TCTGCCTGAAGCGTAAGGCTTCTGCTGTGACAGTGACAAAACGCAGAACTGCTCTGGATG
11I I I I I I I I 11  Mi l l  I I I I  I I I  Mi l l  I I I I  Mi l  I II  I I I  I I I  l l l l l l  I I I I  I II  I 
TCTGCCTGAAGCGTAAGGCTTCTGCTGTGACAGTGACAAAACGCAGAACTGCTCTGGATG
CATCTCTGGTCATTGTATTACCACTGAACTCCATTAACGCCAGATATGATGAAACCAGTG
I I I I I I I I I I I  I I I  I I I I  I I I I  I I I I  I I I  I I I  I I I  I I I  I I I  I I I I  I I I I  I I I  I I I  I I I I  I
CATCTCTGGTCATTGTATTACCACTGAACTCCATTAACGCCAGATATGATGAAACCAGTG 
AGTGACGACTGATTTGCATTCCGGAACGTTCCAGCGCTGCGACACGTTGCAGAGTGGTAT
I I I II I I I I I I I I I I I I I I I I I I I I II I I I I I I I I I I I I I I I I II I I I I I I I I I I
AGTGAC GACTGATTTGCATTCC GGAAC GTTCCAGCGCTGCGACAC GTTGCAGAGTGGTAT 
AACTGCTGTCCGTTGTCATGGGAAACCGTTGTCACACCGGGGCACTGATATATGTGTAAA
l l l l l l l l l l l l l l l l l l l  l l l l l l l l l l l l l l l l l l  I I I I  I I I I  I I I  I I I I  I I I  I I I
AACTGCTGTCCGTTGTCAT-GGAAACCGTTGTCACACC-GGGCACTGATATATGTGTAAA 
ATCCTGAAAAAACGGTAGAAAGTATTTGTTTGCCGTATTAACGAAACCCCGGCCCCATAA
II I I I  l l l l l l l l l l l l l l l l l l l l l  l l l l l l l l l l l l l l l l  I I I I I I I  I I I  I
AT-CTG-AAAAACGGTAGAAAGTATTTG-TTGCCGTATTAACGAA--CCCGGCCAC AT-A 
TAAATTATTTTTGC TC AATAATC AGAC GAAGATGGTCAAAAC GC GC C TGATAGACATC AA
I I I I I I I  I I I  I I I  I I I I  I I I I  I I I  I I I  11 I I I I  I I I I  I I I I  I I I  I I I  I I I  I I I  I I I  I I I
TAAATTA-TTTTGCTCAATAATCAGACGAAGATGGTCAAAACGCGCCTGATAGACATCAA 
GCCCC TC GTATATC CACAGC AAAATAAC TGCCC GGTGGGGTGTGGTTAATAACAGACATC
I I I I I I II I I I I II I I I I I I I I I I I I I I I I I I II I I I I I I I I I I I I I I I I I I I I I II I
G-CCCTCGTATATCCAC AGC AAAATAACTGCCC GGTGGGGTGTGGTTAATAAC AGAC ACC 
GATGTGGTCCCCTGAGATA 921
l l l l l l l l l l l l l l l l l l l
GATGTGGTCCCCTGAGATA 1267122
67
1 2 6796 9
126



























Figure 4.12: E. coli clone L94 sequence alignment. Alignment of E. coli clone L94 to 
Accession NC 002695.1 {E. coli 0157:H7 strain Sakai, complete genome). Identity 
match was 92% and the mutation was observed (C->G) at nucleotide 395 of the query 
strand (see boxed area).
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s b j c t 1267426
Query 728
s b j c t 1267375
Query 788
s b j c t 1267330
Query 848
s b j c t 1267283
TCATTAGTATTTACCACTGAACTCCATTAAACGCCAGATATGGATGAAACCAGTGAAGTG 667
m u  m u  i i i i i i i i i i i i i i i i  i i i i i i i i i i i i  i i i i i i i i i i i i i  m i
TCATT-GTATT-ACCACTGAACTCCATT-AACGCCAGATAT-GATGAAACCAGTG-AGTG 1267427  
ACGACTGATTTTGGCATTCCGGTAACGGTTCCCAGCGGCTGCGACACGGTTTGCAGAGTT 727
i i i i i i i i i i i  i i i i i i i i i  m i  i i n n  n n n n n i  n n n n i
ACGACTGATTT— GC ATTCCGG-AACG- -TTCCAGC -GCTGCGAC ACG- -TTGCAGACT -  1267376
GGCTATTAACTGCCTGGTCCCGG 11IGI I LATGGAAAACCCG'I ITfa I 'lCACACTCGGGGT 787
i n  i i i i i i i  m i  i n  n n n n i  i n n  n u n  m i
-GGTA-TAACTGC -  -TGTCC— GTT--GTCATGGAAA--CCGTT -  -GTCACAC -CGGG- -  1267331
CATCTTGATTATATTTGTGGTAAAAATCrrGAAAAAACCGGTAGAAAGGTATnTGGTTG 847
n  i n  i n n  i n  m m  i i i i i i i  n n n n i  m m  n i l
CA— CTGA-TATATGTGT--------AAAATC -TGAAAAA— CGGTAGAAA-GTATTT— GTTG 1267284
GCTCGCTATTAACGGAACC 866
i i i i i i i i  i n n
 CCGTATTAAC-GAACC 1267269
Figure 4.13: E, coli clone L4 sequence alignment. Alignment of E. coli clone L4 to 
Accession NC 002695.1 (E. coli 0157:H7 strain Sakai, complete genome). Identity 
match was 78% and the mutation was not observed (sequence quality was poor).
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6.0 Discussion
Whether or not Stx-2 binds to Bcl-2 family proteins seems to be a controversial 
topic. Previous research has indicated that Stx-2 binds Bcl-2 (190) however this could 
not be repeated in the studies performed in Chapter 2. The effects that Stx-2 has on the 
apoptosis of neutrophils has also been debated in the past (51,118) and studies performed 
in Chapter 3 showed that a Stx-2-induced delay in neutrophil apoptosis was observed for 
up to 12 h, and could be due to the binding of Stx-2 with Bak in the endoplasmic 
reticulum. An additional method to determine if binding between Stx-2 and apoptosis 
related proteins occurs is through the use of a Stx-2 mutant. Annis et al. (4) has used 
mutants to determine the contribution of Bcl-2 family proteins in the endoplasmic 
reticulum or mitochondria numerous times. One study performed by Yin et al. (225) 
indicated that a mutation to a portion of the NWGRI sequence of Bcl-2 resulted in failure 
of heterodimerization with Bax. It was believed that if Stx-2 bound with Bcl-2 family 
proteins through this same binding site, mutation of Stx-2 at the NWGRI sequence should 
also result in the failure of dimerization between Stx-2 and other proteins. The goal of 
these experiments was to perform a point mutation in the stx2 gene, specifically to the 
region encoding the glycine residue within the pentameric sequence NWGRI at amino 
acid position 225, and change it to alanine in a manner similar to that performed by Yin 
et al. (225) with Bcl-2. This gene would then be ligated into pBR322, and finally 
transformed into E. coli 0157:H7 strain 43888 (a Stx-2 negative strain) for purification. 
It was hypothesized that this mutation would result in a mutant protein that was less 
pathogenic than the wild-type due to its inability to trigger the apoptotic pathways. Data
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obtained indicated successful mutation of glycine to alanine at position 225 within stx2. 
This mutant gene was also successfully inserted into pBR322 and transformed into E. coli 
0157:H7 strain 43888 which does not produce either Stx-1 or Stx-2.
In these experiments, a mutant Stx-2 protein was created containing an alanine at 
amino acid position 225 such that the pentameric sequence reads NWARI. Having a 
mutant toxin will help elucidate the mechanisms of Stx-2 action within host cells, 
especially when determining the role of Stx-2 in the apoptotic pathway. Further 
experiments with this mutant toxin will be done to determine the effects it has on Vero 
cell cytotoxicity, neutrophil apoptosis and necrosis rates, as well as activation of caspase- 
8  and caspase-9 within neutrophils.
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CHAPTER 5
THE EFFECTS OF MUTANT STX-2 AND NATIVE STX-2 WITH AN 
INTERLEUKIN- 8  INHIBITOR ON NEUTROPHIL APOPTOSIS, NECROSIS, AND 
CASPASE- 8  AND CASPASE-9 ACTIVATION
1.0 Abstract
Apoptosis is mediated by the Bcl-2 protein family (4, 151, 177, 181) and these 
may bind with Stx-2 through a conserved NWGRI amino acid motif. A mutation was 
introduced into Stx-2 to change the NWGRI sequence to NWARI, influencing apoptotic 
outcomes. Other factors that may influence human neutrophil apoptosis include the 
presence of Interleukin- 8  (IL-8 ), which results in a delay of spontaneous and TNF-a- 
mediated apoptosis in both a dose- and time-dependent manner (96). This process is not 
reliant on inducing expression of Bcl-2 especially within the first 30 h (96). In this study, 
apoptosis and necrosis rates of isolated human neutrophils were examined at intervals of 
0, 6 , 12, 18, 24 and 48 h following exposure to Stx-2 from E. coli 0157:H7 or to mutant 
Stx-2 (G225A cloned from E. coli 0157:H7 strain 90-2380). An IL- 8  inhibitor together 
with Stx-2 was studied to determine if IL- 8  contributed to the delay in apoptosis. 
Caspase- 8  and 9 levels were examined to determine which apoptotic pathway was 
involved. Data indicated that although there was no clear correlation between delayed 
apoptosis due to Stx-2, it was clear that cells exposed to mutant Stx-2 had apoptosis rates 
similar to those of the untreated cells.
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2.0 Introduction
Human neutrophils routinely are subjected to relatively rapid apoptosis 
(programmed cell death) and typically have a short circulating lifespan of approximately 
is 6-18 h (113). Approximately 1010 neutrophils are produced daily, and these account for 
45-75% of the total white blood cell count (113). Neutrophils are the first responders 
during infection, and these cells are capable of phagocytozing foreign material and in an 
attempt to clear the infection, they release reactive oxidative intermediates (113).
Apoptosis is a normal function of cells mediated by the Bcl-2 protein family (46). 
These proteins consist of anti-apoptotic (pro-survival) and apoptotic (pro-death) proteins 
that possess conserved homology domains. It is through these conserved homology 
domains that these proteins interact with each other, and the relative ratio of unbound 
protein type (i.e. pro-survival or pro-death) available in the cell determines the ultimate 
fate of the cell (46).
Exposure of neutrophils to Interleukin- 8  (IL-8 ) results in a delay of spontaneous 
apoptosis as well as of TNF-a-mediated apoptosis in both a dose- and time-dependent 
fashion (96). During the early phases of apoptosis (within the first 30 h) this process is 
not determined by the expression of Bcl-2 (96). Phenomena that can be induced in human 
neutrophils following exposure to IL- 8  included: changing shape (221); actin 
polymerization (216); degranulation (123); and up-regulation of adhesion molecules (43).
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Stimulated neutrophils can release a variety of cytokines including IL- 8  and TNF-a (6 , 
27). TNF-a can rapidly increase neutrophil apoptosis 2 h after exposure (97,143,192).
Data from previous studies have shown conflicting results as to whether 
neutrophil apoptosis is delayed following exposure to Stx-2. Liu et al. (118) concluded 
that Stx-2 derived from E. coli 0157:H7 exhibited both a dose- and time- dependent 
inhibition of spontaneous neutrophil apoptosis, possibly involving the protein kinase C 
pathway. Flagler et al. (51) were unable to demonstrate a Stx-2 and neutrophil interaction 
nor did they observe an altered apoptosis rate when cells were exposed to lpg/mL of Stx- 
1 or Stx-2. In agreement with Liu et al. (118), Suzuki et al. (190) reported that Bcl-2 did 
bind Stx-2. Further analysis of the Bcl-2 protein family (Chapter 2, pg. 56-57) indicated 
that Stx-2 has the potential to bind with all Bcl-2 family members through a conserved 
NWGRI amino acid motif, but binding was not detected to Bcl-2, B c1-X l or Bax isolated 
from Caco-2 cells.
The timing (increase or delay in the rate) of human neutrophil apoptosis was 
examined over the course of 48 h following exposure of cells to 5 ng semi-purified Stx-2 
from E. coli 0157:H7 strain 90-2380 and also to 5 ng mutant Stx-2 (G225A cloned from 
E. coli 0157:H7 strain 90-2380). The impact of IL- 8  inhibitor at concentrations of 
0.0 ImM was also examined at the same time as treatment with Stx-2 to determine if the 
presence of IL- 8  contributed to a delay in apoptosis previously seen in past 
experimentation (Chapter 3, pg. 109-112). Caspase- 8  and caspase-9, cellular components
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critical to apoptosis induction, were evaluated to better understand which apoptotic 
pathways were involved.
3.0 Hypothesis
Neutrophils treated with mutant Stx-2 will show apoptosis rates that align with the 
baseline (untreated) apoptosis rate, resulting from an inability to trigger the apoptosis 
pathway. Alternatively, neutrophils treated with Stx-2 in combination with an IL- 8  
inhibitor will also show apoptosis rates that align with the baseline (untreated) apoptosis 
rate. The presence of IL- 8  will contribute to a delay in apoptosis as opposed to Stx-2 
alone.
4.0 Materials and Methods
4.1 Purification of Stx-2
E. coli 0157:H7 strain 90-2380 was inoculated into LB broth and allowed to grow 
overnight at 37°C with shaking. The following day, the culture was aliquoted into sterile 
100x15mm Petri dishes (lOmL per dish). The lids were removed, and the culture was 
exposed to ultraviolet (UV) light in a biosafety cabinet for 30 minutes. Subsequent to UV 
exposure, the dishes were transferred to a 37°C incubator and allowed to incubate for an 
additional 48 h.
148
Following incubation, the culture samples were pooled and centrifuged at 16,000 
x g for 15 min at 4°C. The supernatant fluid was collected and sterile filtered using 
Millex 0.45pm low protein-binding membranes (Millipore Corp, Bedford, MA). The 
toxin was precipitated using ammonium sulfate precipitation. First, ammonium sulfate 
was slowly added to the supemate until the concentration was 40%. The mixture was 
centrifuged and the supernatant fluid was transferred to a new beaker. The ammonium 
sulfate concentration was increased to 70%, and the mixture was again centrifuged. The 
pellet was resuspended in 25mL PBS and placed into a Slide-a-lyzer® 20 kDa molecular 
weight cut off dialysis cassette (Thermo Scientific, Rockford, IL). The cassette was 
inserted into a tank containing 4L PBS and incubated overnight at 4°C. On the following 
day, the buffer was exchanged and the cassette was incubated at room temperature for an 
additional 5 h with two buffer exchanges during the incubation period. The cassette was 
unloaded and the semi-purified Stx-2 was loaded into a 100 kDa Centricon device and 
spun at 3220 x g for 15 min. The filtrate was collected and processed through an Amicon 
50 kDa device for 15 minutes. The retentate was collected and measured for total protein 
concentration using the A2 8 0  method on the Nanodrop spectrophotometer. An A2 8 0  / A2 6 0  
reading was also performed to determine protein purity. Approximate protein 
concentrations were calculated from this data using the Warburg-Christian Method (211).
4.2 Purification of Mutant Stx-2
Escherichia coli 0157:H7, strain 43888 (the otherwise toxin negative strain), L42 
mutant with the Stx-2 insert was inoculated into LB broth containing 50pg/mL ampicillin
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and allowed to grow for 72 h at 37°C with shaking. Following incubation, the culture was 
placed in a -20°C freezer for 48 h to aid in cellular disruption. The culture was then 
thawed and processed using a B-PER® Bacterial Protein Extraction Reagent (Thermo 
Scientific). The bacterial cells were centrifuged at 5,000 x g for 10 min and 4mL of B- 
PER® reagent was added per gram of cell pellet. The suspension was mixed by pipette to 
homogeneity and allowed to incubate for 15 min at room temperature. The lysate was 
centrifuged at 15,000 x g for 5 min to separate the soluble and insoluble proteins. The 
fluid phase was collected and processed through Pierce Detergent Removal Spin 
Columns (Thermo Scientific) according to the manufacturer’s instructions. The sample 
was then loaded into a Slide-a-lyzer® 20 kDa molecular weight cut off dialysis cassette 
(Thermo Scientific), placed into a tank containing approximately 4L PBS and incubated 
for 48 h at 4°C. The buffer was exchanged and the cassette was incubated for 24 h at 4°C 
and the resultant semi-purified mutant Stx-2 was loaded into a 100 kDa Centricon device 
and centrifuged at 3220 x g for 15 min. The filtrate was collected and 20mL of PBS was 
added. The sample was then processed through an Amicon 50 kDa device for 15 min. 
The retentate was collected and measured for total protein concentration using the A2 8 0  
method on the Nanodrop spectrophotometer. An A2 8 0  / A2 6 0  reading was also performed 
to determine protein purity. Approximate protein concentrations were calculated from 
this data using the Warburg-Christian Method (211).
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4.3 Conjugation of STX2-11E10 Antibody
Horseradish peroxidase (HRP) was conjugated to the mouse STX2-11E10 
antibody (Toxin Technology) using the EZ-Link™ Plus Activated Peroxidase Kit 
(Thermo Scientific). One mg of lyophilized EZ-Link™ Plus activated peroxidase was 
resuspended with lOOpL of MilliQ water and added to lmL PBS containing lmg/mL of 
STX2-11E10. Ten pL of cyanoborohydride was added to this reaction mixture in the 
fume hood and allowed to incubate for 1 h at room temperature. Twenty pL of quenching 
buffer (3M ethanolamine, pH 9) was added and allowed to react at room temperature for 
15 min.
The conjugated antibody was then purified using the Pierce Conjugate 
Purification Kit (Thermo Scientific). An immobilized Iminodiacetic acid column was 
activated by adding 10-20mL of TBS and allowing the fluid to drain through the column. 
When the flow of TBS had stopped, 2mL of Pierce column activator buffer was added 
and once the flow had stopped a second time, it was incubated for an additional 5 min. A 
column wash was then performed with 10-20mL of TBS to remove non-bound nickel. 
The conjugated antibody was added to the activated column followed by 5-10mL of TBS. 
This was then allowed to drain through. Elution buffer (1.7mL) was applied to the 
column forming a blue band indicating the elution front and an additional 0.8mL of 
elution buffer was added and the blue liquid was collected.
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Buffer exchange was subsequently performed on the conjugate by loading it on a 
polyacrylamide desalting column that was previously equilibrated with 50mL of PBS. 
Half mL aliquots of PBS were added to the column for each fraction collected and 16 
fractions were collected in total. Fractions were tested for enzyme activity by adding 2pL 
of each fraction to separate tubes containing lmL TBS with 0.05% Tween-20. Five pL 
from each prepared tube was then added to a 96-well microtiter plate and lOOpL of 1-step 
ABTS (Thermo Scientific) was added to each well. The first three fractions with the 
highest enzyme activity were pooled and stored at 2-8°C.
4.4 Verification of Stx-2 and Mutant Stx-2 Presence and Activity
SDS-PAGE and Western blot were performed to verify the presence of Stx-2 and 
mutant Stx-2 in the semi-purified preparations. SDS-PAGE was performed under both 
reducing and non-reducing conditions. Samples were diluted 1:2 in sample preparation 
buffer (Appendix A, 4.13), and treated in each of three ways; 1) samples were heated at 
95°C for 5 min with P-mercaptoethanol added (reducing), 2) samples were heated at 
95°C for 5 min 3) samples were not heated and P-mercaptoethanol was not added (non­
reducing). Protein from the semi-pure Stx-2 samples was added at 2.4pg/well and from 
the mutant Stx-2 samples at 1.4pg/well. All samples were loaded onto a 4-20% Tris-HCl 
gel cassette (Bio-Rad, Hercules, CA), and run at 300V for 20 min. The gel was then 
stained with GelCode Blue Safe Protein Stain (Thermo Scientific) for 2 h, and destained 
with water overnight until the background was no longer blue, and visible protein bands 
were observed.
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A Western blot was performed under reducing conditions with the Stx-2 and 
mutant Stx-2 samples which were diluted 1:2 in sample preparation buffer. These were 
heated at 95 °C for 5 min with P-mercaptoethanol added. Samples were loaded onto a 4- 
20% Tris-HCl gel cassette (Bio-Rad) in duplicate and run at 300V for 20 min. The gel 
was aligned onto a polyvinylidene fluoride (PVDF) membrane (Millipore Corp), and 
placed into a transfer sandwich consisting of fiber pads and filter paper (Figure 2.1, pg. 
49). The transfer sandwich was placed in a buffer tank containing Tris-glycine buffer 
(TGB) (Appendix A, 4.19) and proteins were transferred at 60V for 4-5 h. After transfer, 
the membrane was processed for Western blotting using the Snap ID Protein Detection 
System (Millipore Corp). The blot holder was opened and thoroughly soaked with MilliQ 
water. The pre-wet blot was placed into the blot holder protein side down and gently 
rolled to remove all air bubbles. A spacer was placed on top of the blot membrane and 
rolled again to ensure contact of the spacer with the blot membrane. The blot holder lid 
was closed and placed into the chamber of the Snap ID system ensuring that the blot 
holder tabs were aligned with the notches of the chamber. To block the membrane, 30mL 
of TBS containing 0.1% Tween 20 and 0.5% dry non-fat milk was added and the vacuum 
was turned on until all the fluid passed through the blot. Next, 3mL of HRP-conjugated 
mouse anti-Stx-2 antibody, STX2-11E10, (lOpg/mL) (Toxin Technology, Sarasota, FL) 
containing lpL of StrepTactin-HRP conjugate (to detect the bands of the Precision Plus 
Protein™ WestemC™ standards) (Bio-Rad) was added to the blot and incubated for 10 
min at room temperature. Once the incubation was complete, the vacuum was turned on 
and the blot was washed three times with 30mL of TBS with 0.1% Tween 20. The blot
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was removed from the Snap ID system and incubated with the Immun-Star WestemC™ 
kit (Bio-Rad) for CCD imaging.
In order to determine if the Stx-2 preparation was biologically active after the 
purification procedure and what type of biological activity the mutant Stx-2 preparation 
had, African green monkey kidney cells (Vero cells) were exposed to the semi-pure 
preparations for 96 h. Vero cells were grown in three 25cm tissue culture flasks. Once 
confluent, the first flask remained untreated, to the second flask 50pL of mutant Stx-2 
was added, and to the third 50pL of Stx-2 was added. The control and test flasks were 
incubated at 37°C in 5% CO2 for 96 h. Each flask was observed at 200x total 
magnification using an inverted phase-contrast microscope for the presence of cytotoxic 
effects.
4.5 Quantitation of Stx-2 and Mutant Stx-2 Using Enzvme-Linked
Immunosorbent Assay (ELISA)
The concentration of Stx-2 and mutant Stx-2 was determined using a sandwich 
“capture” ELISA (Figure 5.1). Two hundred pL of the primary antibody STX2-BB12 
specific to the B-subunit of Stx-2 (20pg/mL) was added to the wells of a 96-well plate 
and allowed to incubate at room temperature for 2 h while shaking. Unbound antibody 
was removed from the wells and 300pL of PBS was added to each well and the plate was 
rinsed with shaking for 5 min to remove excess antibody. This wash was repeated three 
times and then 300pL of blocking buffer was added to the wells and incubated at room
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temperature for an additional 2 h while shaking. Once again, the liquid was removed 
from the wells and they were washed three times using the same procedure described 
above. Once the plate had been copiously rinsed, 200pL of 1:2 dilutions containing 
2 pg/mL to 31.25 ng/mL of a commercial Stx-2 preparation (Toxin Technology) were 
added to the plate in triplicate to generate a standard curve (Figure 5.2). Next the Stx-2 
and mutant Stx-2 were added to the wells of the plate in triplicate and the plate was 
incubated at room temperature for 2 h with shaking. After the wells of the plate were 
emptied and rinsed three times, 200pL of the secondary antibody STX2-11E10 HRP- 
conjugate (5pg/mL) was added to each well and incubated again for 2 h at room 
temperature with shaking. A final series of rinses was performed five times with 300pL 
of PBS incubated at room temperature for 5 min with shaking and 150pL of 1-Step 
ABTS (Thermo Scientific) was added to each well and developed for 10 min at room 
temperature. The reaction was stopped by the addition of lOOpL of 1% SDS and 









Figure 5.1: Setup of a sandwich ELISA. A primary or capture antibody is affixed to a 
microtiter plate and the antigen of interest is bound. A secondary antibody conjugated 
with an enzyme is bound to the antigen and developed with a substrate to produce a color 




= mutant Stx-2 sample 
= Stx-2 sample
= PBS Blank with entire process 
= ABTS Solution only!! (no antibody) 
= empty w dl
Figure 5.2: Setup of the ELISA plate. The standard curve was diluted 1:2 and tested in triplicate. Values listed represent the total 
number of nanograms of commercially prepared Stx-2 per well. Stx-2 and mutant Stx-2 samples were also diluted 1:2 and tested in 
triplicate along with PBS blank and ABTS controls (n=5).
4.6 Isolation of Human Neutrophils
Neutrophils were collected from human blood using the Sigma Aldrich leukocyte 
separation method shown in Figure 3.1 on pg. 96. Three mL of Histopaque™ 1119 was 
added to a 15mL conical tube and 3mL of Histopaque™ 1077 was carefully layered on 
top followed by 6mL of human blood. The tubes were centrifuged at 700 x g for 30 min 
at room temperature. After centrifugation, layer B containing the granulocytes was 
aseptically transferred using a pipette to a 50mL conical tube and an equal volume of 
modified Hank’s balanced salt solution (HBSS) was added. The cells were washed by 
centrifugation at 250 x g for 10 min at room temperature and the supernatant fluid was 
removed. The cell pellet was resuspended in 12mL of 0.2% NaCl for 30 sec to lyse any 
remaining red blood cells. The suspension was then returned to an isotonic state with the 
addition of 12mL of 1.6% NaCl and centrifuged at 250 x g for 10 min. This was repeated 
three times until all red blood cells were lysed. The neutrophils were resuspended in 2mL 
RPMI-1640 (Appendix A, 5.4), assessed for viability with trypan blue, and counted using 
a hemocytometer.
4.7 Analysis of Neutrophil Apoptosis and Necrosis Rates Following Exposure to 
Native and Mutant Stx-2
Neutrophil apoptosis and necrosis rates were measured over time at 0, 6, 12, 18, 
24 and 48 h using the Cell Death Detection ELISA kit (Roche Diagnostics). This ELISA 
detects fragmented DNA and histone complexes. Neutrophils were isolated as described
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previously, a suspension was made in RPMI-1640 containing 50,000 cells/mL and 200pL 
was dispensed into each well of a 96-well plate (see Table 5.1 for time points). A separate 
plate was used for each time point. Three blood samples from different donors were 
tested in triplicate (n=9 total). The negative control consisted of neutrophils only (C), the 
IL-8 inhibitor control consisted of neutrophil suspension plus 0.01 mM IL-8 inhibitor (I), 
while the test samples consisted of the neutrophil suspension plus the semi-pure protein 
preparations containing either 5 ng mutant Stx-2 (M) or 5 ng of Stx-2 (T), or the 
neutrophil suspension plus 5 ng Stx-2 and 0.0 ImM IL-8 inhibitor (TI).
For each time point, the 96-well plate was centrifuged at 200 x g for 10 min and 
the supernatants were collected and held at 2-8°C to assay for necrosis. The cell pellet 
was lysed for 30 min at room temperature with the lysis buffer provided in the kit, the 
plate was centrifuged again at 200 x g for 10 min, and the supernatant fluid was analyzed 
for apoptosis. Twenty uL of each supernatant sample (pre-lysis and post-lysis), positive 
control (DNA-histone-complex), and background control (incubation buffer) were 
transferred to a streptavidin coated plate and 80uL of immunoreagent containing 
incubation buffer, anti-histone biotin, and anti-DNA-POD were added. The samples were 
shaken at 300 rpm for 2 h at room temperature, rinsed three times with 300pL incubation 
buffer each wash, and developed with lOOpL ABTS. Absorbance was measured at 
405nm using a SpectraMax M5 plate reader with SoftMax Pro v5.4.2 (Molecular 
Devices, Sunnyvale, CA).
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1 10,000 cells were added to each well suspended in 200pL RPMI-1640. A separate plate 






Negative control (neutrophils only)
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4.8 Analysis of Neutrophil Casoase-8 and Capase-9 Activation Following
Exposure to Native and Mutant Stx-2
Caspase-8 and Caspase-9 activation were monitored at times 0, 6, 12, 18, 24, and 
48 h after exposure to Stx-2 and mutant Stx-2. In addition, the effect of an IL-8 inhibitor 
was analyzed to better understand the type of apoptotic trigger(s) involved. Enzyme 
activation was detected using the Caspase-Glo® 8 and Caspase-Glo® 9 Assays 
(Promega). All reagents were prepared according to the manufacturer’s instructions with 
the addition of the MG-132 inhibitor. Neutrophils were isolated from whole blood and 
diluted in RPMI-1640 to give a concentration of 50,000 cells/mL. One mL was placed in 
glass test tubes and treated as follows: sample 1, negative control, untreated (C); sample 
2, IL-8 inhibitor added at O.lmM (I); sample 3 mutant Stx-2 added at 0.25 ng/pL (M); 
sample 4, Stx-2 added at 0.25 ng/pL (T); and sample 5, Stx-2 added together with IL-8 
inhibitor at 0.25 ng/pL and O.lmM, respectively (TI). All tubes were allowed to incubate 
at 37°C in 5% CO2  until the elapsed time point. At each time point, the tubes were gently 
mixed and 20pL of neutrophil cell suspension was added in triplicate to wells of a 384- 
well plate for each caspase test. Twenty pL of caspase-8 or caspase-9 reagent was added 
to each well, gently mixed for 30 sec and allowed to incubate at room temperature for 45 
min. After incubation was complete, the plate was assayed for luminescence using a 
SpectraMax M5 plate reader with SoftMax Pro v5.4.2 (Molecular Devices).
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5.0 Results
5.1 Verification of Stx-2 and Mutant Stx-2 Presence and Activity
The purification of Stx-2 from E. coli 0157:H7 strain 90-2380 (native Stx-2) and 
mutant Stx-2 from the L42 mutant of E. coli 0157:H7 strain 43888 (mutant Stx-2) was 
achieved as demonstrated by total protein concentration and purity, SDS-PAGE, and 
Western blot.
To determine total protein concentration and purity of the native and mutant Stx-2 
preparations, optical densities were taken at A2 8 0nm and A2 6 0nm. The total protein 
concentrations were determined to be 0.300 mg/mL for native Stx-2 and 0.110 mg/mL 
for mutant Stx-2 while the purity (as determined by the A2 8 0  / A2 6 0  ratio) was 1.05 for 
native Stx-2 and 0.810 for mutant Stx-2. These values indicate the presence of nucleic 
acid which can influence the total protein concentration accuracy. Correction factors of 
0.81 and 0.63 were applied to the native and mutant Stx-2 values respectively in 
accordance with the Warburg-Christian Method (211). The final protein concentrations 
were determined to be 0.243 mg/mL protein with 3.5% nucleic acid (native Stx-2) and 
0.069 mg/mL protein with 6.0% nucleic acid (mutant Stx-2).
SDS-PAGE of semi-purified native Stx-2 (panel A) and mutant Stx-2 (panel B) 
are shown in Figure 5.3. Target protein load was 2.4 pg for native Stx-2 and 1.4 pg for 
mutant Stx-2. As can be seen by comparing lanes 2, 3, and 4 with each other in panel A,
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Figure 5.3: SDS-PAGE analysis of semi-purified native and mutant Stx-2. A) Broad-range Precision Plus Protein WestemC 
standards (Bio-Rad) are in Lane 1, semi-pure Stx-2 under non-reducing conditions is in Lane 2, semi-pure Stx-2 under heat only 
conditions is in Lane 3, and semi-pure Stx-2 under reducing conditions is in Lane 4. B) Broad-range Precision Plus Protein 
WestemC standards (Bio-Rad) are in Lane 1, semi-pure mutant Stx-2 under non-reducing conditions is in Lane 2, semi-pure Stx-2 
under heat only conditions is in Lane 3, and semi-pure Stx-2 under reducing conditions is in Lane 4. No differences in band pattern 
were observed.
it was evident that there was no difference in the protein profile for the semi-purified 
toxin whether untreated, heated, or subjected to reducing conditions. Similarly, no 
differences were noted in the protein profiles of the mutant Stx-2 under reducing, non­
reducing, or heated conditions despite the faintness of the band patterns. In addition there 
appears to be fewer bands in the mutant Stx-2 preparation than in the native Stx-2 
preparation. It seems likely that this is due to the differences in loading concentration and 
in the purification procedure.
Figure 5.4 illustrates the Western blot of semi-purified native and mutant Stx-2 
treated with the HRP-conjugated STX2-11E10 antibody. There was a band visible in 
each sample at approximately 32 kDa as highlighted by the boxed areas. These bands 
show the A-subunit of native and mutant Stx-2 and confirm the presence of the toxin in 
both samples.
The biological activity of Stx-2 and mutant Stx-2 on Vero cells was observed at 
200x magnification and is illustrated in Figure 5.5. Panel A shows untreated Vero cells 
while panel B corresponds to Vero cells treated with 50pL of semi-purified mutant Stx-2 
and panel C shows Vero cells treated with 50pL of semi-purified native Stx-2. Cytotoxic 
effects typical of Stx-2 were observed in the cell monolayers (rounded, refractile and 
dead cells with monolayer thinning) as evident in panel C of Figure 5.5. Minimal 
cytotoxic changes were observed in the cells from the mutant Stx-2 indicating that the 
point mutation within the NWGRI motif had a profound impact on the ability of Stx-2 to 
cause cellular damage in these otherwise highly sensitive cells.
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5 .
Figure 5.4: Western blot analysis of toxin preparations. Broad-range Precision Plus 
Protein WestemC standards are in Lane 1, semi-pure native Stx-2 preparation probed 
with HRP-conjugated STX2-11E10 is in Lane 2, and semi-pure mutant Stx-2 preparation 
probed with HRP-conjugated STX2-11E10 is in Lane 3. The A-subunit of Stx-2 and 
mutant Stx-2 was detected in the boxed areas of Lane 2 and 3, respectively.
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Figure 5.5: Biological Activity of semi-purified Stx-2 and mutant Stx-2 viewed at 
200x magnification. A) Image of untreated Vero cells after 96 h. B) Image of Vero cells 
after 96 h incubation with 50jj.L semi-purified mutant Stx-2. C) Image of Vero cells after 
96 h incubation with 50pL semi-purified native Stx-2. Cytotoxic effects are evident by 
the large number of rounded and reffactile cells in panel C. Note that the cells treated 
with mutant Stx-2 were similar to controls and showed minimal cytopathic changes.
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5.2 Quantitation of Stx-2 and Mutant Stx-2 Using ELISA
Standard curves were assayed in triplicate and the results are shown in Figure 5.6. 
The average background absorbance was calculated between the quintuplet blanks, and 
this value was subtracted from the total absorbance reading in each well. Three points 
were used to generate a standard curve between 25 and lOOng of Stx-2. The triplicate 
standard curve values were averaged and plotted to produce an average standard curve 
with a correlation coefficient (r2) of 0.9673.
The total Stx-2 protein concentration for the semi-pure preparation was calculated 
by averaging the absorbance of the undiluted triplicate samples assayed as these values 
were within the center of the standard curve. This average value was then entered into the 
standard curve regression equation, and a final protein concentration of 6.42pg/mL was 
obtained.
The total mutant Stx-2 protein concentration for the semi-pure preparation was 
calculated by averaging the absorbance of the 1:2 diluted triplicate samples assayed as 
these values were within the center of the standard curve. The average value was entered 
into the standard curve regression equation, and a final protein concentration of 
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Figure 5.6: Total protein concentration of toxin preparations. Total protein 
concentration of Stx-2 and mutant Stx-2 in the semi-purified preparations. The average 
standard curve shown by the ♦ symbol with correlation coefficient of t*= 0.9673 and 
regression equation of y= 0.0042x - 0.0563. The total calculated Stx-2 concentration was 
6.42pg/mL shown by the ■ symbol and the total calculated mutant Stx-2 concentration 
after 1:2 dilution adjustment was 9.46jig/mL shown by the ▲ symbol.
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5.3 Isolation of Human Neutrophils
Neutrophils from three blood donors were isolated and counted using a 
hemocytometer and the total cell concentration and viability of each sample were 
obtained (Table 5.2). The viability of neutrophils from Donor B was much higher 
(97.3%) when compared to Donor A (85%) and Donor C (86.2%). This was most likely 
due to the effect of multiple red blood cell lysis steps on the suspension. In order to lyse 
contaminating red blood cells, neutrophil suspensions were osmotically shocked. This 
method lysed the red blood cells and undoubtedly some neutrophils accounting for the 
differences in viability noted. The overall health of isolated neutrophils also influences 
how susceptible they are to osmotic damage. Indeed, the maximum number of times the 
suspension can be shocked should be limited to three times. During this experiment, a 
high number of red blood cells were present after granulocyte collection and the full three 
rounds of osmotic shocking were needed to lyse and remove them. This accounted for the 
lower viability seen in the neutrophil suspensions from Donors A and C and this may 
have either increased the initial necrosis and/or apoptosis results or may have made the 
cells more susceptible to the effects of the toxin. Regardless, the results obtained for all 
three donor cell preparations have been presented. Based on the higher viability and the 
overall higher neutrophil cell count from Blood Donor B as compared with those from 
either Blood Donors A or C, all subsequent investigations on the action of native Stx-2, 
mutant Stx-2 or IL-8 inhibitor on necrosis or apoptosis was conducted on neutrophils 
collected from Blood Donor B. Similarly, the caspase-8 and caspase-9 levels were 
assayed in Blood Donor B neutrophils.
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Table 5.2: Viability of Neutrophils Collected from 3 Donors
Blood Donor A 608 107 85.0 6.08 x 1 0 6
Blood Donor B 1128 31 97.3 1.1 xlO 7
Blood Donor C 638 1 0 2 8 6 . 2 6.38 x 106
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5.4 Analysis of Neutrophil Necrosis and Apoptosis Rates After Exposure to
Native Stx-2. Mutant Stx-2. and IL-8 Inhibitor
Necrosis and apoptosis rates were examined for the neutrophil preparation 
isolated from Donor B after 0, 6 , 12, 18, 24, and 48 h of treatment with native Stx-2, 
mutant Stx-2 or IL- 8  inhibitor. Assays were performed in triplicate and the results were 
standardized by expressing the final result as a percent of the positive control provided in 
the kit for each assay. The mean and standard deviation of each test article was 
calculated, and a t-test was performed on seven sample comparisons (neg. control vs. 
native Stx-2, neg. control vs. mutant Stx-2, mutant Stx-2 vs. native Stx-2, neg. control vs. 
IL- 8  inhibitor, neg. control vs. IL- 8  inhibitor & native Stx-2, and IL- 8  inhibitor vs. IL- 8  
inhibitor & native Stx-2) to assess the effects of native Stx-2, mutant Stx-2, and IL- 8  
inhibitor on neutrophil apoptosis and necrosis.
5.4.1 Necrosis Rates
Significant differences were observed between sample comparisons with a 95% 
confidence interval (p < 0.05). Necrosis rates are shown in Figure 5.7 and a summary of 
the statistical comparison is shown in Table 5.3. In comparison with untreated 
neutrophils, the cells showed significantly more necrosis at 6  and 1 2  h when exposed to 
native Stx-2 and at 12, 24, and 48 h when exposed to mutant Stx-2. There were no 
significant differences in necrosis noted between cells exposed to native Stx-2 and mutant 
Stx-2 except at 48 h, where mutant Stx-2 exhibited significantly more necrosis. These
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Neutrophil Necrosis Rates Over Time
















■  Negative Control ■ IL8 Inhibition Control MutantStx-2 * Native Stx-2 ■ Stx-2 with IL-8 Inhibitor
Figure 5.7: Necrosis rates for blood donor B. Data is presented as the average percent 
necrosis when compared to the positive assay control. Error bars represent the standard 
deviation calculated between triplicates. Significant differences were observed between 
treatments with peak necrosis rates for the IL- 8  inhibition control at 48 h, mutant Stx-2 at 
48 h, native Stx-2 between 6-12 h, and Stx-2 with IL- 8  inhibitor peaking at 12 h.
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Table 5.3: Summary of Statistical Analysis for Blood Donor B: Necrosis
* indicates a significant difference (p < 0.05)_________________________
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data show that necrosis is initiated in neutrophils exposed to both native and mutant Stx- 
2, with comparable necrotic effects until 48 h when the mutant Stx-2-treated cells showed 
elevated necrosis, possibly due to cell density differences between wells.
Neutrophils exposed to IL- 8  inhibitor showed significantly less necrosis at 12 h, 
but significantly more necrosis at 24 and 48 h in comparison with the untreated control. 
In addition, neutrophils exposed to a combination of native Stx-2 and IL- 8  inhibitor 
demonstrated significantly more necrosis at 0 h when compared to untreated and IL- 8  
inhibitor-treated samples, but also exhibited significantly less necrosis at 48 h when 
compared to IL- 8  inhibitor-treated neutrophils. Finally, neutrophils exposed to native Stx- 
2 and IL- 8  inhibitor were significantly more necrotic at 0 h and significantly less necrotic 
at 6  h than cells exposed to native Stx-2 alone. These data indicate that IL- 8  inhibitor- 
induced necrosis occurs after 24 h, and that this inhibitor also lowers native Stx-2- 
induced necrosis overall, but only significantly at 6  h. It is believed that the significant 
increases in neutrophil necrosis at 0 h in samples treated with native Stx-2 and IL- 8  
inhibitor are not directly correlated with treatment, rather they are a result of cell damage 
from the neutrophil isolation procedure, especially since the necrosis rates were low 
overall (< 5.3%).
The effects of these treatments on neutrophil necrosis indicated that necrosis 
rates were changed significantly; Native Stx-2-induced necrosis was highest between 6 - 
12 h of exposure, mutant Stx-2-induced necrosis peaked at 48 h, and IL-8 -inhibitor-
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induced necrosis peaked at 24-48 h, and IL- 8  inhibitor with native Stx-2 necrosis rates 
peaked at 1 2  h.
5.4.2 Apoptosis Rates
Significant differences in apoptosis rates (p < 0.05, 95% confidence interval) were 
observed between samples. Apoptosis rates are shown in Figure 5.8 and a summary of the 
statistical comparison is shown in Table 5.4. There was significantly more apoptosis in 
cells exposed to native Stx-2 at 18 h than untreated cells. In addition, neutrophils exposed 
to mutant Stx-2 showed a significant increase in apoptosis when compared to untreated 
cells, however this was not observed until 48 h. It is believed that this significance may 
not be practical since the level of apoptosis detected was extremely low (0 .0 2 % vs. 
0.28%). Comparing native Stx-2 to mutant Stx-2, only a significant increase in native 
Stx-2-induced apoptosis was observed at 18 h. No other statistical differences between 
the two treatments were noted. Overall, these data show that apoptosis was observed for a 
longer period of time in cells exposed to native Stx-2, but this does not equate to a delay 
in apoptosis as the results were the same as the control prior to 18 h. Cells exposed to 
mutant Stx-2 showed equivalent apoptosis rates to the control.
Neutrophils exposed to IL- 8  inhibitor showed an overall trend of higher apoptosis 
than the untreated control at all time points, however significance was only achieved at 0  
and 48 h. Cells exposed to IL- 8  inhibitor and native Stx-2 showed equivalent results to 
untreated controls at 0, 6,12,24, and 48 h, but had significantly more apoptosis at 18 h.
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Neutrophil Apoptosis Rates Over Time
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Figure 5.8: Apoptosis rates for Blood Donor B. Data are presented as the average 
percent apoptosis when compared to the positive assay control. Error bars represent the 
standard deviation calculated between triplicates. Significant differences were observed 
between treatments. The IL- 8  inhibition control, mutant Stx-2, and Stx-2 with IL- 8  
inhibitor-treated samples showed peak apoptosis rates at 0 and 12 h, whereas native Stx- 
2-treated neutrophils showed peak apoptosis rates between 12-18 h. The data support that 
this 0  h apoptosis peak represents cell damage from the neutrophil isolation procedure, 
and the 1 2  h apoptosis peak observed was representative of spontaneous neutrophil 
apoptosis, unrelated to the treatment method. The peak observed at 18 h with Stx-2 
treated neutrophils illustrated the apoptotic effect of the toxin.
176
Table 5.4: Summary of Statistical Analysis for Blood Donor B: Apoptosis
* indicates a significant difference (p < 0.05)__________________________
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In addition these cells also showed significantly less apoptosis at 12 and 48 h than cells 
exposed to IL- 8  inhibitor alone, and the presence of an IL- 8  inhibitor had no effect on 
Stx-2-induced apoptosis. This data show that the apoptotic effect of Stx-2 is exhibited 
between 12 and 18 hours after exposure, despite the presence of IL-8 .
The effects of these treatments illustrated that neutrophil apoptosis rates were 
significantly changed; native Stx-2-induced apoptosis peaked between 12-18 h, mutant 
Stx-2-induced apoptosis peaked at 0 h and again at 12 h, IL- 8  inhibition control peaked at 
0 and 12 h, and Stx-2 with IL- 8  inhibitor peaked at 0 and 12 h. Apoptosis rates were 
highest overall at 0  h for all samples, however this peak represents that cell damage from 
the neutrophil isolation procedure did occur. The apoptosis peak observed at 12 h was 
related to spontaneous neutrophil apoptosis. The peak observed at 18 h with Stx-2 treated 
neutrophils illustrated the apoptotic effect of the toxin.
5.5 Analysis of Neutrophil Caspase-8 and Caspase-9 Activation After Exposure 
to Native Stx-2. Mutant Stx-2. and IL-8 Inhibitor
Caspase- 8  and Caspase-9 levels were measured using luminescence after 
neutrophils isolated from Donor B were exposed in triplicate to native Stx-2, mutant Stx- 
2, and IL- 8  inhibitor for 0, 6 , 12, 18, and 24 h. No blanking was performed on these 
assays as there was a high background in the blanking wells resulting from luminescence 
signal carryover in adjacent positive control wells. The mean and standard deviation of 
measurements were calculated and t-tests performed on seven sample comparisons to
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assess the effects of native Stx-2, mutant Stx-2, and IL- 8  inhibitor on caspase- 8  and 
caspase-9 activation.
5.5.1 Caspase- 8
Caspase- 8  activation was significantly different (p < 0.05, 95% confidence interval) 
between five out of the seven comparisons. Caspase- 8  activation is summarized in Figure 
5.9 and sample comparisons are summarized Table 5.5. No significant differences were 
observed between native Stx-2-treated and untreated cells. A significant increase in 
caspase- 8  activation was observed in mutant Stx-2-treated cells at 0 and 24 h compared to 
the control. In addition, there was a significant increase in caspase- 8  activation at 0 h in 
cells exposed to mutant Stx-2 when compared to native Stx-2.
The IL- 8  inhibitor treated cells showed lower caspase- 8  activation overall when 
compared to the control; significance was achieved at 12 h and beyond. Neutrophils 
exposed to IL- 8  inhibitor and Stx-2 showed significant decreases in caspase- 8  activation 
at 1 2  and 18 h when compared to untreated cells, but did not show any significant 
differences when compared to IL- 8  inhibitor-treated cells. Finally, neutrophils exposed to 
IL- 8  inhibitor and native Stx-2 showed a sustained significant decrease in caspase- 8  
activation after 12 h when compared to native Stx-2 alone.
Caspase- 8  activation was significantly different between these treatments; however 
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Figure 5.9: Relative caspase- 8  levels for blood donor B. Relative caspase- 8  levels in 
cells isolated from Blood Donor B. Error bars represent the standard deviation calculated 
between triplicates. Caspase- 8  activation peaked in all samples at 6  h. It is believed that 
this peak is related to spontaneous neutrophil apoptosis observed at 1 2  h, independent of 
treatment method. Caspase- 8  activation was significantly different between treatments; 
however they all followed the same overall pattern with activation rates peaking at 6  h. 
This is likely related to the spontaneous neutrophil apoptosis peak detected at 12 h, as 
caspase- 8  activation occurs prior to DNA framentation, which is the antigen primarily 
detected in the ELISA. Note that no significant increase in caspase- 8  activation was 
detected in the neutrophils treated with Stx-2.
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Table 5.5: Summary of Statistical Analysis for Blood Donor B: Relative Caspase-8
Levels
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likely related to the spontaneous neutrophil apoptosis peaks detected at 1 2  h, as caspase- 8  
activation occurs prior to DNA fragmentation, which is detected in the ELISA. In 
addition, no significant increase in caspase- 8  activation was detected in the neutrophils 
treated with Stx-2 which indicates that Stx-2 induced apoptosis does not occur through 
the extrinsic apoptosis pathway.
5.5.2 Caspase-9
Caspase-9 activation was determined to be significantly different (p < 0.05, 95% 
confidence interval) for five out of seven comparisons. Caspase-9 activation is 
summarized in Figure 5.10 and sample comparisons are shown in Table 5.6. No 
difference in caspase-9 activation was detected for neutrophils exposed to native Stx-2 
when compared to the untreated and mutant Stx-2-treated neutrophils. At 6  and 12 h there 
was significantly less caspase-9 activation and at 18 h significantly more caspase-9 
activation in neutrophils exposed to mutant Stx-2 when compared to the control.
Neutrophils treated with IL- 8  inhibitor demonstrated significantly less caspase-9 
activation at 6 , 12, and 18h when compared to untreated cells as well as IL- 8  inhibitor 
and Stx-2-treated cells. In addition, significantly less caspase-9 activation was seen at 12 
h in cells treated with IL- 8  inhibitor and Stx-2 versus IL- 8  inhibitor only. Finally, there 
was a significant sustained reduction of caspase-9 activation from 0 to 18 h in cells 
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Figure 5.10: Relative caspase-9 levels for blood donor B. Relative caspase-9 levels in 
cells isolated from Blood Donor B. Error bars represent the standard deviation calculated 
between triplicates. Caspase-9 activation was significantly different between these 
treatments; samples treated with native and mutant Stx-2 showed overall higher caspase- 
9 activation at 18 h, related to mitochondrial membrane permealibilazation (MMP). 
Caspase-9 activation was reduced in all samples treated with IL- 8  inhibitor with 
significance achieved at 6 ,12, and 18 h. This indicates that the intrinsic pathway is not 
utilized in association with spontaneous neutrophil apoptosis.
183
Table 5.6: Summary of Statistical Analysis for Blood Donor B: Relative Caspase-9
Levels
Sample Time Point (h) Unpaired t-test P-value
0 0.9039
Negative Control 6 0.1096




Negative Control 6 0.0219*
vs. 1 2 0.0387*
Mutant Stx-2 18 0.0315*
24 0.2173
0 0.0562
Mutant Stx-2 6 0.2818




Negative Control 6 0.0087*
vs. 1 2 0 .0 0 0 2 *
IL- 8  Inhibitor 18 0.0029*
24 0.5053
0 0.2241
Negative Control 6 0.0004*
vs. 1 2 <0 .0 0 0 1 *
IL- 8  Inhibitor + Stx-2 18 0.0054*
24 0.6707
0 0.7526
IL- 8  Inhibitor 6 0.1296
vs. 1 2 0.0006*




vs. 1 2 0.0034*
IL- 8  Inhibitor + Stx-2 18 0.0042*
24 0.0890
* indicates a significant difference (p < 0.05)
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Caspase-9 activation was significantly different between these treatments; samples 
treated with native and mutant Stx-2 showed overall higher caspase-9 activation at 18 h. 
Significance was only achieved for mutant Stx-2, however the p-value for Stx-2 was 
0.0544 which is very close to the significance threshold. It is believed that the increase in 
caspase-9 activation is directly related to the effect of both mutant and native Stx-2 on the 
neutrophils, resulting from mitochondrial membrane permealibilazation (MMP) which 
can occur simultaneously with DNA fragmentation (78, 160). Caspase-9 activation was 
reduced in all samples treated with IL- 8  inhibitor with significance achieved at 6 , 12, and 
18 h. This indicates that the intrinsic pathway is not utilized in association with 
spontaneous neutrophil apoptosis.
6.0 Discussion
During infection with E. coli 0157:H7, it has been observed that disease 
pathogenesis is enhanced when neutrophils remain within the circulation and tissues to 
provide maximum distribution of toxin (37, 208). It is thought that neutrophils may 
provide a way for Stx-2 to be distributed throughout the body during infection (195). 
Therefore, it is critical that neutrophil necrosis and apoptosis is delayed to increase the 
number of neutrophils present. Previous studies on the impact of Stx-2-induced 
neutrophil apoptosis have shown conflicting results. Liu et al. (118) observed a time- and 
dose-dependent delay in spontaneous neutrophil apoptosis when exposed to Stx-2 
whereas Flagler et al. (51) did not. Preliminary studies performed with supernatant from 
E. coli 0157:H7 strain 90-2380 (Chapter 3) showed that a delay in apoptosis was
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observed in samples up to 12 h. In order to assess why these differences were observed, a 
better understanding of the mechanisms of Stx-2 induced neutrophil apoptosis is needed. 
Yin et al. (225) used mutants to understand Bcl-2 family dimerization between Bcl-2 and 
Bax. It was thought the same technique could be utilized to understand Stx-2 and Bcl-2 
family protein interactions, and confirm if they occur. The goal of these experiments was 
to assess the effects that semi-purified native Stx-2 and Stx-2 containing a G225A 
mutation had on the necrosis and apoptosis rates of neutrophils over a period of 48 h, and 
to determine the role that IL- 8  plays in spontaneous and toxin-induced neutrophil 
apoptosis. Caspase- 8  and caspase-9 levels were monitored over a period of 24 h to 
determine which apoptotic pathways were being utilized, either extrinsic (caspase-8 - 
dependent) or intrinsic (caspase-9-dependent). It was hypothesized that neutrophils 
treated with mutant Stx-2 will show apoptosis rates that align with the baseline 
(untreated) apoptosis rate, resulting from an inability to bind to the BH1 domain of the 
Bcl-2 family pro-survival proteins, and that neutrophils treated with Stx-2 in combination 
with an IL- 8  inhibitor will also show apoptosis rates that align with the baseline 
(untreated) apoptosis rate indicating that IL- 8  was responsible for the delay in apoptosis 
as opposed to Stx-2.
The data obtained in this study on semi-purified Stx-2-induced neutrophil 
apoptosis were not consistent with the data obtained for neutrophils exposed to Stx-2- 
containing supemate from E. coli 0157:H7 strain 90-2380 (Chapter 3). The supemate 
study showed a delay in apoptosis up to and including 12 h. The present data showed no 
significant differences in apoptosis at 0, 6 , 12, 24, and 48h, but showed a significantly
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higher rate of apoptosis after 18 h that was triggered through a caspase-9 dependent 
mechanism. The two major differences between the present and previous studies were 
sample concentration and purity. In the experiments performed in Chapter 3, the exact 
amount of Stx-2 tested was unknown; however in this study, 5 ng/mL of Stx-2 was added 
to each sample. It is possible that this concentration was insufficient to elicit the same 
response to that observed previously. However, the most likely scenario is that the 
supemate used in the previous study had residual LPS which is known to stimulate 
cytokine production in neutrophils including IL- 8  and TNF-a (97). Production of these 
cytokines could impact the timing of apoptosis as IL- 8  is known to delay neutrophil 
apoptosis (96). Neutrophils exposed to LPS release IL- 8  in two phases; 20-30% of the 
total IL- 8  production occurs in the first phase which begins approximately Vi hour after 
exposure and continues uninhibited over several hours, and the remaining IL- 8  
production occurs during the second phase (97) but it is more susceptible to the inhibitory 
effects of other cytokines such as IL-10 (26). In other words, the protective effect of IL- 8  
does not continue throughout the entire period that neutrophils are exposed to LPS 
resulting in a point at which apoptosis occurs. During the supemate study (Chapter 3), the 
delay in apoptosis observed with the Stx-2 exposed neutrophils ceased after 12 h thereby 
supporting this theory. In the present experiment, the chances that LPS were present in 
the semi-purified sample were low, therefore it is believed that these results give a better 
indication of the true effect of Stx-2 on neutrophil apoptosis.
The effect of native Stx-2 exposure on neutrophil necrosis, apoptosis, and 
caspase-8/-9 activation indicated that necrosis was significantly increased 6-12 h after
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exposure and that native Stx-2-induced apoptosis was observed after 18 h and was 
associated with an increase in caspase-9 activation. It is possible that Stx-2-induced 
necrosis can be triggered by mechanisms other than N-glycosidase activity. 
Mitochondrial membrane permeabilization (MMP) results in programmed cell death 
(PCD) as shown in Figure 5.12, and can trigger three outcomes; the activation of caspase- 
9 which results in downstream apoptosis, the activation of apoptosis inducing factor 
(AIF) and EndoG which result in direct DNA fragmentation and apoptosis-like cell death, 
and the release of calcium and reactive oxygen species (ROS) which result in necrosis 
like cell death (78). Calcium is known to be released as part of a stress response 
originating from the ER (Figure 5.12), where Stx-2 is known to be located, or from MMP 
as explained above (78, 160) which may occur if Stx-2 interacts with Bak on the 
mitochondrial membrane. Previous research has stated that apoptosis is induced by Stx-1 
though the ER stress response in human monocytic cells (110), and that DNA 
condensation can occur in cells that overexpress Bax, despite the presence of a caspase 
inhibitor (124, 222), which supports the use of alternative pathways that result in 
apoptosis-like cell death such as those with AIF and EndoG. The data obtained in these 
experiments support the theory that Stx-2 induced cytotoxicity is triggered by either by 
ER stress and calcium release, a direct interaction between Stx-2 and Bcl-2 family 
members at the mitochondrial membrane, or both, thereby resulting in apoptotic and 
necrotic cellular responses through MMP and autophagy, a process that is associated with 
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Figure 5.11: The effects of mitochondrial membrane permeabilization (MMP) on 
programmed cell death (PCD). Figure is adapted from M. Jaattela (78). MMP has many 
downstream cellular effects that can lead to apoptosis-like PCD, true apoptosis, and 
necrosis-like PCD. In these experiments, it is believed that apoptosis-inducing factor 
(AIF) or EndoG may be triggered by Bak activation as a result of cytokine withdrawal or 
binding to Stx-2 at the mitochondrial or ER surface (left box). In addition, the release of 
calcium from the ER may also trigger necrosis-like PCD through autophagy (right box).
189
SPC-Od© | SC-0141 
am ** * *  | BM6-346641 |frc* tw to* | 
2-*mtoo-M?-«CT<»Optop0-m*»iowvV*- 
w y oKypM m t 4 pp*nan t d  rtcohnowtrt* I




FAS: C75 i EOCGI C tf tttm
DR* j n-S-A^flro*|MWSm< (Am- 








Compound « IoEiflMin* | 
OUr^ ftenyAa***} 
Compound}
^  ApooowwXI 
T M M r
A-77SQ24





y-AB  INU103S! AGI4M1 
WM?SP IQPI01501 PJ34 CMWOAtftoi
■rarrx







cell death. This 
diagram is 
courtesy o f Reed 
etal. (160). The 
pathways thought 
to be related to 
Stx-2-induced 
apoptosis are 











and EndoG / AIF 
release.
o
The effect of mutant Stx-2 on neutrophil necrosis, apoptosis, and caspase-8/-9 
activation indicated that necrosis was not remarkably different from native Stx-2, with 
only a slight increase after 48 h; however there was a lack of mutant Stx-2-induced 
apoptosis. In addition, no difference in caspase- 8  and caspase-9 activation was detected 
between native and mutant Stx-2. This shows that the mutation did alter the cytotoxicity 
of the toxin, and did not cause apoptosis of cells at 18 h as seen with native Stx-2. This 
further supports that Stx-2 triggers ER stress followed by calcium release and/or directly 
interacts with Bcl-2 family members such as Bak at the mitochondrial membrane leading 
to downstream effects of MMP on cell death as explained by Jaattela (78) and Reed et al. 
(160).
The effect of IL- 8  inhibitor on neutrophil necrosis, apoptosis, and caspase-8/-9 
activation was remarkably different from native and mutant Stx-2. A steady increase in 
necrosis was observed after 1 2  h and apoptosis rates were highest at 1 2  h, but caspase- 8  
and caspase-9 levels were the lowest, even in the presence of Stx-2. This shows that the 
IL- 8  inhibitor triggered programmed cell death through a caspase-independent apoptotic 
pathway. It is suspected that this pathway involved Bak and destabilization of the 
mitochondrial membrane which then caused the mitochondria to release apoptosis- 
inducing factor (AIF) and EndoG. These molecules lead to DNA fragmentation, 
chromatin condensation, and apoptosis-like programmed cell death, in a fashion similar 
to the pathway shown on the right side of Figure 5.12 entitled “withdrawal of growth 
factors/cytokines”. It is known that exposure to IL- 8  results in a delay of spontaneous 
apoptosis, and without it TNF-a can rapidly increase neutrophil apoptosis 2 h after
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exposure (97, 143, 192). Even though apoptosis rates of neutrophils treated with IL- 8  
inhibitor were consistently higher than the negative control at 6  h and beyond, the data 
from these experiments do not support that the induction of apoptosis was due to TNF-a 
because the low levels of caspase- 8  activation indicated that the extrinsic pathway 
typically triggered by TNF-a was not used. These data do suggest that spontaneous 
neutrophil apoptosis occurred at approximately 12 h in all samples despite the level of IL- 
8  or Stx-2 present, however the negative control showed lower apoptosis rates indicating 
that IL- 8  did have some protective effect against spontaneous neutrophil apoptosis, 
although it was not significant at all time points.
The experiments performed in this study did not show a clear correlation between 
a delay in apoptosis as a result of exposure to Stx-2; however they did demonstrate that 
Stx-2 induced apoptosis was observed at 18 h and that cells exposed to mutant Stx-2 had 
apoptosis rates similar to that of the untreated cells. Data from these experiments 
supported that the mechanism of action of Stx-2 was either through the ER stress 
response and/or interaction with Bcl-2 family members such as Bak at the mitochondrial 
membrane therefore inducing MMP and its downstream effects. Additionally, mutant 
Stx-2 was unable to interact with Bcl-2 family members such as Bak at the mitochondrial 
membrane, preventing the downstream effects of MMP and cell death. However mutant 
Stx-2 was still able to elicit the ER stress response, resulting in calcium release, 
autophagy, and necrosis-like cell death. IL- 8  did not appear to play a major role in the 
delay of spontaneous apoptosis or to Stx-2 induced apoptosis in these experiments, and 
only showed a slight protective effect.
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CHAPTER 6
CONCLUSIONS AND FUTURE STUDIES
1.0 Conclusion and Future Studies
Escherichia coli 0157:H7 is the prototype organism of the STEC group, and has 
caused numerous outbreaks in the United States associated with a wide variety of food 
types since it first emerged in the early 1980’s (159). It is a dominant Shiga-toxin (Stx) 
producing Escherichia coli (STEC) and although many toxic virulence factors are 
produced by E. coli 0157:H7, the Stx toxins have been implicated as the most likely 
inducers of Hemolytic uremic syndrome (HUS) and its symptoms (131). It is important 
to understand the mechanisms by which these toxins elicit cytotoxic responses and how 
they differ between host cell types. By doing so, novel therapies and/or vaccines can be 
created to supplement current treatments, which are currently focused on maintaining 
homeostasis (148). The experiments performed in these studies helped to elucidate the 
mechanisms of Stx-2-induced programmed cell death.
Different cell types within the human body are known to contain different levels 
of Bcl-2 family proteins, and are affected by cytokines and growth hormones in different 
ways. Therefore, apoptotic responses may differ between these cell types. Numerous
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studies have been performed investigating the effects of Stx-1 and Stx-2-induced 
apoptosis on many different cell types. A study by Fujii et al. (54) determined that Stx-2 
induced apoptosis is mediated by C/EBP homologous protein (CHOP) in human brain 
microvascular endothelial cells. Another study performed by Park et al. concluded that 
CHOP enhances NFk-B signals by repression of peroxisome proliferator-activated 
receptor y in intestinal epithelial cells (147). NFk-B controls the up-regulation of IL- 8  
and inhibitor of apoptosis proteins (IAPs) and can inhibit apoptosis by preventing 
caspase-9/-3 activation (184). A third study concluded that shiga-like toxins induced 
apoptosis of Hep-2 cells by cleavage of Poly (ADP-Ribose) (PARP) and activation of 
caspases (35). All of these studies support that shiga-like toxins use different apoptotic 
pathways in the tested cells. This shows it is necessary to investigate the effects of Stx-2- 
induced programmed cell death on each cell type typically associated with disease in 
order to ensure the correct mechanisms are identified.
Human intestinal epithelial cells and neutrophils are two cell types that have been 
associated with the pathogenesis of HUS, and were used in the experiments performed in 
this research. Human intestinal epithelial cells allow toxins produced in the colon to 
translocate into the blood stream using either a microtubule-dependent or -independent 
method (75, 113). Neutrophils are the first line of defense in the human host immune 
system and constitutively undergo apoptosis in the circulation, and have an estimated 
half-life of 6  to 18 h (3, 67, 173, 213). Increased counts of both neutrophils and 
macrophages in circulation have been associated with an increased severity of renal 
failure during HUS (156), suggesting that the normal rate of apoptosis may be altered
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during infection with Stx-2. Previous studies performed by Suzuki et al. (190) have 
indicated that Stx-2 but not Stx-1 interacts with a pentameric sequence, NWGRI within 
the BH1 domain (a highly conserved region) on the pro-survival protein, Bcl-2 (residues 
143 to 147), and this induces target cell death from caspase-3 activation. This same 
sequence is found in other members of the Bcl-2 protein family as well as in Stx-2 
(residues 222-228) (190). Therefore, it is possible that Stx-2 is acting in a similar manner 
to the Bcl-2 protein family by forming heterodimers with these proteins and influencing 
the outcome of the cell’s fate.
The goal of this research was to elucidate how Stx-2 interacts with the Bcl-2 
protein family and to determine what role it plays in host cell apoptosis, especially in 
human neutrophils. In these studies, protein interactions between Stx-2 and select Bcl-2 
family proteins (Bcl-2, B c1-Xl, Mcl-1, Bcl-w, and Bax) were examined using Far 
Western Blot and Co-Immunoprecipitation in a human intestinal epithelial cell model 
(Caco-2). Necrosis and apoptosis rates of human neutrophils as well as the corresponding 
pathways used (e.g. caspase- 8  and/or caspase-9) were also determined following 
exposure to Stx-2 and mutant Stx-2 (G225A) to determine the extent that the pentameric 
sequences plays in regulating apoptosis. The protein interaction studies concluded that 
protein binding between Stx-2 and Bcl-2, B c1-Xl , or Bax was not demonstrated in Caco-2 
cells. One potential interaction was observed, but the identity of this protein was 
unknown. Identifying this interaction could be a challenge; however if the interaction was 
demonstrated in repeat experiments, the binding protein could be identified. First, this 
protein should be isolated from a PVDF membrane or gel, and the amino acid sequence
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determined using Edman degradation or mass spectrometry. Once the protein sequence 
has been determined, it can be compared to a database of known protein sequences using 
the basic local alignment search tool (BLAST) to determine its identity. The protein 
interactions between Stx-2 and this protein can then be determined using the same 
methods used in these experiments, and the presence of this protein can also be identified 
in other cell types, such as neutrophils. In order to confirm protein interactions, 
alternative techniques should be used such as yeast or mammalian two-hybrid systems or 
ultracentrifugation of protein complexes labeled with fluorescent probes. Gaining this 
knowledge will further elucidate the pathway by which Stx-2 programmed cell death 
occurs.
The neutrophil apoptosis studies concluded that Stx-2-induced apoptosis is 
delayed for 12 h after exposure, but only in the presence of crude supernatant fluid. It is 
believed that this observation is due to LPS-induced IL- 8  upregulation, which is known 
to delay neutrophil apoptosis (96). This delay was not observed in neutrophils treated 
with semi-purified Stx-2 as there was no reduction in spontaneous neutrophil apoptosis 
observed within the first 12 h. Instead, a distinct peak of Stx-2 induced apoptosis was 
observed at 18 h in addition to spontaneous neutrophil apoptosis peak observed at 1 2  h. 
Data supported that the mechanism of action of Stx-2 was either through the ER stress 
response and/or interaction with Bcl-2 family members such as Bak at the mitochondrial 
membrane therefore inducing MMP and its downstream effects. IL- 8  did not appear to 
play a major role in the delay of spontaneous apoptosis or to Stx-2 induced apoptosis in 
these experiments, and only showed a slight protective effect. The neutrophil necrosis
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studies concluded that Stx-2-induced necrosis was significantly increased 6-12 h after 
exposure, and that this was triggered by a mechanism other than N-glycosidase activity. 
It is believed that Stx-2 is able to elicit a stress response within the ER that results in 
calcium release, autophagy, and necrosis-like cell death. Further experiments should be 
performed to confirm that the proposed mechanisms are involved in Stx-2-induced 
programmed cell death. To determine if Stx-2 does indeed induce an ER stress response, 
intracellular calcium, calpain, and ROS levels in neutrophils exposed to Stx-2 in a dose- 
dependent manner should be examined. The transcription and protein levels of AIF and 
EndoG should also be examined to determine if these proteins are the cause of caspase- 
independent apoptosis. Cells exposed to Stx-2 in a dose-dependent manner should be 
observed using electron microscopy for the formation of autophagosomes and 
autolysosomes. The presence of all of the above plus confirmation of the identity of the 
unknown protein interaction described previously would confirm that Stx-2-induced 
apoptosis and necrosis is occurring as a result of an ER stress response.
The number of variables involved in toxin-mediated cellular programmed cell 
death provides a challenge when trying to elucidate the molecular mechanisms involved. 
The research performed in these experiments was conducted over a time frame of nine 
years, and hypotheses were initially developed in 2005. Three toxin batches were 
produced during this time and toxin potency was confirmed through Vero cell 
cytotoxicity testing to ensure no batch variation was present. Much progress has been 
made over the last decade to understand the complexities of both cellular apoptosis and 
Stx-2 mechanisms of action including the identification of a number of new proteins and
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signaling pathways that are involved in determining the fate of a cell (78, 160). The 
research performed in these experiments was limited to a small number of proteins that 
were predominantly known to be involved in the process of apoptosis at the time the 
study was designed. However, from this research two molecular mechanisms for Stx-2 
induced apoptosis and necrosis have been proposed. Providing increased knowledge of 
the mechanisms of Stx-2-induced programmed cell death will help future discoveries and 
open up new avenues for treatments and/or vaccines for E. coli 0157:H7 infection.
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APPENDIX A:
MICROORGANISMS, MEDIA, AND REAGENTS
1.0 Microorganisms
The strains of E. coli 0157:H7 used in these studies, the toxins they produced, 
and the origins of each are shown below.
E. coli 0157:H7 strains used
2.0 Microbiological Media
2.1 Lnria Bertani (LB) Agar
10 g Bacto-Tryptone (Difco 0123-01-1)
5 g Bacto-yeast extract (Difco 0127-05-3) 
lOgNaCl
15 g Bacto-agar (Difco 0140-01)
Distilled H2 O to 1 L
Add ingredients to an Erlenmeyer flask. Bring the volume up to 1L with distilled 
H2 O and stir until all ingredients are dissolved. Autoclave on the liquid cycle for 20





National Laboratory for Enteric Pathogens Canada 
National Laboratory for Enteric Pathogens Canada 
American Type Culture Collection 
American Type Culture Collection
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minutes at 121°C, 15psi, and cool to 55 °C , and pour into sterile Petri dishes (20 
mL/plate).
2.2 Luria Bertani (LB) Broth
lOg Bacto Tryptone 
5g Yeast Extract 
lOgNaCl 
1 L distilled H2 O
Add ingredients to an Erlenmeyer flask. Bring the volume up to 1L with distilled 
H2 O and stir until all ingredients are dissolved. Autoclave on the liquid cycle for 20 
minutes at 121°C, 15psi, and store at room temperature.
2.3 LB Agar with 50iig/mL Ampicillin
2.5 g Bacto-Tryptone (Difco 0123-01-1)
1.25 g Bacto-yeast extract (Difco 0127-05-3)
2.5 g NaCl
3.75 g Bacto-agar (Difco 0140-01)
Distilled H2 O to 250mL
Add ingredients to an Erlenmeyer flask. Bring the volume up to 250mL with 
distilled H2 O and stir until all ingredients are dissolved. Autoclave on the liquid cycle for 
20 minutes at 121°C, 15psi and cool to 55 °C , add Ampicillin (2.5mL of a 5mg/mL stock 
solution per 250mL media) and pour into sterile Petri dishes (approx. 20 ml/plate).
2.4 LB Agar with 1% Glucose. 25iig/mL Chloramphenicol. 50iig/mL Ampicillin
5 g Bacto-Tryptone (Difco 0123-01-1)
2.5 g Bacto-yeast extract (Difco 0127-05-3) 
5 g NaCl
5 g Glucose
7.5 g Bacto-agar (Difco 0140-01)
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Distilled H2O to 500mL
Add ingredients to an Erlenmeyer flask. Bring the volume up to 500mL with 
distilled H2 O and stir until all ingredients are dissolved. Autoclave on the liquid cycle for 
20 minutes at 121°C, 15psi, and cool to 55 °C , add antibiotics (2.5mL of 5mg/mL 
Chloramphenicol and 5mL of 5mg/mL Ampicillin per 500mL media) and pour into 
sterile Petri dishes (20 mL/plate).
2.5 LB Agar with 25ug/mL Kanamvcin
2.5 g Bacto-Tryptone (Difco 0123-01-1)
1.25 g Bacto-yeast extract (Difco 0127-05-3)
2.5 g NaCl
3.75 g Bacto-agar (Difco 0140-01)
Distilled H2 O to 250mL
Add ingredients to an Erlenmeyer flask. Bring the volume up to 250mL with 
distilled H2 O and stir until all ingredients are dissolved. Autoclave on the liquid cycle for 
20 minutes at 121°C, 15psi, and cool to 55 °C , add Kanamycin (1.25mL of 5mg/mL 
stock solution per 250mL media) and pour into sterile Petri dishes (20 mL/plate).
2.6 Trypticase Sov Broth with 15% Glycerol
30g Trypticase Soy Broth Powder 
7.5mL Glycerol 
500mL distilled H2 O
Dissolve TSB powder in the distilled water and remove 7.5mL of broth. Add 
7.5mL glycerol and mix well. Autoclave on the liquid cycle for 20 minutes at 121°C, 
15psi, and store at room temperature.
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2.7 SOC Medium
20g Bacto Tryptone 
5g Bacto Yeast Extract 
2ml of 5M NaCl.
2.5ml oflM KCl.
1 0 ml of 1 M MgCl2 
10ml of 1M MgS04  
2 0 ml of 1 M glucose 
ddH20  to 1L
Add ingredients to 900mL of distilled H20 . Bring the volume up to 1L with 
distilled H20  and stir until all ingredients are dissolved. Autoclave on the liquid cycle for 
20 minutes at 121°C, 15psi.
3.0 Antibiotic Stock Solutions
Stock solutions of ampicillin, chloramphenicol, kanamycin, and tetracycline were 
prepared as needed per the recipes below. In all cases, antibiotics were mixed until 
dissolved, sterile filtered with 0.2pm filters (Pall), and added to media in the desired 
concentration.
3.1 Ampicillin (Amnl: Stock of 5 mg/mL in sterile ddwater (sddH2Q).
0.5 g Ampicillin (Sigma A-9518)
Sterile ddH20  to 100 ml
3.2 Chloramphenicol (Chi): Stock of 5 mg/mL in 95% ethanol (EtOHl.
0.05 g Chloramphenicol 
95% EtOH to 10 ml
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3.3 Kanamvcin (Kan): Stock of 5 mg/ml in sterile ddwater (sddH2Q).
0.05 g Kanamycin 
Sterile ddH2 0  to 10 mL
3.4 Tetracycline (Tet): Stock of 5 mg/ml in 95% ethanol (EtOHt.
0.05 g Tetracycline-HCl 
95% EtOH to 10 ml
4.0 Biochemical Reagents
4.1 Phosphate Buffered Saline (PBS), pH 7.4
1.44g Sodium phosphate, dibasic (Na2 HP0 4 )
8 g Sodium chloride (NaCl)
0.2g Potassium Chloride (KC1)
0.24g Potassium Phosphate, monobasic (KH2 PO4 )
1L distilled H20
Add ingredients to flask, bring up the volume to 1L with distilled water, and stir 
until dissolved. Adjust pH to 7.4 using HC1. Autoclave on the liquid cycle for 20 minutes 
at 121°C, 15psi, and store at room temperature.
4.2 0.5M Ethylene Diamine Tetraacetic Acid (EDTA). pH 8.0
46.5 g NaEDTA (Sigma)
200 mL distilled H20
Adjust to pH 8.0 with approximately 5 g of NaOH pellets (Sigma). Autoclave on 
the liquid cycle for 20 minutes at 121°C, 15psi, and store at room temperature.
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4.3 50x Tris-Acetate-EDTA Buffer (TAEL p H  8.5
242g Tris Base 
lOOmL 0.5M EDTA, pH 8.0 
57.1mL Glacial Acetic Acid 
distilled H2 O
Add ingredients to flask, bring up the volume to 1L with distilled water, and stir 
until dissolved. Adjust pH to 8.5 with Glacial Acetic Acid. Store at room temperature.
4.4 DNA Extraction Lvsis Buffer
250pL 10% SDS 
50|iL lONNaOH 
9.7mLdH20
Add ingredients to a conical tube and mix well. If the SDS does not dissolve, 
place tube into a warm water bath for 5 minutes. Vortex to mix. Store at room 
temperature for no longer than 2  months.
4.5 Loading Dve
7mL 0.25% Bromophenol Blue 
7mL 0.25% Cylene Cyanol 
6 mL Glycerol
Add ingredients to a conical tube and mix well. Store at room temperature.






Add ingredients to flask, bring up the volume to 1L with distilled water and stir 
until dissolved. Adjust pH to 8 . 8  with HC1. Store at room temperature or 2-8°C. To use, 
dilute stock 50-fold with deionized water to obtain a lx solution for each native 
electrophoresis run. Mix thoroughly before use.





lmL Bromophenol blue 
Distilled H2 O
Add ingredients to a flask containing 50mL distilled H2 O, bring up the volume to 





Dissolve PMSF in methanol. Vortex to mix. Store at -20°C.
4.9 Acrvlamide/Bisacrvlamide (30%T. 2.67 %C1
87.6g acrylamide
2.4g N’N’-bis-methylene-acrylamide
Bring up volume to 300mL with deionized water. Filter using Whatman #1 paper 
and store at 4°C in the dark.
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4.10 10% (w/v) Sodium Dodecvl Sulfate (SDS)
lOg SDS 
Distilled H2O
Dissolve lOg SDS in 90mL water with gentle stirring and bring volume up to 
lOOmL with deionized water.
4.11 Resolving Gel Buffer (1.5M Tris-HCl). p H 8.8
27.23g Tris base 
80mL deionized water
Adjust to pH 8 . 8  with 5N HC1. Bring total volume to 150mL with deionized water 
and store at 4°C.
4.12 Stacking Gel Buffer (0.5M Tris-HCll. p 6.8
6 g Tris base 
60mL deionized water
Adjust to pH 6 . 8  with 5N HC1. Bring total volume to lOOmL with deionized water 
and store at 4°C.
4.13 Sample Buffer (SDS Reducing Buffer)
3.55mL deionized water
1.25mL 0.5M Tris-HCl, pH 6 . 8
2.5mL glycerol
2.0mL 10% (w/v) SDS
0.2mL 0.5% (w/v) bromophenol blue
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Add ingredients to a conical tube and mix well. Store at room temperature. Prior 
to use, add 50pl p-mercaptoethanol to 950pL sample buffer. Dilute the sample at least 1:2 
with sample buffer and heat at 95°C for 4 minutes.
4.14 lOx Electrode SDS-PAGE (Running) Buffer. Tris-Glvcine p H 8.3




Dissolve ingredients in 700mL deionized water and bring the total volume up to 
1L. Do not adjust pH with acid or base. Store at 4°C. If precipitation occurs, warm to 
room temperature before use. Prior to use, dilute 50mL lOx stock with 450mL deionized 
water for each electrophoresis run. Mix thoroughly.
4.15 10% Ammonium Persulfate (APS) (made fresh daily)
lOOmg ammonium persulfate 
lmL deionized water
Dissolve lOOmg ammonium persulfate in lmL of deionized water and vortex to 
mix well.
4.16 6% Stacking /12% Resolving Acrvlamide Gel
Resolving Gel (lOmL):
4 mL Acrylamide/Bisacrylamide (30%T, 2.67%C)
2.5mL Resolving gel buffer 





lmL Acrylamide/Bisacrylamide (30%T, 2.67%C)
1.25 Stacking gel buffer 
2.75mL distilled H2 O 
5pL TEMED 
25|4.L APS
Add resolving ingredients to a conical tube in the order listed. Mix gently and 
allow to de-gas for at least five minutes. Carefully pipette resolving gel solution into gel 
casting stand until 3A full. Gently add a layer of water and allow to solidify. Pour off 
water and prepare stacking gel in the same manner. Insert comb into the top of the gel 
casting stand and allow to solidify.
4.17 Coomassie Blue Staining Buffer
lg Coomassie Blue R250 
lOOmL Glacial Acetic Acid 
400mL Methanol 
500mL Distilled H2 O
Add acetic acid to distilled water followed by methanol and Coomassie blue. Mix 
well and filter with Whatman #1 filter paper to remove large particles. Store at room 
temperature.
4.18 Coomassie Blue Destain Buffer
200mL Methanol 
lOOmL Glacial Acetic Acid 
700mL Distilled H2 O
Add lOOmL glacial acetic acid to 700mL of dEhO followed by 200mL methanol 
and mix well. Store at room temperature.
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4.19 lOx Western Blot Transfer Buffer (Tris Glycine). pH 8.3
30.3g Tris base 
144.0g Glycine 
Distilled H2 O
Dissolve ingredients in 700mL deionized water and bring the total volume up to 
1L. Do not adjust pH with acid or base. Store at 4°C. If precipitation occurs, warm to 
room temperature before use. Prior to use, dilute 1:10 with deionized water for each 
electroblot transfer. Mix thoroughly.
4.20 Blocking Buffer (5% Dehydrated Skim Milk)
5g dehydrated skim milk powder 
lOOmL lx Phosphate Buffered Saline (PBS)
Add 5g of dehydrated skim milk powder into lOOmL PBS. Vortex until dissolved. 
For extended storage, store at -20°C.
4.21 1 Ox Tris Buffered Saline (TBS!
24.20g Tris Base 
292.4g NaCl 
Distilled H2 O
Add ingredients to 500mL distilled water, adjust the pH to 7.5 with HC1 and bring 
the volume up to 1L. Dilute 1:10 with distilled water prior to use. Store at 2-8°C.
4.22 0.05% Tween Tris Buffered Saline (TTBS). p H 7.5
1L lx TBS 
0.5mL Tween 20
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Add Tween 20 to 1L lx TBS and mix well. Store at room temperature.





Add ingredients and mix until dissolved. Sterile filter with 0.2pm filters (Pall) and 
transfer aliquots into 15mL conical tubes. Store at -20°C.
5.2 Trypan Blue
0.04g Trypan Blue
lOOmL lx Phosphate Buffered Saline (PBS)
Add ingredients and mix until dissolved. Sterile filter with 0.2pm filters (Pall) and 
store at room temperature.
5.3 HBSS Modified (no Ca++ or Mg++)
2 bottles pre-measured, powdered HBSS modified (no Ca++ or Mg++) (Atlanta 
Biologicals, Atlanta GA)
0.70g sodium bicarbonate 
2L distilled H20
Add ingredients and mix well. Adjust pH to 7.2 with HC1. Sterile filter into 
autoclaved bottles using 0.2pm filter units (Nalgene Nunc, Rochester, NY). Incubate 
media overnight at 37°C for sterility check. Store at 2-8°C.
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5.4 RPMI-1640 with 10% FBS
10.44g RPMI-1640 powder 
Distilled H2 O up to 1L 
2 .0 g sodium bicarbonate 
lOmL non-essential amino acids, lOOx 
50mL Fetal Bovine Serum (FBS)
Add ingredients and mix well. Adjust pH to 7.2 with HC1 if required. Sterile filter 
into autoclaved bottles using 0.2pm filter units (Nalgene). Incubate media overnight at 
37°C for sterility check. Add 200mL FBS and return to incubator for an additional 
overnight sterility check. Store at 2-8°C.
5.5 DMEM Modified (5% FBS. Hepes. Bicarbonate. High Glucose, and non- 
essential amino acids)
2 bottles pre-measured, powdered DMEM modified (DMEM-4.5, high glucose 
with L-glutamine, 25mM HEPES buffer, without sodium pyruvate) (Atlanta 
Biologicals)
7.40g sodium bicarbonate
20mL non-essential amino acids, lOOx
1.8L distilled H2 O
lOOmL fetal bovine serum (FBS)
Add ingredients (except FBS) and mix well. Adjust pH to 7.2 with HC1. Sterile 
filter into autoclaved bottles using 0.2pm filter units (Nalgene). Incubate media overnight ' 
at 37°C for sterility check. Add 200mL FBS and return to incubator for an additional 
overnight sterility check. Store at 2-8°C.
5.6 Caco-2 Media
18.8g Eagles Minimal Essential Medium (Atlanta Biologicals) 





40mL non-essential amino acids, lOOx
3.6L distilled H20
400mL Fetal Bovine Serum (FBS)
Add ingredients (except FBS) and mix well. Sterile filter into autoclaved bottles 
using 0.2pm filter units (Nalgene). Incubate media overnight at 37°C for sterility check. 




MAINTENANCE OF EUKARYOTIC CELL CULTURES
1.0 Vero Cell Growth and Crvopreservation
African green monkey kidney (vero) cells (designated CCL-81) were obtained 
from the American Type Culture Collection (ATCC) and cellular morphology was 
confirmed by microscopic analysis. Aliquots of vero cells (lmL containing lx 106  
cells/vial) were cryopreserved in DMEM modified with 5% FBS (Appendix A, 5.5) and 
5% dimethylsulfoxide (DMSO), and stored in liquid nitrogen. Working cell lines were 
maintained in DMEM modified medium for five passages per stock vial, and grown at 
37°C in an open system containing 5% CO2 .
2.0 Caco-2 Cell Growth and Crvopreservation
Caco-2 cells (designated HTB-37) were obtained from the ATCC and cellular 
morphology was confirmed by microscopic analysis. Aliquots of cells were 
cryopreserved in Caco-2 media (Appendix A, 5.6) and 5% dimethylsulfoxide (DMSO), 
and stored in liquid nitrogen. Working cell lines were maintained in Caco-2 media for 
five passages (passage #42-46) per stock vial and grown at 37°C in a closed system.
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